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Abstract 
‘Prediction and Detection of Hypoglycaemia in Type 1 Diabetes’ 
Sankalpa Neupane 
Patients with Type 1 Diabetes still suffer from recurrent and troublesome 
hypoglycaemia despite improvements in glucose monitoring, insulin delivery and 
structured education.   
The key objectives of my thesis were to explore ways to identify patients at greater risk 
to develop hypoglycaemia and to investigate novel ways to prevent hypoglycaemic 
episodes by detecting this early and with ease. This might ultimately translate into 
reduction in overall risk of hypoglycaemia occurrence in those with Type 1 Diabetes. 
I investigated potential factors that could predict persistent presence of severe 
hypoglycaemia in the HypoCOMPaSS study, a multi-centre UK study examining clinical 
strategies to reduce burden of hypoglycaemia. Looking at a subset of these participants 
who underwent detailed hypoglycaemic clamp studies, I found no obvious parameters 
predicting persistent risk of severe hypoglycaemia.  
I then examined whether individual genetic factors might contribute to risk of persistent 
severe hypoglycaemia, exploring the association between polymorphisms in 
Angiotensin Converting Enzyme ACE gene and severe hypoglycaemia in 77 
participants in HypoCOMPaSS study. Interestingly, I found that the homozygous DD 
ACE gene polymorphism was associated with a significantly increased risk of severe 
hypoglycaemia.  
Considering then practical approaches to trying to minimise hypoglycaemia risk, I 
examined the efficacy and safety of a novel implantable Continuous Glucose Monitoring 
Senseonics CGM System in 10 subjects with Type 1 Diabetes from the Cambridge 
cohort of the pivotal European PRECISE 1 study. In keeping with the global data, I 
found in Cambridge participants that this novel system was safe and its efficacy was 
comparable to commercially available Continuous Glucose Monitoring. This device was 
useful in detecting hypoglycaemia early with high device satisfaction among the users. 
I also explored alternative non-invasive methods to measure blood glucose and detect 
hypoglycaemia easily using breath sample in Type 1 Diabetes participants during 
experimental hypoglycaemia. The concentration of Isoprene exhaled in breath was 
significantly raised during hypoglycaemia.  
Finally, I looked at the stability of ‘diluted insulin aspart (NovoRapid®)’ in ambient 
temperature and CSII over 30 days. Both neat and diluted insulin aspart were stable 
beyond 30 days and could potentially be used by patients with T1D requiring very low 
insulin doses to avoid hypoglycaemia.  
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1 Introduction 
   
 Epidemiology of Type 1 Diabetes  
 
The global incidence of diabetes is increasing rapidly.  According to a 2015 
estimate from the International Diabetes Federation, 415 million adults aged 20-
79 have diabetes worldwide, including 193 million who are undiagnosed.  It is 
estimated that by 2040, the number of people affected by diabetes could be as 
high as 642 million[1].  
Diabetes Mellitus is classified in 4 broad categories –Type 1 diabetes (T1D), 
Type 2 Diabetes Mellitus (T2D), Gestational Diabetes (GDM) and diabetes due 
to other causes for e.g. diabetes due to genetic defects, drug induced diabetes, 
diabetes due to endocrinopathies etc.[2]. 
T1D previously encompassed by the terms insulin-dependent diabetes or 
juvenile-onset diabetes, results from a cellular-mediated autoimmune 
destruction of the β-cells of the pancreas, accounts for 5–10% of those with 
diabetes[2].  It is one of the commonest autoimmune disorders in children. 
Around 86,000 children develop T1D each year worldwide[1].  The UK has the 
world’s fifth highest rate of T1D diagnosis in children aged 0 to 14 based on 
estimates from the International Diabetes Federation as 24.5 per 100,000 
children in this age group are diagnosed with the condition every year[3]. 
T1D can occur at any age, with a peak incidence around puberty[4]. In many 
populations, the incidence is somewhat higher in males than in females, and a 
1.3- to 2.0-fold male excess in incidence after about 15 years of age exists in 
most populations. The incidence of childhood-onset T1D varies markedly 
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among countries. East Asian and native American populations have low 
incidences (approximately 0.1–8 per 100,000/year), while the highest rates are 
found in Finland (>60 per 100,000/year), Sardinia (40 per 100,000/year), and 
Sweden (47 per 100,000/year). The risk is highest in European-descent. About 
10 %–20 % of newly diagnosed childhood cases of T1D have an affected first-
degree relative. Those with an affected sibling or parent have a cumulative risk 
of 3 %–7 % up to about 20 years of age, as compared with <1 % in the general 
population. The cumulative incidence among the monozygotic co-twins of 
persons with T1D is less than 50 %[4].  
 
 Pathophysiology and Natural History of Type 1 Diabetes  
  
T1D is a common metabolic condition occurring as a consequence of the 
autoimmune destruction of pancreatic beta cells[5]. This is characterised by an 
absolute or relative insulin deficiency leading to hyperglycaemia. 
Hyperglycaemia presents as polyuria, polydipsia, and in extreme situations if 
untreated, may lead to diabetic ketoacidosis which is potentially fatal.  It may 
also co-exist with other autoimmune disorders like primary hypothyroidism, 
Addison’s disease and pernicious anaemia.  
This chronic autoimmune condition is caused by T-cell mediated inflammation 
and destruction of pancreatic β-cells. Classically, auto antibodies to antigens 
such as glutamic acid decarboxylase GAD (GADAs), insulin [Insulin Auto 
antibody (IAAs)], Zinc transporter 8 (ZnT8As) and protein tyrosine [Insulinoma 
Antigen 2 (IA-2) (IA-2As)] may be present. Antibodies can be seen in 80-90% of 
the people with T1D[6]. However antibodies are often not seen in some 
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populations for example people from Afro-Caribbean descent [7].  Although the 
exact reason is not known, some speculate that T1D in African populations is 
mediated by  novel autoantibodies that may have not been uncovered[8].  
Furthermore those diagnosed with T1D clinically but with negative auto 
antibodies may actually have been non-Type 1 diabetes for example  Maturity 
Onset Diabetes of the Young (MODY)[9].  
It is not known if pancreatic beta cell inflammation is the response to other 
triggering factors such as viral infection.  Several theories have been postulated 
to explain the initiation of this destructive autoimmune process. Some have 
explained this on the basis of molecular sharing between beta cells and an 
environmental factor or loss of immune tolerance[10]. The discovery of a 
susceptible gene locus, the Human Leukocyte Antigen (HLA) complex, has 
provided insight into the contribution of genetic susceptibility in type 1 
diabetes[11].  Among the three classes of HLA genes, the strongest association 
is found with HLA class II genes. These genes are involved in antigen 
presentation and therefore may influence the way beta cell antigen is presented 
leading to auto-self-reactivity.  DR and DQ genotypes have been associated 
with T1D.  HLA-DR3 and HLA-DR4 are associated with T1D in Caucasians [12-
14].   
Underpinning the heritability, monozygotic twins have shown a concordance 
rate of 30 - 50 % compared with dizygotic twins whose rate is lower at 10%[15].  
It is hypothesised that T1D may be triggered by various environmental factors 
in the individuals who are genetically prone to develop the condition. Various 
factors which have been suggested but are unproven in the activation of 
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autoimmunity are congenital Rubella infections, enteroviral infection and early 
introduction of cow’s milk in infancy effect [16-19].  
The Diabetes Prevention Trial-Type 1 (DPT-1) suggested that although 
metabolic changes may occur 2 years prior to presentation, significant c-peptide 
level changes were seen only 6 months prior to diagnosis and that insulin 
sensitivity may play a vital role in the period before the overt presentation leading 
to the diagnosis.  At the time of diagnosis up to 50% of beta cell function may 
still be preserved[20]. 
Prolonged hyperglycaemia is associated with poor outcome [21, 22].  Diabetes 
related complications in humans can be either macrovascular or microvascular. 
Microvascular disease affects eye, nerve and kidney leading to retinopathy, 
neuropathy and nephropathy respectively. Macrovascular disease largely 
comprises peripheral vascular, cardiovascular and cerebrovascular disease [23-
27].  Hence tight glycaemic control is being advocated by clinicians to minimise 
morbidity and mortality associated with poor glycaemic control [28, 29]. 
 
 Management of glycaemia in Type 1 Diabetes  
 
Many technical and healthcare changes have occurred over the last few years 
in T1D. New insulin analogues continue to be developed and have been widely 
adopted in T1D [30]. The combination of rapid acting ‘bolus’ insulin given before 
meals and/or as ad hoc doses to correct high blood glucose values, with long-
acting background insulin replacement ( termed ‘basal’ insulin ) allows people 




   
 
Figure 1-1: Standard Basal Bolus Insulin Regimen  
 
A ‘basal bolus’ insulin regimen with 3 bolus injections of rapid acting insulin (red) for meals with, 
in this case, once daily background insulin (blue). 
 
 
Variable bolus insulin is adjusted with counting carbohydrates in meals. Below 
is an example of larger carbohydrate containing lunch and smaller carbohydrate 





   
Figure 1-2: Basal Bolus insulin with variable carbohydrate intake  
 
Rapid-acting insulin (red) for meals with, in this case, twice daily background insulin (blue) 
 
 
This regimen is flexible and patient can miss meal in contrast to those on twice 
daily mixed insulin regime where people are required to eat to give insulin 
injection as shown in Figure 1-3 [32].  
 
Figure 1-3 Basal Bolus Insulin with missed meal 
 
Example of missed (or carbohydrate free) breakfast. Rapid acting insulin (red) for meals with, in 




   
 
 Structured patient education 
The flexibility offered by modern variable insulin regimens presents a challenge 
for people with T1D, who need to learn and use many self-management skills 
beyond simply checking blood glucose concentration and administering insulin 
[32-34]. For example, many people with T1D adjust doses of meal-time rapid-
acting insulin depending on the carbohydrate content of food, meaning that they 
need training to count carbohydrates accurately. Concept of flexible meal 
related insulin dose adjustment was reported as early as the 1930s. This 
became practicable since home blood glucose monitoring was possible[35]. 
Diabetes Teaching and Treatment Programme (DTTP) developed in Germany 
was one of the first few education programmes in the modern era.  This was a 
residential 1-week programme.[35, 36].  Educational packages have emerged 
in the UK over the last one and half decades [37-41]. The largest and best 
established of these in the UK is the DAFNE programme (Dose Adjustment For 
Normal Eating), described below, but a number of broadly similar smaller 
structured education programmes are also being used in UK services [39, 42, 
43]. The DAFNE course is based on a patient education model developed in 
Germany. This was modified from Germany’s Diabetes Teaching and Treatment 
Programme (DTTP) as a 5-day non-residential course. This programme was 
first integrated in T1D care in the UK in 2002[35]. In a randomized controlled 
trial, DAFNE improved blood glucose control and patient well-being [37].  As per 
early 2018 data, 6,445 DAFNE courses have been delivered in the UK resulting 
in 43,880 DAFNE graduates and 41 DAFNE courses were planned for February 
2018[44].  It has also been adopted in Australia, New Zealand and 
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Singapore[35]. DAFNE continues to be effective with improved glycaemic and 
patient-reported outcomes [39, 41, 45].   People experience not only lower 
average blood glucose concentrations, reflected by lower HbA1c values, but 
also less hypoglycemia and improvement in their ability to detect a falling blood 
glucose sooner [35, 40, 42, 45, 46].  
DAFNE and similar programmes provide education in skills required to self-
adjust insulin doses, such as carbohydrate counting, adjustment for 
exercise/activity, illness, stress, alcohol, travel and the menstrual cycle [40-43]. 
 
 Continuous subcutaneous insulin infusion (CSII /‘insulin 
pumps’) therapy  
Dr. Arnold Kadish developed the first insulin pump in the early 1960s, which was 
as big as a Marine backpack.  Since then, insulin pumps have become much 
more refined and have decreased to the size of a pager [47, 48].  
With continuous subcutaneous insulin infusion (CSII), rapid-acting insulin is 
pumped in constantly as a basal insulin replacement via an indwelling 
subcutaneous infusion cannula, self-inserted typically into abdomen, buttock, 
thigh or arm. The infusion set is removed typically every 3 days and a fresh set 
inserted at a different site[49]. People can then use the pump to deliver an insulin 
bolus to cover meals and/or corrections for high glucose values as needed. 
Figure 1-4  illustrates a daily profile with changes in insulin infusion to cover 





   




Early CSII models were cumbersome and unreliable but the last decade has 
seen increased uptake in many developed countries in both children and adults 
[48, 49]. Used judiciously, CSII can improve glucose control [50-57] but they are 
more complex technically and medically and thus unlikely to replace injections 
as standard treatment for insulin-requiring diabetes in the near future [54, 58-
61]. 
Currently in the UK, NICE (National Institute for Care Excellence) guidance is 
that, in adults, CSII should be considered in those  with HbA1c value of greater 
than 69 mmol/mol (8.5%) in spite of optimized therapy with injections and /or if 
hypoglycaemia is a significant  problem [62]. 
 
 Continuous Glucose Monitoring 
Continuous glucose monitoring (CGM) has been commercially available since 
2000 [63]. They measure interstitial glucose continuously.  The CGM system 
 
34 
   
usually consists of a self-inserted subcutaneous sensor linked wirelessly to a 
receiver. 
Amperometric CGM sensors measure interstitial glucose. The sensor typically 
is a needle type electrode that contains enzyme. Glucose is oxidized into 
hydrogen peroxide by glucose oxidase at the working electrode to generate an 
electrical current. The sensor then measures glucose concentration by detecting 
changes in the electric current in the interstitial fluid[64, 65]. There is a delay of 
5-15 minutes between the blood and interstitial glucose depending on the 
specific technology used in the CGM system[60].  
CGM receivers can be stand-alone handheld devices or linked to an insulin 
pump that acts as the receiver. Users need to calibrate the system by performing 
SMBG testing [66]. These CGM systems could be real-time CGM (RT-CGM) or 
indeed could be blinded for professional use. In the former system, receivers 
can display real-time information about both absolute blood glucose values and 
indicate the direction and speed of change. The system can be set to alert the 
patient if values are outside target ranges or, with predictive algorithms, to sound 
an alarm if glucose values are changing rapidly and/or predicted to move outside 
the target range [67]. 
 
Accuracy of various CGM systems had historically been inferior to blood glucose 
meters for measurement of capillary blood glucose such that there was 
increased risk of error in the clinical application of CGM values [68, 69].  
Accuracy of CGM systems have without a doubt improved over the last 2 
decades[70].  However, this is still frustratingly inaccurate for some [60, 70-73]. 
The sensors are also susceptible to pharmacological interventions including 
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commonly prescribed medications. For example, paracetamol can falsely 
elevate CGM glucose values.  Recently advanced CGMs are less susceptible 
to these interferences [74-76].  I have discussed this further in chapter 4.  
Furthermore, lag time particularly when glucose is falling rapidly remains a 
problem [77, 78]. Some people do also find this painful where as others are 
fatigued by alarms and the wear time of CGM reduces as a result. Perhaps as 
a consequence of these initial trial evidence suggested only modest benefits in 
glycaemic outcomes from CGM. The use of CGM in clinical practice is still 
relatively low not only due to above factors but also because of the costs of the 
CGM systems [60, 61, 70, 73, 78-80]. 
 
Latest CGM systems however are shown to be more advanced, accurate and 
usable with improved patient related outcomes[60, 65, 70, 71, 81, 82]. Two 
recently published studies have shown effectiveness of CGM in T1D treated with 
MDI. DIAMOND (Effect of Continuous Glucose Monitoring on Glycemic Control 
in Adults With Type 1 Diabetes Using Insulin Injections)  and GOLD (Continuous 
Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults 
With Type 1 Diabetes Treated With Multiple Daily Insulin Injections) randomised 
studies used Dexcom  system (Dexcom,Inc., San Diego, CA) to demonstrate 
improved HbA1c in people  with T1D using CGM  in addition to SMBG  compared 
to those using SMBG only[81, 83, 84]. The benefit of CGM was also 
demonstrated in pregnant women with T1D. The CONCEPTT randomised 
controlled trial (Continuous glucose monitoring in pregnant women with type 1 
diabetes) showed that use of CGM during pregnancy was associated with 
 
36 
   
improved neonatal outcomes and the women spent more time in target during 
CGM use[85].      
People using CGM are required to do SMBG tests for insulin dosing on a day to 
day basis and also to confirm glycaemic excursions when using most of the  
currently available commercial systems with the exception of some  latest CGM 
sensors[64, 70, 86].  Recently real time CGM systems have been approved in 
Europe and the United States as non-adjunct to glucose meter testing  i.e. users 
are allowed to use glucose values observed from CGM to guide day to day  
insulin dosing without the need to perform adjunct SMBG test.[69, 70, 86-88].  
G5 Mobile CGM systems (Dexcom,Inc., San Diego, CA) was approved by FDA 
in 2016 for non-adjunctive use for insulin dosing [87].  However users still need 
to do SMBG testing twice a day to calibrate the sensor and also in situations 
where users experience symptoms that do not match the CGM data[89] . 
Since then their technology has further advanced. Sixth generation Dexcom G6 
system is factory calibrated and does not require SMBG testing to calibrate the 
sensor or to aid insulin dosing (non- adjunct use)[90-92].  
Abbott’s FreeStyle Libre Flash glucose monitoring system is a different category 
of glucose monitoring system. This system uses wired enzyme technology to 
measure interstitial glucose concentration and is factory calibrated with sensor 
life up to 14 days. Users do not need to do calibrations with blood glucose meter 
readings to maintain sensor accuracy [89, 93]. This particular feature is 
convenient to people. However, this system is not real time and does not push 
the data although users can view 8 hours of glucose history. Users are required 
to scan the reader to observe glucose readings[93].  Accuracy and effectiveness 
in improving glycaemic control of this system is shown to be comparable with 
 
37 
   
other real time CGM system [65, 94-98].  Second version of this Flash Glucose 
monitoring system has been approved by European regulatory body and this 
comes with optional real time alarms[99].  
I have further discussed CGM later in this chapter. 
 
 Pancreas / Islet transplant 
Beta cell replacement in the form of Islet or pancreas transplantation is one of 
the therapeutic options for people with T1D who suffer from recurrent severe 
hypoglycaemia that has not responded to other treatments or for those with 
suboptimal glycaemic control who also have had a renal transplant and are 
currently  on immunosuppressive therapy [62].  
I have further discussed islet transplantation for management of 
hypoglycaemia in hypoglycaemia sub section of this chapter.   
Whole organ pancreas transplantation has a reasonable success rate for graft 
survival and insulin independence[100].  In the UK as in many countries, this is 
largely combined with kidney transplantation, but pancreas / islet alone 
transplantation may be performed where indicated – usually for recalcitrant 
severe hypoglycaemia [62, 100, 101].  Similarly, islet transplantation involves a 
lesser procedural complexity but, like whole-organ transplantation, the risks of 
anti-rejection therapy including immunosuppression must be weighed against 




   
 Hypoglycaemia in Type 1 Diabetes  
 
Risk of long-term complications in T1D can be minimised by good glycaemic 
control through intensive insulin therapy aimed to lower average blood glucose 
levels on a daily basis[24].  However, for many people with T1D who are on 
insulin therapy, this blood glucose lowering comes at a cost of increasing risk of 
suffering from “overshoot” episodes of low blood glucose known as 
hypoglycaemia[105].  Hypoglycaemia is the main complication of treatment with 
insulin. Hypoglycaemia is usually defined as a plasma glucose level <3.9 
mmol/L (70 mg/dL) [106].  
Historically there has been no universal definition of clinical hypoglycaemia [107, 
108]. Various biochemical cut off values including 3.9 mmol/L, 3.5 mmol/L, 3 
mmol/l, 2.8 mmol/l have been used both in clinical management and reporting 
of clinical trials[108, 109]. Cut-off value of 3.9 mmol/l  to report hypoglycaemia 
was proposed by American Diabetes Association work group in 2005  to bring 
uniformity in reporting biochemical hypoglycaemia in clinical trials [110]. This 
work group categorised, and defined hypoglycaemia as described below. 
 
1) Severe hypoglycemia. 
An event requiring assistance of another person to actively administer 
carbohydrate, glucagon, or other resuscitative actions. These episodes may be 
associated with sufficient neuroglycopenia to induce seizure or coma.  Plasma 
glucose measurements may not be available during such an event, but 
neurological recovery attributable to the restoration of plasma glucose to normal 
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is considered sufficient evidence that the event was induced by a low plasma 
glucose concentration. 
2) Documented symptomatic hypoglycemia. 
An event during which typical symptoms of hypoglycemia are accompanied by 
a measured plasma glucose concentration ≤3.9 mmol/l. 
3) Asymptomatic hypoglycemia. 
An event not accompanied by typical symptoms of hypoglycemia but with a 
measured plasma glucose concentration ≤3.9 mmol/l.  
4) Probable symptomatic hypoglycemia. 
An event during which symptoms of hypoglycemia are not accompanied by a 
plasma glucose determination (but that was presumably caused by a plasma 
glucose concentration ≤3.9 mmol/l).  Since many people with diabetes choose 
to treat symptoms with oral carbohydrate without a test of plasma glucose, it is 
important to recognize these events as “probable” hypoglycemia. Such self-
reported episodes that are not confirmed by a contemporaneous low plasma 
glucose determination may not be suitable outcome measures for clinical 
studies that are aimed at evaluating therapy, but they should be reported. 
5) Relative hypoglycemia. 
An event during which the person with diabetes reports any of the typical 
symptoms of hypoglycemia, and interprets those as indicative of hypoglycemia, 
but with a measured plasma glucose concentration >3.9 mmol/l. This category 
reflects the fact that patients with chronically poor glycemic control can 
experience symptoms of hypoglycemia at plasma glucose levels >3.9 mmol/l as 
plasma glucose concentrations decline toward that level. Though causing 
distress and interfering with the patient’s sense of well-being, and potentially 
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limiting the achievement of optimal glycemic control, such episodes probably 
pose no direct harm and therefore may not be a suitable outcome measure for 
clinical studies that are aimed at evaluating therapy, but they should be reported. 
 
There has been controversy around using ≤3.9 mmol/l of glucose concentration 
as a cut off value to define hypoglycaemia. Some argue that this is of no clinical 
significance and may well falsely inflate frequency of hypoglycaemia[107-109]. 
Recently, International Hypoglycaemia working group has recommended 
defining hypoglycaemia as glucose concentrations below 3 mmol/L when 
reporting clinical trials[111]. 
 
For many people fear of hypoglycaemia is the main factor that limits 
improvement in glycaemic control as attempts to achieve recommended 
glycaemic targets results in unacceptable episodes of hypoglycaemia[105].  
Severe Hypoglycaemia (SH)  is defined as any such episodes that requires third 
party assistance to recover from hypoglycaemia [110]. The Diabetes Control 
and Complications Trial (DCCT) demonstrated that intensive glycaemic control 
with insulin therapy in T1D prevents progression and development of 
complications but this came with a three-fold rise in SH [24, 112, 113].  People 
with T1D typically experience 2 episodes of mild hypoglycaemia a week and can 
self-treat these minor episodes with carbohydrate intake and thus prevent 
severe hypoglycaemia [114].  The rate of Severe Hypoglycaemia in T1D is 
variable in different patient populations with one study reporting an annual 
incidence of 1.0 – 1.7 episodes per patient per year [115]. The risk of Severe 
Hypoglycaemia is skewed with a small proportion of people with T1D 
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representing vast episodes of SH.  For e.g.in a study of 1076 people with T1D, 
5% represented 54% of all SH episodes in the whole cohort [107, 116]. 
SH is potentially fatal as it can be associated with falls, injury, arrhythmias and 
seizures.  Even without physical harm, it results in increased anxiety among 
people with diabetes and their care givers [117-119].  Fear of hypoglycaemia is 
higher in those who have already experienced SH[120]. 
In addition to the effects of aggressive insulin therapy on its own, risk of 
hypoglycaemia is compounded for some people who lose their defensive 
responses against hypoglycaemia classified as Impaired Awareness of 
Hypoglycaemia (IAH), increasing further the risk of suffering from severe 
hypoglycaemic episodes [105, 116, 121, 122] .  
Glycaemic goals in diabetes is a trade-off between glycaemic control and 
iatrogenic hypoglycemia. People with T1D have individualised glycaemic targets 
so they achieve lowest possible HbA1c without significant burden of 
hypoglycaemia on a day to day basis[117]. 
 Physiologic defence mechanisms against Hypoglycaemia  
There are several physiological defence mechanisms against hypoglycaemia in 
human subjects without diabetes [123].  Brain uses glucose as its fuel [124].  
Brain is limited in several ways when it relies on glucose to function.  Firstly, 
brain cannot synthesize glucose in brain and so has to rely on peripheral organs 
to supply glucose to brain. Secondly, it cannot store glucose to any significant 
degree. Thirdly although brain can use alternative energy sources in the form of 
lactate and ketones, these alternative fuels cannot be generated in minutes if 
blood glucose is falling rapidly [123, 125].  So brain is one of the first organs to 
be affected by falling blood glucose levels [106].  As a result, when blood 
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glucose starts falling, several physiological pathways gets activated to prevent 
glucose level falling below a level where brain glucose supply gets compromised 
and these pathways aim to raise blood glucose levels. These 
mechanisms/pathways are also termed hypoglycaemia counter regulation [125, 
126].  
The first response to a falling blood glucose in non-diabetes is suppression of 
insulin release from pancreatic beta cells [125]. This starts at a plasma glucose 
of around 6 mmol/L and is maximally supressed below 4mmol/L[125]. Thus, 
insulin mediated suppression of hepatic glucose production and peripheral 
glucose utilisation is reduced even before hypoglycaemia is reached in healthy 
individuals[125, 127, 128].  
 
If glucose level falls below the physiological range, glucagon and epinephrine 
secretion are triggered, typically at around 3.8 mmol/L. Epinephrine is not critical 
for counter regulation in healthy subjects but becomes important in Type 1 
diabetes where glucagon responses to hypoglycaemia become deficient in the 
first few years after diagnosis.[125].  Both glucagon and epinephrine are fast 
acting in defence against hypoglycaemia. Glucagon increases glucose 
production through gluconeogenesis and hepatic glycogenolysis.  Epinephrine 
on the other hand can also stimulate renal glucose production and reduce insulin 
mediated glucose uptake in the periphery in addition to increasing hepatic 
glucose production[129]. Other counter regulatory hormonal responses to 
hypoglycaemia include increased release of norepinephrine (at sympathetic 
nerve terminals but spilling over into the blood stream), cortisol and growth 
hormone. Growth hormone and cortisol have modest role in acute 
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hypoglycaemia but may have a more significant role in prolonged 
hypoglycaemia [129, 130]. Diagram below illustrates the counter regulation 
mechanism in humans[125]. 
 
 
Adapted from Cryer, P.E.[125], Glucose counter regulation: prevention and correction of 
hypoglycemia in humans 
  
 
In addition to neurohumoral responses, symptoms are generated which can 
alert the individual to a falling glucose. These warning symptoms of 
hypoglycaemia are typically categorised in two broad categories: autonomic and 
neuroglycopenic. Autonomic symptoms include sweating, palpitations, shaking 
and hunger whereas confusion, speech difficulty, drowsiness, odd behaviour 
and incoordination are predominantly neuroglycopenic symptoms due to 
cerebral dysfunction caused by brain glucose deprivation [125, 127, 131]. 
Symptoms of hypoglycaemia prompt individuals to take corrective action 
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(carbohydrate /glucose intake) to prevent glucose from further drop. If glucose 
falls below 2.8 – 3 mmol/L cognitive impairment starts to develop [106, 132]. 
 
 Impaired defence against Hypoglycaemia in Type 1 Diabetes  
Insulin suppression as a first defence against iatrogenic hypoglycaemia is 
absent in T1D subjects. Loss of endogenous insulin leads to loss of cessation 
of paracrine signalling of  cells to release glucagon thus increasing the risk of 
hypoglycaemia in people with T1D.  Furthermore, not only glucagon response 
is lost within 5 years of diagnosis in T1D subjects, catecholamine counter 
regulation is also diminished in those with longer duration of diabetes[132] with 
the glycaemic threshold for sympathoadrenal activation being shifted to lower 
glucose concentrations [126, 132, 133].  
The attenuated epinephrine response in the presence of defective glucagon 
response with no endogenous beta cell insulin results in defective counter 
regulatory mechanisms in T1D[132].  Associated with this, people fail to 
recognise a declining plasma glucose and develop loss or impairment in ability 
to recognise hypoglycaemia, known as impaired awareness of hypoglycaemia 
(IAH). They do not experience typical symptoms of hypoglycaemia and miss the 
opportunity to treat their symptoms to prevent further decline in plasma glucose 
and at greater risk to develop severe hypoglycaemia (SH) [133].  In people with 
IAH, threshold of autonomic and sympatho adrenal response falls to or below 
threshold for cognitive impairment [107, 134].  IAH affects 25 to 40 % of the 




   
The imperfection in the exogenous insulin physiology means people are already 
prone to hypoglycaemia. The drive to achieve perfect glycaemia increases the 
risk even further and some people with T1D experience either frequent mild 
hypoglycaemia on a regular basis or severe hypoglycaemia which is potentially 
fatal[21, 112].   
Although the exact mechanisms leading to IAH and impaired counter-regulation 
remain to be determined, there is no doubt that antecedent biochemical 
hypoglycaemia itself reduces symptoms and counter regulatory hormone 
responses to subsequent hypoglycaemia in both T1D and non-diabetic subjects 
[136, 137]. This potentially creates a vicious cycle of recurrent hypoglycaemia.  
This concept of ‘Hypoglycaemia associated autonomic failure’ (HAAF) was 
postulated by Cryer[136].  This concept of HAAF is extended to include sleep 
and exercise related HAAF[126].  Hypoglycaemia in itself is a major contributor 
of HAAF. Antecedent hypoglycaemia, exercise and sleep significantly increases 
the burden of hypoglycaemia[127]. 
 Cranston et al. showed that restoration of awareness of hypoglycaemia is 
possible by rigorous avoidance of hypoglycaemia for 3 weeks. This was 
independent of disease duration or initial metabolic control[138].    
In day to day clinical practice, various other factors are implicated in the 
causation of hypoglycaemia. These include missed meals; carbohydrate 
inaccuracy leading to overestimation of bolus insulin; exercise; alcohol; 
behavioural problems; liver disease; renal impairment; extremes of age; co 
existing autoimmune conditions particularly hypothyroidism and Addison’s 
disease etc. [106, 107, 129, 131].   
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Various hypothesis has been postulated to explain IAH on the basis of central 
mechanisms. Some of these are: 
 
1.Brain Glucose metabolism hypothesis 
Certain parts of brain are shown to exhibit decreased glucose uptake in 
response to hypoglycaemia in those with IAH.  Fluorodeoxyglucose (FDG) 
uptake in sub thalamic region, amygdale and ventral striatum  were diminished 
in those with IAH compared to  those who had preserved hypoglycaemia 
awareness [139-141].  
Mangia et al. demonstrated that recurrent hypoglycaemia in T1D was 
associated with reduced cerebral circulation to thalamus and hypothalamus 
region[139, 142]. It is speculated that IAH is caused by reduced neuronal 
responses in certain parts of the brain due to habituation of higher behavioural 
responses to hypoglycaemia and hence the failure to trigger counter regulatory 
responses [139]. 
 
2.Brain Glycogen supercompensation  
Some preliminary studies indicated that increase in brain glycogen aimed to 
obtain additional metabolic substrates from local sources contributed to 
impaired sympatho adrenal response during hypoglycaemia thus contributing to 
IAH in T1D[115, 139, 143, 144].  However brain glycogen levels are very low 
and not so reliable additional reserve[115].  Subsequent studies failed to back 





   
3.Brain fuel Hypothesis  
Brain may be able to maintain metabolic activity during hypoglycaemia by 
increasing uptake of non-glucose fuels for e.g. lactate and ketones. Increased 
blood brain barrier monocarboxylic acid (MCA) transporter promoting increased 
lactate uptake could potentially contribute to IAH[139, 146]. 
 
4.Brain neuronal communication hypothesis  
Neuronal communication in the brain is dependent on the release of classical 
neurotransmitters for e.g. potent inhibitory neurotransmitter Gamma-
Aminobutyric Acid (GABA). This is normally decreased in hypoglycaemia. 
Recurrent hypoglycaemia is found to be associated with failure to decrease this 
GABA in interstitial fluid in Ventromedial Hypothalamus (VMH) and consequent 
reduction in epinephrine & glucagon response resulting in HAAF [139, 147, 148].  
 
Neuro imaging studies have provided some insight into differences in brain 
responses to hypoglycaemia  between  individuals with preserved 
hypoglycaemia awareness  and those with IAH [107] . Hypoglycaemia is shown 
to lead to activation and deactivation of certain regions of brain. This includes 
activation of thalamus (autonomic response), anterior cingulate (stress 
response), insula (food seeking response) and deactivation of hippocampus 
(memory), visual cortex (vision) and lateral orbito-frontal cortex)( [107, 149, 
150]). Functional studies of the brain in T1D people with IAH is associated with 
decreased activation in stress areas of the brain possibly caused by repeated 
episodes of hypoglycaemia[140, 151].  Reports suggest that those with IAH may 
 
48 
   
not perceive hypoglycaemia to be stressful and unpleasant and that these 
individuals may not motivated to avoid hypoglycaemia [152, 153].  
A recent study examining brain responses to experimental hypoglycaemia in 
T1D and healthy controls using magnetic resonance imaging showed that 
thalamic cerebral blood flow changes correlated with autonomic symptoms and 
anterior cingulate cortex blood flow changes correlated with epinephrine 
response respectively. The findings suggested that these regions of the brain 
may play a part in counter regulation [154].   
 
Given the complexity of responses to hypoglycaemia, it is likely that a number 
of adaptations at cellular and whole body system levels all contribute to some 
degree in defective counter regulation and thus IAH[115]. However, there is lack 
of complete understanding of central pathophysiology of IAH and the research 
to understand this is ongoing[152, 155]. 
 
 Cardiac autonomic neuropathy : 
There have been several reports of ‘dead in bed’ syndrome in people with T1D 
including young individuals[156, 157]. Studies exploring underlying cause have 
suggested that these episodes are caused by disturbances in cardiac rate and 
rhythm including QT interval prolongation caused by a number of factors 
including acute hypoglycaemia on the background of cardiac autonomic 
neuropathy[156, 158].  Hypoglycaemia is also associated with raised plasma 
catecholamine levels and lowering of serum potassium, both of which may 
augment the arrhythmogenic effect of QT prolongation[159-161].  A study by 
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Adler et al in 12 healthy individuals showed that antecedent hypoglycaemia 
impaired autonomic cardiovascular  autonomic function[162].  
Cardiac autonomic neuropathy can have wide range of features including 
exercise intolerance, orthostatic hypotension, resting tachycardia, decrease 
heart rate variability, abnormal blood pressure regulation, dizziness, 
presyncope, asymptomatic myocardial ischemia and infarction [163, 164]. 
Autonomic neuropathy was previously suspected to be one of the factors 
contributing to IAH by some [165-168].  Although acute and antecedent 
hypoglycaemia has been implicated in impaired cardiac function, lowering of 
arrythmia threshold and hence sudden cardiac death; IAH as such is not found 
to be associated with cardiac autonomic neuropathy[162-165, 169]. One recent 
study found no difference in measures of autonomic function between adults 
with long-standing T1D adults who had IAH, and carefully matched T1D with 
preserved hypoglycaemia awareness[165].  
 
 Clinical strategies to reduce hypoglycaemia  
 
 Education  
Various structured education packages such as Dose Adjustment For Normal 
Eating (DAFNE) have been shown to reduce hypoglycaemia in T1D[170]. 
Although not specifically targeted at hypoglycaemia, these programmes do 
achieve this by allowing people with diabetes to match better insulin dosing to 
varying insulin requirements. [34, 37, 41, 45, 171].  People with T1D are trained 
to do meticulous adjustments of insulin by Capillary Blood Glucose Testing 
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(CBGT) in presence of various clinical and social situations. This minimises 
insulin mismatch and bolus insulin dosing errors. The diabetes educator’s role 
is pivotal in re-enforcing and consolidating the skills and understanding 
individual’s self-management skills following their enrolments in structured 
education courses [171, 172].   
 Psychological intervention  
Targeted education programmes aimed more specifically at hypoglycaemia to 
improve hypoglycaemia awareness have shown to improve SH[170].  For 
example, HyPOS programme trained people about hypoglycaemia symptom 
awareness using diaries and performing blood glucose estimation.  Burden of 
hypoglycaemia improved 6 months post intervention along with improvement in 
IAH. They observed reduction in SH after 31 months follow up period although 
not in the first 6 months of intervention period [173, 174] . Enhanced version of 
Blood glucose awareness training (BGAT- II) was psycho-educational and 
behavioural [175] intervention programme that has been shown to be effective 
in training people to be able to recognize hypoglycaemia and reduce SH [176-
178]. Hypoglycaemia Awareness Restoration Therapy (DAFNE–HART) 
incorporated diabetes education with two psychological approaches 
motivational interviewing & cognitive behaviour therapy. This helped restore IAH 
and reduce SH. This was further associated with improvement in behaviour and 
worry around hyperglycaemia [179, 180]. Another psycho-analytical training 
programme ‘‘Hypoglycemia Anticipation, Awareness and Treatment Training’’ 
(HAATT) also  demonstrated benefit in reduction of SH  in adults with T1D[181]. 
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 Continuous subcutaneous insulin infusion (CSII / ‘insulin 
pumps’)  
CSII is now a stablished therapeutic option in the pathway of T1D 
management[29]. This has been endorsed by NICE as well [62, 182].  This has 
shown to be particularly beneficial in reduction in SH in T1D [53, 54].  A meta-
analysis by Pickup et al. found that SH was significantly lower in CSII users 
compared to MDI users with the greatest reduction seen in those with higher 
burden of SH on MDI[59]. In the Cochrane database systematic review, Misso 
et al. similarly observed a beneficial effect of CSII on SH and glycaemic 
control[53].  However not all systematic review favoured CSII over MDI in terms 
of hypoglycaemia reduction [50, 107, 183].    
 Continuous glucose monitoring (CGM) 
Use of CGM and its glycaemic benefits has already been discussed earlier in 
this chapter.  Real time CGM with alerts and predictive alarms can alert users 
of impending hypoglycaemia prompting them to take corrective action to 
prevent severe events.[53, 79]  NICE recommends real time CGM in those 
with significant burden of hypoglycaemia [62, 70]. CGM benefits those with 
IAH as well [170, 184].  The current UK use of CGM though is low, likely due to 
multiple factors including costs, inaccuracy, lag time, information overload, lack 
of time and skills among health care professionals etc. [55, 61, 70, 78, 185].  
Alarm fatigue and sleeping through alarms remains a problem in CGM 
users[186].  One of the potential problems for CGM alone is that it requires 
users to take action as otherwise insulin delivery continues in presence of 
hypoglycaemia[187].   
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Previous literature was not always in favour of stand-alone CGM in clinically 
significant hypoglycaemia reduction[73, 80, 107, 188, 189].  Little et al. 
suggested that this could be largely due to patient selection and study 
design[107].  However, data are emerging to show that CGM reduces 
hypoglycaemia.  A recent study showed that RT-CGM reduced the number of 
hypoglycaemic events in people with T1D on MDI with problematic 
hypoglycaemia [190]. Similarly, Reddy et al. found that CGM reduced time spent 
in hypoglycaemia in T1D with IAH compared with flash glucose monitoring[191]. 
 Sensor augmented pump therapy (SAP) /Automated Insulin 
Delivery  
Modern CSII can be integrated with CGM, also known as sensor augmented 
pump therapy (SAP) have shown benefits in glycaemic improvement [79, 170, 
192].  RealTrend study showed that people in SAP with LGS arm of the study 
who were compliant with use of the sensor achieved significant reduction in 
HbA1c compared to those on using CSII only [188].  Eurythmics study 
demonstrated glycaemic improvement with SAP compared to MDI therapy[193]. 
These and other studies did show that SAP therapy can offer better glycaemic 
control compared to MDI alone or CSII alone particularly if sensor compliance 
is maintained. [97, 192].    SAP system has evolved, and some system comes 
with a feature to suspend basal insulin delivery automatically if hypoglycaemia 
is observed in the CGM [Low Glucose Suspend (LGS)] to prevent further drop 
in blood glucose and avoid SH.  SAP with LGS feature suspends insulin delivery 
automatically for up to 2 hours [187, 194].  A study by Choudhary et al. found 3 
weeks usage of Paradigm Veo (Medtronic, Inc., Northridge, CA) insulin pump 
with LGS function was associated with reduced nocturnal hypoglycaemia[187]. 
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LGS also minimised anxiety regarding hypoglycaemia among people with Type 
1 diabetes and their  caregivers[187].  In ASPIRE (Automation to Simulate 
Pancreatic Insulin REsponse) study, 3-month period use of SAP therapy where 
basal insulin delivery was interrupted at a pre-set sensor glucose value was 
associated with reduced nocturnal hypoglycemia, without increase HbA1c 
compared to those on SAP only [195].  Similarly  study in children found that  
those on SAP with LGS spent significantly less time in hypoglycaemia compared 
to those on SAP alone[196].  
 
Latest generations SAP are more advanced and automatically suspend insulin 
delivery earlier when hypoglycaemia is predicted by CGM [Predictive Low 
Glucose Suspend (PLGS)]. For example, Medtronic MiniMed 640G pump 
(Northridge, CA) with SmartGuard® system automatically suspends insulin 
infusion not only when hypoglycaemia occurs but also when hypoglycaemia is 
predicted. Data are emerging to support that these SAP with PLGS reduce 
hypoglycaemia[197, 198].  Abraham et al. showed its benefit in reduction of 
biochemical hypoglycaemia and hypoglycaemia events in children and 
adolescent compared with sensor-augmented pump therapy (SAP) alone[198]. 
This feature was not associated with adverse outcomes in the form of diabetes 
ketoacidosis or worsening of metabolic control [197, 199]. Recently PROLG trail 
demonstrated that Tandem Diabetes Care Basal-IQ pump integrated with 
Dexcom G5 sensor and a PLGS system algorithm significantly reduced time 
spent in hypoglycemia in adults, adolescents and children with T1D compared 
to SAP therapy alone[200]. 
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CSII technology is progressing rapidly to allow insulin delivery to be automated. 
Closed Loop (or “artificial pancreas”) integrates CSII with CGM controlled by an 
algorithm which varies insulin delivery through CSII in real time using continuous 
glucose data received from CGM. This has shown not only to increase time in 
target but also reduce time spent in hypoglycaemia [54, 201-205].  
To date, Closed Loop (CL) has really not been tested in a hypoglycaemia group. 
 
 Pancreas / islet transplant 
NICE recommends Islet / pancreas transplantation for people with T1D if they 
suffer from intractable SH that has not responded to other treatments in addition 
for those with suboptimal glycaemic control who are already on 
immunosuppressive therapy for kidney  transplant  [62]. 
Beta cell replacement is one of the treatment options for recalcitrant SH at least 
in theory [103, 206-208]. The issues however revolve around post-surgical 
complications and immunosuppression post islet / pancreas transplantation 
[102, 209, 210]. Islet transplantation is technically and surgically less 
challenging compared to pancreas transplant [104, 210, 211]. Furthermore, 
advances in immunosuppression therapy which are largely steroid free 
('Edmonton protocol') have led to minimise complications related to 
immunosuppression [210, 212, 213].  
Gerber et al. reported a significant reduction of SH in a median follow up of 51 
months following islet transplantation in those who had failed pancreas 
transplantation. The benefit was seen even in those who needed exogenous 
insulin.  Beta cell replacement has shown to improve counter regulatory 
response in short term as well as long term [214-216]. For example in a stepped 
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hypoglycaemic clamp study, Rickels et al. demonstrated recovery of glucagon 
secretion and improvement in epinephrine secretion 6 months post intrahepatic 
islet transplantation thus supporting role of islet transplantation in IAH 
reversal[215]. The same group had previously observed that glycaemic 
thresholds for activation of counter regulatory hormone and symptom responses 
appeared  normal after islet transplantation[216].    
Meyer et al. showed that islet graft function improved hypoglycaemia counter-
regulation by increasing endogenous glucose production (EGP) and decreasing 
systemic glucose disposal. This may in part explain reduction in SH post-
transplant in T1D [217].   
Although pancreas / islet transplant looks encouraging in the management of 
debilitating hypoglycaemia, various obvious logistical challenges still remain. 
Paramount are the cost and skills of the centres to delivery this service, supply 








 Outline of thesis 
 
In summary, despite advances in glucose monitoring, insulin delivery and beta 
cell replacement, many people with T1D have persisting problems with recurrent 
hypoglycaemia, hypoglycaemia unawareness and remain at risk of severe 
hypoglycaemia [170, 179, 180, 220-222].  This has a significant impact not only 
at personal level to people with T1D and their care givers but also remains a 
huge challenge to health system as well [221-224].  
As discussed above and as elucidated by Little et al. impaired counter-
regulation, hypoglycaemia-associated autonomic failure, psychosocial and 
behavioural factors have been reported to be the main underlying drivers of 
severe hypoglycaemia in T1D [107]. However, data is limited in terms of 
underlying biomedical factors that could predict future occurrence of SH 
particularly in those with highest burden of hypoglycaemia. The HypoCOMPaSS 
study was a UK based multi-centre study that examined problematic 
hypoglycaemia and looked at interventions to improve IAH and minimise 
SH[225].  A proportion of these participants underwent insulin camp studies 
before the intervention.  It would be logical to examine biomedical factors 
measured at baseline clamp study to explore if these factors could predict the 





   
There have been reports of association between polymorphisms in Angiotensin 
Converting Enzyme gene and SH in Scandinavian studies (discussed in detail 
in subsequent chapter), but these findings have not been convincingly replicated 
by other investigators beyond single group of researchers [226-230].  
Underpinning mechanisms to explain this association to SH are also not clear. 
Study of this association in a high-risk group may provide some insight.   
 
CGMs system have been shown to improve time in range and reduce 
hypoglycaemia in people with T1D as discussed above [81, 83].  But existing 
CGMs do have some draw backs which contribute to poor compliance and 
satisfaction among the CGM users[70]. One of the issues are short sensor life, 
sensors falling off etc. Implantable CGM system with long sensors life could 
potentially address some of the issues.  
 
Monitoring blood glucose regularly is a key to minimise hypoglycaemia for 
people with T1D  whilst maintaining good glycaemic control[231].  However, this 
is limited by painful and less convenient method of self-monitored blood glucose 
testing using capillary blood sample obtained by pricking own finger [232, 233]. 
Volatile Organic Compounds (VOCs) in exhaled breath have been explored as 
a non-invasive alternative to measuring glucose levels with a view to improve 
people’s compliance with home blood glucose monitoring. VOCs in exhaled 
breath have been studied in experimental setting to measure glucose [234, 235]. 
However, insulin could potentially be one of the important confounders in these 
studies[236]. Furthermore, these studies did not examine VOCs during 
hypoglycaemia.  So, there a need of randomized study, examining exhaled 
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VOCs to detect glucose levels eliminating potentially confounding effect of 
insulin and also the need to study the exhaled VOCs in extreme range of glucose 
values such as hypoglycaemia.   
Accuracy of low dose insulin delivery is nor very reliable. This may be an issue 
for those people withT1D requiring very low doses of insulin [237-240].  Diluting 
insulin may offer greater accuracy.  There is no published literature reporting 
stability of diluted insulin in CSII at 30 days or beyond.     
 
In my thesis, I have looked at novel ways to predict and detect hypoglycaemia 
which would ultimately help reduce the overall burden of hypoglycaemia in T1D. 
Chapter 2 is the sub-analysis from the main HypoCOMPaSS study.  The 
HypoCOMPaSS study was a UK based multi-centre study that examined 
problematic hypoglycaemia and looked at interventions to improve IAH and 
minimise SH. A sizeable subset underwent insulin clamp studies to measure 
hypoglycaemia responses in depth (before and/or after intervention). Here I 
have explored the symptoms, hormonal responses and cognitive performance 
in the baseline hyperinsulinaemic hypoglycaemic clamp studies, looking for 
predictors of favourable (or not) outcomes. 
In chapter 3, I have explored biological factors that may contribute to the 
persisting risk of SH in HypoCOMPaSS participants.  Here, I have described 
association between the polymorphisms in Angiotensin Converting Enzyme 
ACE gene and residual SH.  
In chapter 4, I have described a study of a novel implantable CGM [(Senseonics 
CGM System), now called the Eversense® CGM System] in T1D.  Here I 
examined the efficacy and safety of this novel system in the Cambridge cohort 
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from the pivotal European PRECISE 1 study.  I have also discussed patient 
satisfaction and hypoglycaemia from Cambridge participants.  
In chapter 5, I have looked at alternative methods to measure blood glucose and 
detect hypoglycaemia early. Here, I have described a pilot study measuring 
Volatile Organic Compounds (VOCS) in exhaled breath in T1D during 
hyperinsulinaemic clamp studies. 
In chapter 6, I have described in vitro study looking at the stability of ‘diluted 
insulin aspart (NovoRapid®) in ambient temperature and CSII over 30 days.  
Use of diluted insulin is targeted for people with T1D requiring very low insulin 
doses to maintain glycaemia and avoid hypoglycaemia. 
In chapter 7, I have concluded the overall finding of my studies and analyses. 
I have listed study responsibilities and achievements during my PhD in the 








   
2 HypoCOMPaSS sub Analysis : Examination for 
potential predictors of  severe hypoglycaemia 
from baseline hypoglycaemic clamp study 
 
 Background  
HypoCOMPaSS study was a 6 month Randomised Control Trial ( RCT ) with an 
18 month post RCT extension looking at clinical interventions to reverse 
impaired awareness of hypoglycaemia ( IAH) and thus reduce rates of severe 
hypoglycaemia (SH) in a cohort of 96 adults with T1D[241]. The specific clinical 
strategies used in the study were hypoglycaemia awareness training and 
optimized insulin delivery via insulin pumps or multiple injections with or without 
the use of real time continuous glucose monitoring (RT CGM).  The rationale 
was to use (and compare) these clinical interventions to avoid hypoglycaemia in 
order to reverse impaired awareness.  
The main HypoCOMPaSS RCT design and study procedures is attached as 
Appendix 10  [241]  In the main hypo-COMPaSS study, 96 participants were 
randomised to four intervention groups.  
Baseline characteristics of the participants who took part in main 
HypoCOMPaSS study is attached as Appendix 3. 
 
At the end of 6 months RCT, awareness of hypoglycaemia improved as 64 % of 
participants showed an improvement in  GOLD score (responder) and 39 % had 
resolution in Impaired Awareness of Hypoglycaemia (IAH)  i.e. those with  GOLD 




   
In my work presented in this chapter, I have examined rates of SH as an 
important metric of hypoglycaemia burden.  SH can be measured both by the 
number of people affected in a time period and by the average SH rates. In the 
main HypoCOMPaSS study, a total of 77% of participants were affected by SH 
over the 6 months preceding the study. At the end of RCT period, SH rate 
improved significantly by more than 10-fold. Despite this overall reduction in SH, 
20 % of participants experienced SH episodes during the 6 months RCT period.  
In the follow up period, SH rate remained low with only 30 %, 27% and 29% of 
total participants experiencing SH episodes post RCT at 6, 12 and 18 months 
respectively.  In general, comparing the SH rates during the RCT and follow up 
period with the rates seen during the 6 months preceding the RCT illustrated the 
marked baseline burden of SH in the study group, being 8.88±1.4 
episodes/patient/year. This was reduced to (episodes/patient-year ± SEM)] 
0.82±0.2, 0.84±0.3, 0.75±0.2, 0.81±0.3 at the end of RCT, and post RCT at 6, 
12 and 18 months respectively (Table 2-1).  
I have also analysed data looking at the proportion of participants who did not 
experience any episode of severe hypoglycaemia during the 6 months 
HypoCOMPaSS study intervention and 18 months follow up period shown in 
Table 2-2 and the proportion demonstrating Gold score Response and 
Resolution respectively among HypoCOMPaSS cohort at the end of RCT period 




   
Table 2-1:Severe Hypoglycaemia episodes at baseline, 6 months during 
HypoCOMPaSS study intervention and 18 months post RCT follow up period  
  Severe Hypoglycaemia 
(Episodes/patient/year) 
 





6 months RCT intervention period*  
(N=90)  
0.82±0.2  
6 months post RCT * 
(N=90)  
0.84±0.3 
12 months post RCT * 
(N=89)  
0.75±0.2 
18 months post RCT* (N=89)  0.81±0.3 
Data shown are mean ±SEM 
*Cumulative episodes inclusive of RCT intervention period  
 
 
Table 2-2 :Participants who did not experience any episode of severe hypoglycaemia 
during 6 months HypoCOMPaSS study intervention & 18 months follow up period 
 None  At least 1  
 
Total (96)  
Severe hypoglycaemia during 
6months RCT    
N 72 18 90 
Valid Percent 75% 18.8% 93.8% 
    
Severe hypoglycaemia during study 
(6 months RCT & 18months FU )   
    
N 63 26 89 
Valid Percent 65.6% 27.1% 92.7% 





   
Table 2-3:Hypoglycaemia awareness status at the end of 6 months HypoCOMPaSS 
study intervention with Gold score response indicating improvement of score compared 
to baseline score and Gold score resolution indicating restoration of awareness 
(improvement of scores below threshold value of 4) 
 Yes No  
 
Total 
Gold Score Response    
N 54 31 85 
Valid Percent 56.3% 32.3% 88.5% 
    
Gold Score Resolution    
    
N 33 52 89 
Valid Percent 34.4% 54.2% 88.5% 
Missing values n=11 
 
 
In summary, the HypoCOMPaSS study demonstrated a significant restoration 
of awareness of hypoglycaemia and associated reduction in severe 
hypoglycaemia (SH) in a UK cohort of T1D people [225]. However, the 
intervention(s) could not eliminate SH completely.  
25 participants underwent stepped hypoglycaemic clamp sub-study at baseline 
before the intervention. Analysis of biomedical factors observed and measured 
at baseline clamp study could potentially predict occurrence of severe 
hypoglycaemia during the study period and also response to interventions. 
 
 Objective of this sub analysis 
 
The primary objective of this sub-analysis from the main Hypo-COMPASS study 
was to explore symptoms, hormonal responses and cognitive performance in 
the baseline hyperinsulinaemic hypoglycaemic clamp study looking for possible 
determinants of response / non-response to clinical interventions. The 
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hypothesis that I was testing here was that biomedical factors  i.e. cognitive 
performance, hypoglycaemic symptoms and counterregulatory hormones 
response observed during experimental hypoglycaemia in the baseline clamp 
study would predict either improvements in awareness and/or future risk and 
occurrence of SH in the high-risk participants.  Underpinning this hypothesis is 
the important clinical question of whether some people with longstanding T1D 
and IAH just have “irreversible” deficits in defences against hypoglycaemia. 
 
 Study Design and statistical plan   :  
 
The main HypoCOMPaSS RCT design, study procedures and the results are 
attached as Appendix 10 [225, 242].  
In short , there was a 4 week run in period as outlined in appendix 10  before 
the 24 week RCT period.  During the RCT intervention period, participants were 
followed up at study visits every 4 weeks.  Participants were invited to attend for 
further follow up 6, 12 and 18 months after the RCT.  
 Participants  
For this sub analysis all people who underwent hypoglycaemic clamp sub-study 
at baseline were included. 
 Hyperinsulinemic hypoglycaemic clamp procedure 
Clamp studies were conducted in a clinical research facility within respective 
institutions before and after the 24-week HypoCOMPaSS study intervention.  
Participants were fitted with a retrospective CGM sensor (Medtronic iPro, 
MiniMed, CA, USA) to be worn for five to seven days preceding the study day. 
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This was downloaded on the morning of the study to determine whether any 
antecedent biochemical hypoglycaemia had occurred over the 24-hour period 
prior to the clamp. Studies were rescheduled on another day if any CGM and/or 
self-monitored capillary glucose below 3.0 mmol/l was detected during the 
preceding 24 hours. For participants who required rescheduling, a further 72 
hours of CGM was organized.   All participants were advised to fast from 22:00 
h and to avoid caffeine for 24 h before the study.  Participants were admitted to 
the clinical research facility at 7 am on the day of the study. On arrival, an 
intravenous cannula was inserted in the ante-cubital vein of the non-dominant 
arm and blood glucose was stabilized using sliding scale insulin infusion aiming 
initially for blood glucose 6.0–7.0 mmol/l and then 5.0–6.0 mmol/l between 10.30 
am and 11 am for clamp initiation.   A second retrograde cannula was inserted 
into a vein on the dorsum of the non-dominant hand which was heated to 50-60 
°C to arterialise venous blood.  During this period of stabilization, participants 
practiced cognitive function tests demonstrated to be sensitive to 
hypoglycaemia - Four Choice Reaction Time and Stroop tests. Cognitive 
Functions tests during clamp studies are explained as appendix 2.[243-245].  
 
At the start of the clamp, a primed infusion of 60 mU/m2/min soluble human 
Actrapid insulin in a 4% solution of autologous blood in 0.9% sodium chloride 
was started via the non-dominant antecubital vein catheter.  Infused in parallel, 
the rate of infusion of 20% dextrose was adjusted as needed, aiming to stabilize 
plasma glucose at 5.0 mmol/l at 40mins followed by step-wise lowering to 3.8 
mmol/l, 3.4 mmol/l, 2.8 mmol/l and 2.4 mmol/l.  Each step lasted 40 min allowing 
20 min to achieve the new target level and 20 min for stabilization at that level.  
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Samples for plasma glucose were obtained every 5 min and analysed in real-
time.  Participants were kept blinded to their real-time glucose levels throughout 
the study.  At the end of each clamp stage, participants were asked to complete 
a semi-quantitative symptom questionnaire consisting of 9 items (autonomic 
symptoms=pounding heart, shaking / tremor, hunger and sweating and 
neuroglycopenic symptoms=drowsiness, difficulty speaking, headache, 
clumsiness / incoordination and confusion).  Each item was scored from 1 
(absent) to 7 (maximal) and for ease of interpretation converted to a scale of 0 
to 6 with a minimum-maximum possible score range of 0 to 54.  Symptom 
questionnaire was followed by cognitive function tests- Four Choice Reaction 
Time and Stroop tests (attached as appendix 2). These tests have been 
demonstrated to be sensitive to hypoglycaemia [243-247].  
Additional blood samples were taken at regular intervals for the later 
measurement of insulin and the counter-regulatory hormone response 
(metanephrine, growth hormone, glucagon and cortisol).   
 Analytical methods: 
Arterialized plasma glucose was measured in real time using Yellow Springs 
analyser (YSI STAT Plus, Farnborough, UK, intra- assay coefficient of variation 
(CV) 1.5 % and inter assay CV 2.8 %). Plasma insulin was measured by an 
enzyme linked immunosorbent assay (DAKO) Glostrup, Denmark; intra assay 
CV 1.8 % and inter assay CV 7.8 %).  Glucagon was measured by an enzyme 
linked immunosorbent assay (Alpco Diagnostics, NH, USA, intra assay CV 1.6 
% and inter assay CV 2.4 %).  Cortisol level were measured using a 2 step 
sandwich immunoassay (Roche Modular E 170 platform, Elecsys cortisols 
reagents, intra assay CV 1.4 % [ based on a mean value of 535 nmol/l].  
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Metanephrines were measured by an enzyme linked immunosorbent assay 
(Alpco Diagnostics, NH, USA, intra assay CV 12 % [ based on a mean value of 
652 pmol/l] and inter assay CV 12.2 % [based on a mean value of 350 pmol/l]). 
Growth hormone was measured by an enzyme linked immunosorbent assay 
(Alpco Diagnostics, NH, USA, intra assay CV 1.4 % and inter assay CV 4.5 %).  
All samples were measured in a single central laboratory in the same batch.  
 
 Clamp sub study :statistical considerations 
The glucose monitoring data included area under the curve for the glucose 
values of <3mmol/L.  Different definitions were used to define resolution of 
unawareness and responders for the primary end point. ‘‘Resolution’’ in IAH 
after the intervention was defined as improvement in Gold questionnaire score 
below the accepted unawareness threshold value of 4. ‘‘Non-responders’’ for 
IAH were defined as those with no improvement in Gold Score. ‘‘Responders’’ 
were defined as those with improved IAH score.  
Glucose thresholds for the onset of symptoms, counter-regulatory hormone 
responses and impairment of cognitive function were determined according to 
protocols in literature [123, 132, 243-245, 248, 249].  Glucose thresholds for 
onset of hormone responses were defined statistically as the glucose value at 
the time of onset of a sustained (≥2 successive time points) increase in hormone 
concentrations ≥2 standard deviations (SD) above the mean of the five baseline 
measurements for that hormone. Thresholds for an increase in total, autonomic 
and neuroglycopenic symptoms were determined as the glucose value at the 
time at which the symptoms score increased ≥ 2 over baseline on ≥ 2 successive 
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time points. Where no defined changed occurred, the lowest measured glucose 
level during the respective clamp was used as the threshold for that individual 
in keeping with published literature.  Incremental areas under the curve for 
symptoms were calculated using incremental symptom scores (subtracting the 
symptom score at the end of stage 1 of the clamp from the scores obtained in 
stages 2-5).  Incremental areas under the curve for hormones were calculated 
by subtracting the mean hormone levels achieved during euglycaemia (first 40 
minutes of the clamp), from subsequent hormone levels during the rest of the 
clamp.  For hormones, single missing values were replaced with linear 
interpolation and the trapezoidal rule was used for calculation of the "area under 
curve".  
For the Four-Choice reaction time, glucose thresholds were determined as the 
plasma glucose level when the reaction time first exceeded twice the coefficient 
of variation of the stable baseline measurements. For Stroop tests, glucose 
thresholds were determined as the plasma glucose level where performance 
first deteriorated ≥2 standard deviations below the mean baseline performance. 
 
I examined baseline clamp parameters - symptoms responses; hormonal 
responses and plasma glucose (mmol/l) threshold at which cognitive function 
deteriorated against “response” & ‘‘resolution’’ in awareness (the main study 
outcome) and Severe Hypoglycaemia during RCT and follow up period. 
Data were analysed using IBM SPSS Statistics for Windows, Version 22.0. 




   




 Results  
Successful clamped hypoglycaemia studies were completed in 25 participants 
at the start (baseline) of the 6 months RCT study.  
 
 Plasma  Glucose & Dextrose infusion  Rates (DIR)  
Plasma glucose and Dextrose Infusion Rate (DIR) during studies is shown in 




   
:  
Figure 2-1:Plasma Glucose during studies 
 




   
 
Figure 2-2 : Dextrose Infusion Rate (DIR) during studies 
 































Data shown are mean ±SEM  
 
Data was missing for GOLD score response and SH episodes during RCT & 
follow up period. Therefore, sub analysis of biomedical parameters in the 
baseline clamp was not available for all 25 participants. This is summarised in 
the Figure 2-3. The details of GOLD score response, GOLD score resolution is 





   
Figure 2-3: Summary of the sample size available for sub analysis in the baseline clamp 
 
Each Subsection is explained in relevant section of the results  
 
 
 Responder vs Non Responder in Baseline Clamp 
There were no differences in symptoms and hormonal responses at baseline 
clamped hypoglycaemia in participants who showed an improvement in GOLD 
score (Responder) compared to those who did not show a response (Non 
Responder)Table 2-4. 
 
The plasma glucose (mmol/l) threshold at which cognitive function deteriorated 






















N = 23 
(Responder:16,  Non Responder:7 )
GoldScore Response in Baseline Clamp
N=23
(Resolution: 9 , Non Resolution:14 )
GoldScore  Resolution in Baseline Clamp
N=24
(None: 20, At least 1: 4)
RCT period SH 'Ye's Vs 'No' in Baseline Clamp
N= 24
(None: 16, At least 1:8)
RCT & Follow up period SH 'Yes' Vs 'No' in Baseline Clamp
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word [2.5(2.2,3.1) vs 2.7(2.4,3.3), P0.41] & four choice reaction time 
[2.4(2.2,2.9) vs 3.2(2.3,2.9), P 0.067].  
 
 
Table 2-4: Symptoms and hormonal responses in baseline clamped hypoglycaemia in 
those who showed an improvement in GOLD score (responder) at the end of 6 months 
HypoCOMPaSS study intervention compared to baseline GOLD score 






































Autonomic   290.0±68.3 260.0±74.6 0.79  
Neuroglycopenic  370.0±83.5 265.7±60.4 0.44  
 
Hormones AUC  
    
 
 
GH  1532.2(1085.1,1890.2) 2627.4(955.8,4088.6) 0.11  
Normetanephrines   57461.9±7558.7 66008.6±6559.8 0.495  
Glucagon  29560.5±5259.8 
 
34284.9±11138.5 0.665  
Cortisol  52585.6±5538.3 41204.3±6438.0 0.241  
     
Data shown are mean ±SEM or Median (IQR) 
* Independent sample T-Test or Mann Whitney U Test     
 
 
 Resolution vs Non Resolution in Baseline Clamp 
Similar to the pattern seen above for responders, there was no difference in 
symptoms and hormonal responses at baseline clamped hypoglycaemia in 
participants who showed resolution in IAH (GOLD score at end of RCT below 
the threshold  score of 4) compared to those who did not show  resolution ( Non 
Resolution ) as shown in Table 2-5. 
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The plasma glucose (mmol/l) threshold at which cognitive function deteriorated 
was similar in ‘Resolution’ and ‘Non Resolution’ as measured by Stroop Colour 
word  [2.7(2.2,3.6) vs 2.5(2.4,3.1) ,P0.27] and four choice reaction time.  




Table 2-5 :Symptoms and hormonal responses in baseline clamped hypoglycaemia  in 
those who showed resolution in Impaired Awareness of Hypoglycaemia (IAH)  i.e. those 
with  GOLD score below threshold  score of 4 at the end of  6 months HypoCOMPaSS 
study intervention 







































Autonomic  326.7±86.3 251.4±65.9  0.49  
Neuroglycopenic 220(121.3,749.7) 260(174,.2,377.2)  0.29  
 
Hormones AUC  
    
 
 
GH 1429.4±279.6 2042.5±357.8  0.23  
Normetanephrines  66315.6±12162.4 56043.6±5052.7  0.38  
Glucagon 34455.5±8087.4 
 
28775.9±6234.1  0.58 
Cortisol 53687.8±8435.7 46186.4±4861.4  0.41  
Data shown are mean ±SEM or Median (IQR) 
* Independent sample T-Test or Mann Whitney U Test     
 
 
 RCT period Severe Hypoglycaemia Yes Vs No in Baseline Clamp 
I also examined whether baseline measures prior to the RCT could predict 
severe hypoglycaemia during the RCT period.  Similar to findings for the Gold 
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score, there were no differences in symptoms and hormonal responses at 
baseline clamped hypoglycaemia in participants who experienced at least one 
episode of severe hypoglycaemia during 6 months RCT period compared to 
those who did not experience any severe hypoglycaemia episode (Table 2-6). 
 
The plasma glucose (mmol/l) threshold at which cognitive function deteriorated 
was similar in ‘None’ and ‘At least 1’ SH as measured by Stroop Colour word 










   
Table 2-6: Symptoms and hormonal responses in baseline clamped hypoglycaemia in 
those who did and did not experience any episode of severe hypoglycaemia during 6 
months HypoCOMPaSS study intervention 






































Autonomic 256.0±57.0 340.0±116.9 
 
 0..54 





    
 
 
GH 1679.7±244.0 2160.3±846.2 
 
 0.46 
Normetanephrines 58908.5±6296.0 60037.5±10500.9 
 





 0.40  
Cortisol 48340.5±4821.3 48870.0±9850.2 
 
 0.96 
Data shown are mean ±SEM or Median (IQR) 
* Independent sample T-Test or Mann Whitney U Test     
 
 
 Total study period Severe Hypoglycaemia Yes Vs No in Baseline 
Clamp 
Severe hypoglycaemia is an infrequent and unpredictable occurrence, even in 
those at risk. To increase the power to detect a difference, I also examined 
whether baseline clamp parameters were associated with rates of SH over the 
total 2 year period (6 month RCT plus 18 month follow-up).  Again and 
importantly, I found no difference in symptoms and hormonal responses at 
baseline clamped hypoglycaemia in participants who  experienced  at least one 
episode of severe hypoglycaemia during total study duration (6 months RCT 
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and 18 months post RCT follow up period) compared to those who did not 
experience any severe episode (Table 2-7). 
The plasma glucose (mmol/l) threshold at which cognitive function deteriorated 
was similar in ‘None’ and ‘At least 1’ SH groups as measured by Stroop Colour 





Table 2-7 :Symptoms and hormonal responses in baseline clamped hypoglycaemia in 
those who did not experience any episode of severe hypoglycaemia during total study 
duration (6 months RCT and 18 months post RCT) 








































Autonomic 295.0±66.9        220.0±75.5  0.49  





    
 
 
GH 1640.8±289.1 1997.8±448.2 
 
 0.49 
Normetanephrines 60413.8±7822.1 56462.5.5±5383.1 
 
 0.74  
Glucagon 44337.1±13733.2 29458.5±8733.1 
 
 0.47  
Cortisol 48676.9±5762.8 47932.5±6013.2  0.93  
Data shown are mean ±SEM  





   
 Discussion  
 
The hypothesis I was testing here was that differences in biomedical responses 
to experimental hypoglycaemia would predict the degree to which IAH and SH 
could be improved by subsequent clinical strategies.  My findings suggest that 
this is not the case. There was no difference in symptoms and hormonal 
responses at baseline clamped hypoglycaemia in participants who showed an 
improvement in GOLD score (Responder) or a resolution of IAH (Resolution) 
compared to those who did not show a response (Non Responder and Non 
Resolution of IAH respectively).  
Furthermore, there were no differences observed in symptoms and hormonal 
responses at baseline clamped hypoglycaemia in participants who experienced 
at least one episode of severe hypoglycaemia during total study duration (6 
months RCT and 18 months follow up period) compared to those who did not 
experience any severe hypoglycaemia episode. 
 
In summary, there were no obvious measurable factors or parameters during 
experimental hypoglycaemia that could be identified to predict persistent 
problematic hypoglycaemia in these high-risk people. 
Age, duration of diabetes, tight glycaemic control, psychosocial issues, 
behavioural factors, previous SH and impaired awareness of hypoglycaemia are 
major risk factors to severe hypoglycaemia[241, 250]. ‘Hypoglycaemia-
associated autonomic failure’ do contribute to IAH and thus ultimately to severe 
episodes [107, 126, 251].  Cranston et al. showed that avoidance of 
hypoglycaemia improves awareness of hypoglycaemia [138].  However, this did 
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look at those with severe episodes.  Data is limited in terms of underlying 
biomedical factors that could directly predict future occurrence of SH particularly 
in those with highest burden of hypoglycaemia.  
Findings of this analysis is difficult to compare with published literature largely 
because most of the prospective trials have excluded people with severe 
hypoglycaemia[107].  It was logical to examine biomedical factors measured at 
baseline clamp study to explore if these factors could predict the occurrence of 
SH in the participants during the study period.   
There are two obvious important clinical implications of this. The first is that there 
is no obvious “target” to consider for potential further study or even intervention 
here, other than the clinical strategy of trying to avoid biochemical 
hypoglycaemia.  
The second though is that the apparent negative findings can be regarded as 
clinically encouraging. There is no evidence here in this group of people with 
long standing diabetes and a baseline burden of hypoglycaemia for the 
existence of a group with “irreversibly suppressed” responses to hypoglycaemia.  
Based on these clamp data, the recommendation for clinicians and Health Care 
Professionals remains that all T1D people with problematic hypoglycaemia 
could benefit from targeted clinical strategies to minimise the burden of 
hypoglycaemia. The interpretation is limited though because of the relatively 
small numbers undergoing clamp studies who had continuing SH. In the 




   
3 HypoCOMPaSS ACE genotype sub study   
 
 Background  
 
 Severe Hypoglycaemia in HypoCOMPaSS study    
As previously discussed, various targeted interventions and clinical strategies 
aimed at reducing the burden of hypoglycaemia in a well-phenotyped UK cohort 
of HypoCOMPaSS participants reduced severe hypoglycaemia significantly and 
restored awareness of hypoglycaemia in most participants [225].  However, 
these extensive clinical interventions could not eliminate SH completely.  At the 
end of HypoCOMPaSS RCT period, one fifth of participants were still suffering 
from SH episodes and around one third continued to experience SH during the 
18 months post-RCT follow up period.  
In the sub analysis of baseline clamp study from the main HypoCOMPaSS 
detailed in chapter 3, I could not identify factors in baseline clamp study that 
could predict future occurrence of SH in the high-risk participants.  
Although, as presented in the last chapter, there were no obvious measurable 
parameters that could be identified from experimental hypoglycaemia (insulin 
clamp studies) to explain the lack of response in some, this still leaves open the 
possibility that underlying biological drivers are contributing to SH in a subset of 
people with T1D who are resistant to targeted clinical interventions aimed at 
improving IAH and minimising severe hypoglycaemia.   
In this chapter, I have examined the residual risk of severe hypoglycaemia. 
Severe hypoglycaemia (SH) affects up to 30% of individuals with established 
T1D each year and remains one of the most feared complications[117-119].  
 
82 
   
Risk of hypoglycaemia varies markedly, and the distribution is skewed so that 
most problematic severe hypoglycaemia clusters in a subset of those with 
T1D[116]. In addition to IAH, many environmental and behavioural factors may 
contribute to mild, moderate and severe hypoglycaemia (SH) in T1D.  For 
example, some may have preserved awareness of a falling blood glucose but 
be slow to take action when they start to get warning, resulting in SH rather than 
“moderate” self-managed hypoglycaemia. Others may have psychosocial 
factors which lead them to avoid hyperglycaemia, ignore or minimise risk or just 
accept as normal.  A current RCT is examining whether psychological factors 
can be successfully targeted [252]. As well as these “behavioural” factors 
though, the question remains as to whether certain people have an underlying 
biological predisposition to hypoglycaemia, for example with brains that are 
more sensitive to the effects of an interruption in fuel supply.  
Increasing data are emerging to suggest that genetic factors contribute 
significantly to SH risk. In support of this, a number of (largely Scandinavian) 
studies have reported an association between hypoglycaemia risk and genetic 
variants in the Renin Angiotensin system (RAS) [226-228, 230, 253-255]. 
  Renin Angiotensin System (RAS) and  SH 
Renin-Angiotensin System (RAS) was first described by Stanley Peart in 1975.  
Since then there have been numerous studies on the physiological effects of 
this system in the human body. There are three important components to this 
system: 1) renin, 2) angiotensin, and 3) aldosterone (Figure 3-1).  Renin, which 
is released primarily by the kidneys, stimulates the formation of angiotensin in 
blood and tissues, which in turn stimulates the release of aldosterone from the 
adrenal cortex. RAS plays an important role in regulating blood volume and 
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systemic vascular resistance, which together influence cardiac output and 
arterial pressure (Figure 3-1). The role of RAS in the development of 




Figure 3-1 : RAS physiology in human   
 
Ref : [257] 
 
 
The RAS has a major influence on electrolyte and fluid balance. The primary 
substrate of the RAS system is Angiotensinogen, which is cleaved by renin to 
form angiotensin I. This is then cleaved by Angiotensin Converting Enzyme 
(ACE) to yield active angiotensin II[256].  ACE inhibitors produce vasodilation 
by inhibiting the formation of angiotensin II and are used as therapeutic agents 
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for prevention and treatment of hypertension, heart failure and coronary artery 
disease [257, 258]. 
Within the ACE gene, frequently occurring polymorphisms can alter the activity 
of the RAS system.  The ACE gene in humans is located on chromosome 17q23. 
This consists of 26 exons and 25 introns spread over ∼24 kb. Intron 16 contains 
a restriction fragment length polymorphism based on the presence (insertion I) 
or absence (deletion D) of a 287-base pair (bp) non-sense DNA domain alu 
repeat sequence forming 3 genotypes  II & DD homozygotes and ID 
heterozygote[259].  In 1990, Rigat et al. showed that this insertion/deletion (I/D) 
polymorphism in the ACE gene accounted for half of the variance of the serum 
ACE enzyme levels[260]. Serum ACE concentrations were significantly higher 
in homozygotes with the shorter deletion allele (DD) than in heterozygotes (ID) 
or in homozygotes with the longer insertion allele (II)[261].  In addition to ACE 
concentration, serum ACE activity is determined by the I/D polymorphism of 
ACE gene with the D allele conferring higher tissue and serum ACE activity[228].  
The Insertion /Deletion polymorphism in the ACE gene, serum ACE activity and 
other polymorphisms in RAS have been reported to be associated with SH. The 
homozygous DD ACE genotype has been associated with risk of severe 
hypoglycaemia compared to ID & II [226-228, 253, 254].   
Serum ACE concentrations were shown to be significantly higher in 
homozygotes with the shorter deletion allele (DD) than in heterozygotes (ID) or 
in homozygotes with the longer insertion allele (II) absence of ‘I’ allele in ID & 
DD [261].  In addition to ACE concentration, serum ACE activity is determined 
by the I/D polymorphism of ACE gene with the D allele conferring higher tissue 
and serum ACE activity[228].  
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Homozygous DD ACE genotype has been associated with risk of severe 
hypoglycaemia compared to ID & II [226-228, 253, 254]. Presence of ‘I’ allele 
results into lower ACE activity and ‘D’ allele leading to higher activity,  thus 
homozygous DD (absence of ‘I’ allele) conferring higher tissue and serum ACE 
activity[228]. 
ACE genotype has been implicated in a number of health conditions[262]. The 
D allele has been associated with hypertension, preeclampsia, heart failure, 
cerebral infarction, diabetic retinopathy and nephropathy[262]. Interestingly, the 
‘I’ allele is found at increased frequency in endurance athletes such as long-
distance runners, climbers, rowers. The Insertion / Deletion polymorphism in the 
ACE gene, serum ACE activity and other polymorphisms in RAS have been 
reported to be associated with SH. Specifically; the homozygous DD ACE 
genotype has been associated with risk of severe hypoglycaemia compared to 
ID & II [226-228, 253, 254].   
The association suggests that low ACE activity might be favourable for 
performance conditions with limited substrate availability for fuelling body 
metabolism, perhaps including brain functioning?  Such conditions occur in 
endurance athletes during competition and, perhaps also by analogy, in people 
with diabetes during hypoglycaemia [255, 262, 263]. 
A study noted local RAS system in various organs in the body including 
brain[264]. This brain system modulates local metabolism in the brain when 
substrate availability limited with a view to increase efficiency and limit release 
of noxious stimuli so that brain can maintain function longer[255, 265].   
Hypoglycemia is similar situation with low substrate (glucose) availability in the 
brain[255]. To date, these associations in T1D between SH and polymorphisms 
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in RAS & serum ACE activity have been reported in Scandinavian studies, 
largely reported by a single research group, but have not been replicated 
convincingly elsewhere [229, 230].  
There have been some case reports of familial increases in circulating ACE 
levels due to intronic mutations in ACE gene[266-268]. Interestingly there was 
no evidence of functional consequences in these individuals for e.g. RAAS 
activation or cardiovascular end organ damage. These supported the pre-
existing hypothesis that membrane-bound ACE rather than circulating ACE are 




In this chapter I have examined ACE genotype and enzyme activity to see 
whether there was an association with risk of severe hypoglycaemia (SH).  I 
examined (1) SH data from the RCT and (2) data from the post-RCT clamps, 
reasoning that any effects of RAS were likely to be seen more easily once 
educational/ behavioural features had been optimised.  In particular, for clamp 
studies, I anticipated that any effects of ACE genotype might manifest as 
increased cognitive deterioration in those with DD genotype during 





   
 Objectives  
 
My hypothesis was that following clinical optimisation, the presence of the “at 
risk” DD genotype in the ACE gene would be associated with (1) persisting 
severe hypoglycaemia in UK HypoCOMPaSS participants with T1D and (2) 
greater cognitive decline during experimental (clamped) hypoglycaemia at the 
end of the RCT. 
 
 Study Design  
 
The study protocol, participant information sheets and consent forms were 
approved by an independent Research Ethics Committee and the study was 
carried out in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from each participant for the main study. Participants 
signed an additional consent form for this sub-study and also provided additional 
blood samples.  Clamp protocol design is attached in the appendix 5. 
 
 Study Procedure ACE genotype sub study  
 
 Participants :ACE genotype sub study  
For this sub study all people participating in the Hypo-COMPASS study were 
invited.  77 out of 96 participants agreed to participate in this sub study.  
 Analytical methods: ACE genotype sub study  
Additional blood samples (10 ml) were collected in these 77 participants at the 
time of planned venepuncture for the main Hypo-COMPASS study following 
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informed consent. 5 ml of the blood sample was centrifuged and stored at -20 
for serum ACE level analysis. The remaining 5 mls was transferred to two EDTA 
tubes and transported to Institute of Metabolic Science, Cambridge for the 
genetic analysis. 
 
 Serum ACE analysis    
Serum ACE activity was measured using a rapid spectrophotometric method 
(Trinity Biotech Plc Bray, Co. Wicklow, Ireland, intra assay CV 5% [based on a 
mean value of 61 U/L] and inter assay CV 2 % [based on a mean value of 59 
U/l]).    
 Detection of ACE gene Polymorphism :  
DNA was extracted from frozen whole blood.  The insertion / deletion 
polymorphism of the ACE gene was identified by polymerase chain reaction 
(PCR) using two primers flanking the site of insertion.  Fragments of 191 bp (D 
allele) and 479 bp (I allele) were separated on a 2 % agarose gel and stained 
with SYBR Safe DNA Gel Stain. Visualisation was then done on a UV 
transilluminator. To prevent mistyping of ID to DD by preferential amplification,   
additional PCR amplification protocol was used utilising ACE 2 sense primer 
along with standard ACE anti-sense[269]. 
 Statistical Considerations 
The main HypoCOMPaSS study planned to recruit 100 participants based on a 
pilot study where intervention gave a Clarke score (an alternative to the Gold 
score for assessing hypoglycaemia awareness but ranked using a similar scale) 
of 2.6 + 1.9 vs 4 + 1.8 in control group. Although a post-hoc analysis, we 
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performed a power calculation in order to estimate our power for detecting a 
difference. For this ACE genotype sub study, if we assume that we might see 
similar differences in awareness scores between genotypes, a sample size of 
22 in each group at 95% significance would give us 80% power.  
Assuming that the I/D ACE genotype will show a Hardy–Weinberg distribution 
as in previous samples of T1D, we expected  25% of people to have high risk 
(DD), 25% to have II and 50% to be ID genotype. 
We therefore aimed to approach all participants in HypoCOMPaSS.  Assuming 
that there would be a high percentage participation of 90%, this gave likely 
samples of >23 in each target genotype.  
Baseline clinical characteristics and demographics between genotypes were 
examined using One-Way ANOVA except for gender analysis where Chi square 
test was used for categorical data. SH, biochemical hypoglycaemia and Gold 
scores were analysed using one way ANOVA.   
In the analyses below, where numbers are small, I have compared the DD “risk 
group” with combined “non risk group (ID and II groups).  When analysed as risk 
ACE genotype ‘DD’ Vs. non risk ACE genotype ‘Non DD’ (ID/II), an independent 
sample T test was used to compare the genotypes.  Chi Square test and Fisher 
exact Test was used to examine Responder (Improvement in Gold score) and 
Resolution (Improvement in Gold score below threshold value of 4) respectively.  
SH episodes were also analysed for those who were not on Angiotensin 
Converting Enzyme Inhibitor (ACEI) therapy.  Further, SH episodes during the 
study were examined exclusively for participants who had 1 or more baseline 
SH episodes before being enrolled in the study.  
SH episodes in ACE genotypes were examined in post RCT follow up period.  
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Data were analysed using IBM SPSS Statistics for Windows, Version 21.0. 
(Armonk, NY: IBM Corp) and a p value less than 0.05 was considered 
statistically significant. 
All data are presented as mean with SEM. 
 
  Results –ACE genotype sub study  
 
Data were analysed for 77 of the total 96 HypoCOMPaSS participants who took 
part in this sub study.   
 Baseline characteristics of participants-ACE genotype sub 
study 
Table 3-1 shows the distribution of ACE genotype in participants. The 
distribution was broadly as expected with just half the participants being in the 
ID group. There was no differences between ACE genotypes in terms of gender, 
age, HbA1c or duration of diabetes.  
 
Baseline diabetic retinopathy status was similar across genotypes as shown in 
Table 3-1.  Hypertension data across genotypes could not be analysed as 
baseline Blood Pressure was not consistently recorded.  Different 
antihypertensive tablets were recorded but clinical indications of these 
antihypertensive agents could not be established (i.e. hypertension, 
cardiovascular prevention or microalbuminuric diabetic nephropathy etc.).  
  
There were no differences between ACE genotypes in the baseline (pre-RCT) 
rates of severe hypoglycaemia (DD 9.4±3.3, ID 8.2±1.8, II 8.3±3.8 
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episodes/person/year,p 0.940, N= 77) as shown in Table 3-1 and Figure 3-2 .  
The differences remained similar when analysed as risk vs non-risk ACE 
genotype [(DD 9.4±3.0, Non DD 8.2±1.6 episodes/person/year, p 0.72, n =727) 
(Figure 3-3 )].   
 
Study Intervention groups in the main HypoCOMPaSS Multiple Daily Injection 
(MDI), Continuous Subcutaneous Insulin Infusion (CSII), MDI with Real Time 
CGM  (RT)  and CSII with Real Time CGM (RT) were similar across the ACE 




   


























Age (years(n=77) 48.6 ± 1.3 47.1±2.9 49.8±1.7 47.0±3.2 0.650 
Duration of diabetes 
(years) n=77 
29.3±1.4 29.9±3.0  29.2±1.9 29.1±3.0 0.976 
HbA1c (%) baseline 
(n=77) 
8.2±0.1 8.2±0.1 8.1±0.1 8.7±0.3 0.223 
Severe 
Hypoglycaemia at 
baseline (n=77)  
(episodes/person/year) 
 
8.5±1.4 9.4±3.2 8.2±1.8 8.3±3.8 0.940 
 
 
Gold Score at baseline 
(n=77) 
5.3±0.1 5.4±0.2 5.4±0.1 5.0±0.25 0.279 
Diabetic Retinopathy  
(n=76) 
46 13 24 9 0.172 a 
Data shown are mean ±SEM    
* One way Anova      
a Chi Square Test   






   





























   
Figure 3-3: Baseline Severe Hypoglycaemia - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE 
genotypes  





























   











MDI(n) 19 4 13 2 0.77 a 
CSII(n) 18 6 8 4  
MDI with RT (n) 22 6 11 5  
CSII with RT(n) 18 5 11 2  
a: Chi Square test 
 
 
     
 Serum ACE levels and Glycaemic control of participants at the 
end of 6 months RCT period -ACE genotype sub study 
There were no differences between ACE genotypes in terms of HbA1c at the 
end of the  6 months RCT study period. 
As anticipated (and in keeping with previous literature), serum ACE activity level 
was significantly higher in the DD ACE genotype. The difference persisted even 





   
Table 3-3 : Glycaemic control and serum ACE levels of participants at the end of 6 






















































ACE activity (U/l) 












ACE activity (U/l) 






















Data shown are mean ±SEM  






   
 Severe Hypoglycaemia during RCT study period-ACE genotype 
sub study 
Despite no differences in baseline SH (as seen in Figure 3-2 and Figure 3-3 
above), SH episodes in DD ACE genotype were markedly and significantly 
higher during the 6 months RCT study period (DD 1.44±0.48, ID 0.33±0.19, II 
0.50±0.36 episodes/person/year, p 0.032 (Figure 3-4 ). This difference was also 
apparent when analysed as risk vs. non-risk ACE genotype, [(DD 1.44±0.48, 
Non DD 0.37±0.17 episodes/person/year, p 0.009, n =77) (Figure 3-5)].  The 
differences remained significant when those treated with ACEI therapy were 
excluded [(DD 1.59±0.62, ID 0.22±0.12, II 0.62±0.62 episodes/person/year, p 
0.02, n =52) (Figure 3-6)]. As above, the differences persisted in this analysis of 
those not on ACEI when we compared risk vs non-risk ACE genotype [(DD 
1.59±0.62, Non DD 0.30±0.15 episodes/person/year, p 0.006, n =52) (Figure 
3-7 )].  When those treated with either ACEI and/or ARB were excluded, 
differences were not statistically significant, likely because of reduced power 
[(DD 1.3±0.6, ID 0.2±0.14, II 0.72±0.72 episodes/person/year, p 0.097, n =40)]. 
Finally, I performed a further specific analysis of SH during the study including 
only the participants who had one or more episode of SH in the preceding 12 
months prior to the study.  SH was significantly higher in the DD group in this 
sub group analysis as well (DD 1.6±0.52, Non DD 0.41±0.19 
episodes/person/year, p 0.009). 
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Data shown are mean ±SEM  








   
Figure 3-5 : Severe Hypoglycaemia during 6 months RCT study - at risk ‘DD’ Vs ‘Non 
DD’ (ID/II) ACE genotypes 
































   
Figure 3-6 : Severe Hypoglycaemia during 6 months RCT study period across ACE 


































   
Figure 3-7 : Severe Hypoglycaemia during 6 months RCT study - at risk ‘DD’ Vs ‘Non 
DD’ (ID/II) ACE genotypes excluding those on ACEI therapy     



























Data shown are mean ±SEM  
 
 
 Biochemical  Hypoglycaemia during the 6 months RCT study 
period -ACE genotype sub study 
There was no effect of the ACE genotype on the magnitude and duration of 
“biochemical hypoglycaemia” (glucose < 3.0mmol/L) during 6 month RCT period 
measured using monthly blinded CGM [(AUC DD 485±198, ID 302±47, II 
212±50, p 0.27, n =75) (Figure 3-8)].   This effect remained non-significant when 
examined as risk vs non-risk ACE genotype [(AUC DD 485±198, Non DD 
281±38, p 0.130, n =75). (Figure 3-9)].   
There was no difference between genotypes when lower threshold of 
hypoglycaemia glucose (≤2.5mmol/L) was used (AUC DD 126±26, Non DD 
134±24, p 0.86)]. 
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Figure 3-8: Biochemical hypoglycaemia (Glucose < 3.0 mmol/L) during 6 months RCT 


































   
Figure 3-9: Biochemical hypoglycaemia (Glucose < 3.0 mmol/L) during RCT study 
period - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes    






























 Awareness of Hypoglycaemia assessed at the end of 6 months 
RCT  study period -ACE genotype sub study  
Awareness of Hypoglycaemia assessed at the end of 6 months RCT study 
period did not show ACE genotype difference in mean Gold score Questionnaire 
[(DD 4.25±0.36, ID 4.22±0.24, II 3.91±0.51 , p 0.82,n=72) (Figure 3-10 )]. As 
expected, this effect remained non-significant when examined as risk vs non risk 
ACE genotype. [(DD 4.25±0.36, Non DD 4.15±0.22, p 0.82, n=72) (Figure 3-11)] 
Furthermore, at the end of the 6 months RCT study period, there were no ACE 
genotype differences in the proportion of participants who either “responded” i.e. 
improvement in Gold score Questionnaire or “resolved” (resolution of IAH), i.e. 
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improvement in Gold score Questionnaire below a threshold value of 4 [ (p 0.56 
& 0.96 respectively)  (Figure 3-12 & Figure 3-13) ]. This effect remained non-
significant when examined as risk vs non-risk ACE genotype [(p 0.41 & 0.79 
respectively) Figure 3-14 & Figure 3-15]. 
 
 
Figure 3-10 : Awareness of Hypoglycaemia assessed by Gold score at the end of 6 






















   
Figure 3-11 : Awareness of Hypoglycaemia assessed by Gold score at the end of 6 
months RCT study period - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes    






















   
Figure 3-12 :Proportion of participants whose Awareness of Hypoglycaemia improved 























   
Figure 3-13 : Proportion of participants whose Awareness of Hypoglycaemia improved 
below a threshold value of 4 as assessed by Gold score at the end of 6 months RCT 





















   
Figure 3-14 : Proportion of participants whose Awareness of Hypoglycaemia improved 
as assessed by Gold score at the end of 6 months RCT study period - at risk ‘DD’ Vs 
‘Non DD’ (ID/II)  ACE genotypes    






















   
Figure 3-15: Proportion of participants whose Awareness of Hypoglycaemia responded 
(i.e. improved below a threshold value of 4) as assessed by Gold score at the end of 6 
months RCT study period - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes    




















 Clamped hypoglycaemia at the end of 6 months RCT study -ACE 
genotype sub study  
In the main HypoCOMPaSS study, 23 participants successfully completed the 
hyperinsulinemic hypoglycaemic clamp procedure at end of the 6 months RCT 
study.  21 of those participants took part in ACE genotype sub study. 7 of these 
21 participants were on ACEI therapy at the time of clamped hypoglycaemia. 
 
To explore the possible underlying mechanism of increased risk of severe 
hypoglycaemia in DD ACE genotype, I examined end-of-RCT clamped 
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hypoglycaemia results in these 14 participants who were not on ACEI therapy.  
Clamp procedure is explained in the appendix 5.   
 
Symptoms scores and cognitive function were assessed during stepped 
hypoglycaemia along with counter-regulatory hormones measurement in 
chapter 2. In this subset, due to relatively small numbers participating in clamp 
studies in each group, I have analysed the data comparing risk ‘DD’ vs ‘Non-
DD’ (ID and II) ACE genotypes.  
  
Demographic details of these 14 participants who were not on ACEI therapy is 




   
Table 3-4: Baseline characteristics of participants who took part in clamp procedure at 
end of the 6 months RCT and were not on ACEI therapy  
 All 





















Age (years) 47.6±2.5 44±4.3 51.1±2.3 0.17 
Duration of diabetes 
(years) 
33.9±2.9 28.7±4.3  39.1±3.0 0.07 
HbA1c (%)baseline 7.9±0.2 7.8±0.3 7.9±0.4 0.78 
 
HbA1c (mmol/mol) baseline 62.9±2.7 62.1±3.3 63.6±4.5 0.78 
Severe Hypoglycaemia at 
baseline   
(episodes/person/year) 
 
9.9±3.9 10.1±6.8 9.7±4.3 0.95 
 
 
Gold Score at baseline 5.4±0.2 5.7±0.2 5.1±0.4 0.22 
Data shown are mean ±SEM  
* Independent sample T-Test     




Plasma glucose and dextrose infusion rate (DIR) for these 14 participants who 
took part in clamp procedure at end of the 6 months RCT and not on ACEI 





   
Figure 3-16: Plasma glucose for 14 participants who took part in clamp procedure at 
end of the 6 months RCT and were not on ACEI therapy 















































   
 
Figure 3-17:  Dextrose Infusion Rate (DIR) for 14 participants who took part in clamp 
procedure at end of the 6 months RCT and were not on ACEI therapy 



































 Symptoms and hormonal responses in End RCT clamped 
hypoglycaemia-ACE genotype sub study  
In keeping with the Gold score reported in main RCT, the plasma glucose levels 
at which participants first felt low was comparable in DD ACE genotype 
compared to Non DD (ID/II) ACE genotypes (answer to the question ‘‘do you 
feel hypoglycaemic?’’ during stepped hypoglycaemic clamp) in participants not 
on ACEI therapy. Total AUC values for autonomic symptoms, neuroglycopenic 
symptoms and total symptoms were also comparable in both DD and Non DD 
ACE genotypes. Similarly, total AUC values for plasma metanephrine were also 




   
Given the prior hypothesis about ACE genotype affecting the sensitivity of brain 
to fuel deprivation, I also examined a specific neuroglycopenic symptom subset 
comprising scores for confusion, difficulty in speaking and clumsiness. These 
have been suggested to be more indicative of cognitive dysfunction[270].  Total 
‘cognitive dysfunction’ scores were high in DD genotype, but this did not reach 
statistical significance (Table 3-5).   
 
 
Table 3-5: Symptoms and hormonal responses at end RCT clamped hypoglycaemia in 
those who were not on ACEI - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes 
 







































Autonomic  514.3±144.6 357.1±109.3  0.40  
Neuroglycopenic 405.7±108.4 508.6±116.4  0.53 
  
Total Cognitive  
Dysfunction Symptoms  § 
 



















     
Data shown are mean ±SEM or Median (IQR) 
* Independent sample T-Test or Mann Whitney U Test     






   
 Cognitive Function Tests in End RCT clamped hypoglycaemia-
ACE genotype sub study 
The plasma glucose at which cognitive function deteriorated as measured by 
Stroop Colour Word was significantly higher in ‘DD’ ACE genotype compared to 
‘Non DD’ (ID/II) ACE genotypes [ (3.4(2.8,3.9) vs 2.9(2.4, 3.0),P 0.038 ] in those 
not on ACEI therapy as shown in Table 3-6 & Figure 3-18 (mean values). 
 
The plasma glucose threshold for deterioration of cognitive function (n=13 as 
one subject had no data collected for this parameter) as measured by four – 
choice reaction also appeared to be higher in the risk ‘DD’ ACE genotype but 




Table 3-6: Glucose (mmol/l) threshold at which cognitive function deteriorated in End 
RCT clamped hypoglycaemia in participants who took part in ACE genotype sub study 





























     
Data shown are Median (IQR) 






   
Figure 3-18:Plasma glucose threshold at which Stroop Colour Word deteriorated in End 
RCT clamped hypoglycaemia in those who were not on ACEI- at risk ‘DD’ Vs ‘Non DD’ 
(ID/II) ACE genotypes 
Glucose threshold Stroop Colour Word
Without those on ACEI

























The total AUC values for cognitive function tests as assessed by Four choice 
reaction time and Stroop tests (Black & White reading, Colour reading and 
Colour Word reading) during stepped clamped hypoglycaemia were comparable 




   
Table 3-7 : Cognitive Function Tests in End RCT clamped hypoglycaemia   
in those who were not on ACEI - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes 








     
Cognitive Function AUC      
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Data shown are mean ±SEM  




I have further explored to see if participant’s cognitive function deteriorated 
during experimental blinded hypoglycaemia before the point at which subjects 
felt low (answer to the question ‘‘do you feel hypoglycaemic?’’).  I found that in 
the DD ACE genotype group, cognitive function deteriorated significantly at 
earlier glucose values before the subjects developed hypoglycaemic symptoms   
compared to Non DD (ID/II) ACE genotypes when measured by Stroop Colour 
Word. On the contrary, participants with Non DD (ID/II) ACE genotypes felt low 




   
Although a similar trend was observed in at risk DD ACE genotype when 
measured by four choice reaction, this did not reach statistical significance 





Table 3-8: Glucose (mmol/l) threshold at which cognitive function deteriorated minus 
glucose levels subjects felt low (mmol/l) in End RCT clamped hypoglycaemia in 










Glucose difference for   














Glucose difference for  






     
Data shown are mean ±SEM  




 Post-Randomised Controlled Trial follow-up period (post RCT) - 
ACE genotype sub study 
All participants of the main HypoCOMPaSS attended for further follow up visits 
at 6, 12 and 18 months after completion of RCT period. Given that SH is a 
relative infrequent event that clusters in time, even in those at greatest risk, I 
examined data collected over the whole 2 year period to see if there was an 
association with ACE genotype.  In summary, there was no statistical difference 
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in SH between ACE genotypes in follow up period (cumulative SH at each follow 
up period) although SH (episodes/person/year) was numerically higher in at risk 
DD ACE genotype. [(6months DD 0.86±0.30, Non DD 0.50±0.20, p 0.33, n =77, 
(Figure 3-19), [(12 months DD 1.06±0.57, Non DD 0.41±0.14, p 0.11, n=76, 




Figure 3-19 : Severe Hypoglycaemia 6 months post RCT - at risk ‘DD’ Vs ‘Non DD’ 

































   
Figure 3-20: Severe Hypoglycaemia 12 months post RCT - at risk ‘DD’ Vs ‘Non DD’ 
(ID/II) ACE genotypes 
































   
Figure 3-21: Severe Hypoglycaemia 18 months post RCT - at risk ‘DD’ Vs ‘Non DD’ 

































In line with main HypoCOMaSS study, the majority of the participants in this sub 
study were female and they had almost 3 decades of diabetes, with sub-optimal 
glycaemic control. There were no differences between ACE genotypes in terms 
of gender, age, HbA1c or duration of diabetes. Study Interventions (allocated by 
chance randomisation) were similarly distributed across the genotypes. In 
keeping with previous studies, serum ACE level was significantly higher in DD 




   
There were no differences between ACE genotypes in the baseline rates of 
severe hypoglycaemia (DD 9.4±3.0, Non DD 8.2±1.6 episodes/person/year). 
The main finding was that, following clinical optimisation during the RCT period, 
episodes of severe hypoglycaemia were reduced both in risk DD and Non DD 
(ID/II) ACE genotypes but residual SH was significantly high in DD ACE 
genotype [(DD 1.44±0.48, Non DD 0.37±0.17 episodes/person/year, p0.009)] 
and remained significant even when examined without ACEI therapy. 
Many non-biologic or ‘environmental factors’ including diabetes education, self-
management skills, hyperglycaemia avoiding behaviour,  psychosocial issues, 
behavioral factors[107, 271] could have potentially contributed to SH at baseline 
in the participants at HypoCOMPaSS study. When these non-biologic factors 
were minimized during the RCT period, this might have enriched the underlying 
genetic factors contributing to SH in these participants. This could explain why 
we saw higher rates of SH in at risk DD ACE genotype compared with other 
genotypes during the RCT but not at baseline (where overall rates were higher 
and likely that many contributors to this).  When SH episodes were further 
examined at 6 months, 12 months and 18 months post RCT follow up period, 
the difference was lost although the SH rates remained numerically higher in DD 
ACE genotype.  One obvious explanation is that that the difference was lost 
during the follow up period when environmental and behavioural factors were 
again more prevalent following the end of the intensive RCT support period.  
This reinforces the concept that environmental factors largely contribute to SH 




   
I also tried to examine what the potential mechanism for an effect of ACE 
genotype to alter SH risk might be. There was no effect of the genotype on 
magnitude and duration of biochemical hypoglycaemia measured using blinded 
CGM.  Furthermore, there was no effect of genotype on impaired awareness of 
hypoglycaemia status as the proportion of participants whose IAH status 
improved or awareness to hypoglycaemia restored were similar in both DD and 
non DD ACE genotype. So, my findings show that DD ACE genotype is 
associated with residual risk of severe hypoglycaemia during study period 
without significant difference in improvement in IAH or indeed exposure to 
hypoglycaemia as compared to non-risk group. 
I therefore examined the clamp data to try to understand mechanistically why 
this might be the case. 
Counter-regulatory responses in the DD ACE genotype were no less as 
indicated by metanephrine responses which were similar in both genotypes (and 
if anything, the response was on the higher side in DD group). Similarly, there 
were no differences in the autonomic or total neuroglycopenic symptom scores. 
However, cognitive function as assessed by the most cognitively demanding of 
the Stroop tests, the Stroop Colour Word, deteriorated earlier during stepped 
clamped hypoglycaemia. I also found a trend towards a greater deterioration in 
4 CRT and a trend towards greater symptomatic scores of cognitive 
dysfunctions in the DD group.  Although this did not reach statistical significance, 
these are clinically significant. 
I also found that in DD ACE genotype cognitive function deteriorated at earlier 
glucose values when measured by Stroop Colour Word before the subjects 
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developed hypoglycaemic symptoms.  In contrast, participants with the “non-risk 
“genotype felt low before their cognitive function started to decline.   
A limitation of the “end of RCT” clamp sub group analysis is the fact that this 
may not be sufficiently powered to show differences due to the smaller number 
of participants in each category.  Nevertheless, this may be a significant signal 
which merits replication in larger studies in future.  
Although Gold score is a validated tool it does not characterise IAH.  
Furthermore, it does not detect change in IAH.  [122, 272].  So, my findings may 
have been limited by this.  Recently a new questionnaire has been designed to 
address this issue[272]. 
   
My findings are consistent with the previous Scandinavian studies in the UK 
cohort, showing that the DD ACE genotype is associated with increased risk of 
severe hypoglycaemia[226, 228].  Furthermore, my data suggest that this might 
be mediated via greater cognitive dysfunction during hypoglycaemia in DD 
group and less in the presence of at least one copy of the I allele. This would be 
consistent with the data showing that the I allele seems to be associated with a 
greater tolerance of reduced substrate delivery e.g. in endurance athletes.  The 
DD genotype neither increased the risk of biochemical hypoglycaemia nor 
awareness of hypoglycaemia but affected people’s ability to take action during 
mild hypoglycaemia episode, thus putting them at risk of severe episode (SH).  
One possibility is that preserved cognitive function in II/ ID genotypes allows 
somebody with T1D the opportunity to take judicious action once symptoms alert 
to prevent a further fall into deeper hypoglycaemia resulting in a severe episode. 
By contrast, an earlier deterioration in cognitive function in DD genotype during 
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hypoglycaemia (and thus judgement / decision making) might result in a greater 
propensity for a falling glucose to result in severe hypoglycaemia.  
The findings of the study also raise the possibility that altering brain RAS activity 
therapeutically might even protect cognitive function and reduce risk of severe 
hypoglycaemia in those with T1D at risk of exposure to low blood glucose. I 
speculate that altering ACE activity therapeutically by brain-penetrant ACEI 
therapy in a selected at risk T1D people might protect against severe 
hypoglycaemia [270]. Some observational “population” data appear 
contradictory to this finding with some showing increased hypoglycaemia in 
people treated with ACEI perhaps attributable to a prescribing bias (e.g. avoiding 
other anti-hypertensives such as beta-blockers in those with problematic 
hypoglycaemia) and/or only certain ACEI being centrally active[254, 273]. For 
example, Ramipril, Trandolapril, Captopril, Fosinopril and Lisinopril cross the 
blood-brain barrier[274].  Other potential compounding factors like insulin effect 
and behavioural aspects of the people were overlooked in these retrospective 
studies [273, 275, 276]. Essentially these population studies had confounding 
environmental factors contributing to the SH.  This study has minimised these 
factors and has studied residual SH risk.  
 
In summary, my findings support the broad hypothesis that certain people may 
be at greater risk of hypoglycaemia due to their underlying biology, an important 
point for clinicians aiming at intensifying glucose control in diabetes.  
I speculate that future systemic treatment with brain-penetrant ACEI in T1D 
people with DD ACE genotype and high serum ACE might reduce brain RAS 
signalling and thus protect against cognitive dysfunction during hypoglycaemia.  
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One of the challenges of performing trials studying ACEI and severe 
hypoglycaemia is that majority of people with T1D are likely to be on ACEI 




   
4 Accuracy & Use of  a novel Continuous 
Implanted Glucose Sensor  
 
 Background  
 
This study extends my interest in looking for methods to improve hypoglycaemia 
burden in people with type 1 diabetes. As a treatment modality, CGM has been 
shown to improve glycaemia and/or reduce time spent in hypoglycaemia and is 
approved by NICE for T1D people with disabling hypoglycaemia [62, 182]. 
However, the benefits of these traditional CGM systems are dependent on 
adherence with the system as discussed in previous chapters [70, 80, 277]. 
Some factors including adhesive issues, skin reactions and the need to change 
/ reinsert the sensor every few days can limit use and nullify potential 
benefits[278].  
The Senseonics Continuous Glucose Monitoring System CGM [(Senseonics 
CGM System), now called Eversense® CGM System (Senseonics, Inc., 
Germantown, MD, USA] is a novel implantable glucose monitoring device [279, 
280]. The Eversense® CGM system as commercially available consists of a 
glucose sensor implanted in the upper arm, a transmitter which is worn over the 
sensor attached using adhesive and the application (app) in a mobile platform 
which displays glucose continuously.   
The sensor of the system is a micro-fluorometer that is encased in a translucent 
biocompatible polymer capsule. It consists of glucose-indicating fluorescent 
hydrogel, light emitting diode and antenna. Glucose concentration is measured 
by means of fluorescence from the glucose-indicating hydrogel, which is 
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polymerized onto the capsule surface over the optical cavity. The light emitting 
diode serves as the excitation source for the hydrogel.  The antenna receives 
both power and communication from externally worn transmitter. The final 
information is transmitted to smart phone via bluetooth [279, 280]. In contrast to 
other traditional CGM systems which utilize electrochemical enzyme-based 
glucose sensors, in this system no chemical compounds are consumed or 
formed, and the glucose-indicating hydrogel is not subject to the instability 
characteristics of enzymes[279-282]. 
This implantable CGM is indicated for continually measuring interstitial fluid 
glucose levels in adults with diabetes for period lasting between 3 to 6 months 
(latter in Europe). 
A key part of the evidence allowing the licensing of the Eversense® system was 
the pivotal European PRECISE 1 study (and the subsequent US PRECISE II 
study).  Cambridge was a study site within PRECISE1 study and I was the 
research fellow involved and responsible for all aspects of the study in 
Cambridge.  As described below, there were some minor differences in the 
hardware of the system trialled compared with the final commercial product. The 
transmitter size was smaller in the trial.  By design, this was not a study looking 
to see whether using the system improved glycaemic outcomes such as reduced 
hypoglycaemia but rather a study to examine efficacy and safety of this novel 
CGM system.  In this chapter, I present data below from the Cambridge cohort 





   
 Study Objective 
 
The primary efficacy end point of the study was the accuracy of the Senseonics 
CGM System compared with a standard reference measurement (YSI glucose 
analyzer) as mean absolute relative difference (MARD) This was assessed 
during in-clinic visits. 
The primary safety objective was to assess device related serious adverse 
events of this system.   
Secondary end points included Error Grid Analysis and alarm performance. I 
also explored quality of life and a device-related questionnaire. 
 
 Study Design and Methods 
This was a prospective, single‐arm, multi‐centre investigation enrolling 81 adults 
with diabetes mellitus across 6 sites in Europe subjects.  Five of the 81 subjects 
were used for platform and procedure evaluation and five were designated for 
site training. The intent-to-treat analyses of the primary efficacy outcome thus 
included 71 participants. Below, I have presented data from the Cambridge 
cohort within this trial that I was personally responsible for studying. 
 
 Participants 
Between July 3, 2014 and March 5, 2015, 10 adults with T1D were enrolled from 
the Wolfson Diabetes Endocrine clinic in Cambridge University Hospitals NHS 
Trust (Addenbrooke’s Hospital), Cambridge as a part of multicentre study.  
Inclusion criteria for the study were: 
1. A clinical diagnosis of Type 1 diabetes more than 1 year from diagnosis 
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2. age 18 years or above  
3. on insulin therapy  
4. willing to comply to study with protocol requirements 
  
Exclusion criteria for the study were: 
5. history of severe hypoglycaemia as defined by American Diabetes 
Association[110] in preceding 6 months 
6. diabetic ketoacidosis in the past 6 months 
7. females who were lactating or pregnant or intending to become pregnant 
during the course of the investigation 
8. any condition preventing or complicating the placement, operation or 
removal of the sensor 
9. any skin condition that may affect sensor insertion or transmitter 
placement 
10. any medical condition or illness that in the judgment of the investigator 
might interfere with the procedures, results or compliance during the 
course of this investigation, including anaemia, symptomatic coronary 
artery disease, unstable angina, myocardial infarction or stroke within 6 
months of screening, uncontrolled hypertension (defined as systolic 
pressure >160 and diastolic pressure >100), congestive heart failure, any 
seizure disorder, renal failure defined as any prior dialysis or an estimated 
glomerular filtration rate (eGFR) below 60 mL/min per 1.73 m2 using 
CKD-EPI formula[284], history of cardiac arrhythmia 
11. currently receiving any of the following therapies, or likely to need such 
treatment during the follow-up period of this study a) immunosuppressant 
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therapy b) chemotherapy for any form of cancer c) anti-coagulant therapy 
d) chronic systemic glucocorticoids (excluding topical, optical or nasal, 
but including inhaled e) antibiotic treatment for chronic infection (e.g. 
osteomyelitis) 
12. presence of any other CGM system with a transmitter located in either 
upper arm 
13. any condition requiring or likely to require the use of magnetic resonance 
imaging (MRI)  
 Study design and procedures 
This was a prospective, single‐arm, multi‐centre investigation. 
Details of the study design have been summarised in subsequent sub section 
in this chapter and is also shown below. 
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The study protocol, participant information sheets and consent forms were 
approved by an independent Research Ethics Committee (NRES Committee 
Yorkshire & The Humber – Sheffield) and the study was carried out in 
accordance with the Declaration of Helsinki.  Written informed consent was 
obtained from each participant.  The investigation included 11 in‐clinic visits to 
the Wellcome Trust Clinical Research Facility (WTCRF) as described later. 
 
 Senseonics CGM system  
Senseonics, Inc. (formerly Sensors for Medicine and Science, Inc. or “SMSI”), a 
medical device manufacturer headquartered in Germantown, Maryland, USA, 
developed a currently novel CGM system intended for measuring interstitial fluid 
glucose levels in adults with diabetes mellitus. The Senseonics CGM system 
measures interstitial fluid glucose levels continuously. Other commercially 
available transcutaneous continuous glucose monitoring devices currently have 
shorter operating lives of up to 7 days. The Senseonics sensor is intended to be 
inserted subcutaneously with no sensor part protruding from the skin and the 
operating life is intended to be up to 6 months or until the end of life indicator is 
reached. 
The experimental Senseonics CGM System that I studied consisted of:  
1. A small Sensor, (approximately 3.3 mm [0.130”] diameter x 15.7 mm 
[0.620”] length) which has a ring that elutes the steroid dexamethasone 
(Figure 4-2).  
2. A battery‐powered external Transmitter (“Transmitter”) (Figure 4-3)   
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3. A mobile Medical Application for display of glucose information that runs 
on a Handheld Device [(HHD- Apple Inc. (iPod)](Figure 4-4). 
 
 




Figure 4-3 Transmitter 




   
 




Accessories to the system include  
1. A blunt dissector (Figure 4-5 ) for creating a pocket under the skin. 
2. An insertion tool (Figure 4-6 ) used to place the sensor into the pocket.  
3. A transmitter, worn externally over the sensor insertion site (Figure 4-7), 
which powers the sensor and receives signals from the sensor across the 





   
 












   
 
 
The sensor does not contain a battery or other stored power source; instead it 
is powered discretely, as needed, by a simple inductive magnetic link between 
the two components. Between readings, the sensor remains electrically dormant 
and fully powered down. At each query (set to a default of approximately every 
five minutes with a duration of 60 milliseconds) the transmitter first sends the 
power (via magnetic link) to activate the sensor, then uses this same magnetic 
link to capture the reading. This operational mode is commonly referred to as 
“speak when spoken to”[285]. 
The transmitter calculates the measured glucose value, the rate of change in 
glucose and all alarms that need to be alerted to the user. This information is 
then transmitted via bluetooth low energy with AES‐CCM encryption to the 
Mobile Medical Application. The Mobile Medical Application displays glucose 
values, trends, and graphs as well as alerts. In addition, the wearer can be 
alerted where necessary through activation of the vibratory motor within the 
transmitter worn on the skin. The transmitter also contains digital storage media 
that enable extended data and profile information to be retrieved, downloaded 
to a computer or other electronic device, and reviewed by the physician or 
subject[285]. 
The limited efficiency of the inductive magnetic link limits the range for both 
power and signal “telemetry” to less than 2 centimetres. This intrinsic limitation 
of physics benefits the design by reducing the potential for crosstalk and 




   
 Visit  Schedules 
On a screening visit, following history, general physical examination and 
laboratory evaluation, the subject’s eligibility was determined.  Eligible subjects 
were then recruited for the study and invited for sensor insertion.  Each subject 
had 2 sensors inserted on Visit 2 (Day 0) in upper arms with one sensor 
designated as primary sensor. Subjects were asked prior to insertion which arm 
they preferred as the primary sensor: self‐reported dominant arm or self‐
reported non‐dominant arm. The suggested primary sensor was in the non-
dominant arm. Subjects then attended the Wellcome Trust Clinical Research 
Facility (WTCRF) for 8 further in‐clinic visits, consisting of three 8‐hour daytime 
study visits (Days 1, 90, and 150) and five 24‐hour overnight visits (Days 14, 30, 
60, 120, and 180) to evaluate sensor performance. Sensors were removed at 
the completion of Visit 10 (on Day 180) or earlier if the life of sensor was prior to 
day 180.  Subjects then attended for a final follow up visit (Day 190) to evaluate 
healing of sensor removal sites. Between in‐clinic visits, subjects wore the 
transmitter over the sensor at home except during transmitter charging, bathing 
or any other water activity.  
Subjects and clinicians were display‐blinded to all Senseonics CGM system 
glucose values during the in‐clinic visits. The glucose alert/alarm features of the 
Senseonics CGM Mobile Medical Application were unavailable while the 
subjects were display‐blinded. Of note, subjects were given access to the 
glucose data collected on the transmitter including glucose alerts/alarms, during 
home use i.e. for the majority of the study period. Of note, this was an important 




   
 
 24‐Hour Overnight Visits 
Each overnight visit was approximately 24 hours in duration. Changes in the 
subject’s concomitant medications, medical conditions, and the occurrence of 
medical adverse events since the last visit were reviewed.  The subject’s total 
diabetes and medication history was reviewed at each visit. An intravenous 
cannula was placed for blood sampling.  In addition, blood was drawn for a Full 
Blood Count and dexamethasone measurement Full blood Count was done to 
check anaemia status as a safety management. The Full Blood Count was 
analysed in the clinical haematology laboratory at Addenbrooke’s Hospital. 
Dexamethasone was measured to ensure there was no systemic absorption of 
the dexamethasone from the sensor. The samples for dexamethasone were 
stored at minus 80 degree for later measurement. Both transmitters were placed 
over the sensors at least 30 minutes prior to the first blood draw and sensor 
readings were taken throughout the visit.  The secondary sensor was used and 
calibrated in 8hr visits only.  Here I present primary sensor data. 
Venous blood samplings were performed for plasma glucose determinations 
using YSI in WTCRF.  Blood sampling for plasma glucose were performed at 
15‐minute intervals during the daytime (7:00 – 23:00) and at 2‐hour intervals 
during the night-time (23:00 – 7:00) for a total of approximately 24 hours.  More 
frequent sampling was done at glucose values ≤4.44mmol/L to ensure subject 
safety.  This sampling was no more frequent than every 5 minutes and did not 




   
Subjects were required to perform at least two Capillary Blood Glucose testing 
(CBGT) for calibration. CBGT in the clinic were done concurrent with or prior to 
(within 5 minutes) blood draws taken for plasma glucose determinations. 
A subset of subjects was exposed to a mixed meal challenge with the 
expectation of raising the glucose level to >11.10 mmol/L for >30 minutes 
followed by the induction of hypoglycaemia with an insulin bolus at ~4 hours 
after the start of the mixed meal challenge to reach a glucose level of ~3.06 
mmol/L with subsequent carbohydrate rescue. The sequence of the mixed meal 
and hypoglycaemic challenge was determined based on clinical feasibility on 
the day of each visits.  
Menu for the mixed meal challenge was designed after discussion with the 
dietitians and is attached in the Figure 4-8. 
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The Insulin doses for hypoglycaemia induction was cautiously decided based 
on participant’s insulin: carbohydrate ratios; glucose correction factor and 
precedent physical activity as well.  Participants used their own brand of bolus 
insulin. Some individuals needed more than one bolus insulin dose to achieve 
target glucose level of 2.9mmol/L or less.  Investigators were encouraged to 
perform these challenges to allow a range of glucose values to be created but 
these were not mandatory. Subjects without defined insulin: carbohydrate ratios 
and glucose correction factors, as well as subjects and those at high risk for 
complications due to hypoglycaemia or hyperglycaemia did not undergo the 
mixed meal or hypoglycaemia challenges.  
Free choice of meals and snacks was served meals to the subjects at other 
times of the day. Subject used their usual home insulin regimen for meal insulin 
coverage.  In fact, mixed meal or hypoglycaemia challenges were not performed 
after the first few months of the study as the emerging experience was that 
sufficient glucose values in hypoglycaemia and hyperglycaemia range were 
experienced without participants needing to be subjected to experimental 
manipulation.  Approximately 75 blood samples were obtained at each 24‐hour 
overnight visit.  
 8‐Hour Daytime Visits 
Each daytime visit was approximately 8 hours in duration. The study procedure 
was similar to the 24 hours visit with the exception that venous sampling for 
determination of plasma glucose sampling period was for 8 hours during the day 
and subjects did not stay overnight. A free choice of meals and snacks was 
served, and the subjects used their own home insulin dosing parameters to 
cover the meals. Subjects did not undergo mixed meal or hypoglycaemia 
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challenges during 8-hour visit.  Approximately 33 blood samples were obtained 
at each 8‐hour visit. 
 Home Use Days 
Subjects maintained their normal daily activities during home use days and used 
the study-supplied glucometer to self-manage their diabetes. Participants were 
advised to check their home blood glucose profile at least 4 times a day using 
study supplied CE-marked ACCU-CHEK® Aviva self‐monitoring blood glucose 
(SMBG) meter (Roche Diagnostics GmbH, Germany) using ACCU-CHEK Aviva 
test strips (distributed by Roche Diagnostics Ltd, West Sussex, UK). Subjects 
were provided with a transmitter to wear over the sensor at all times (except 
while charging, bathing or during any other water activities) from the end of 
insertion visit until the end of visit of the study. Subjects were provided with a 
handheld device [(HHD- Apple Inc. (iPod)] capable of running the Mobile 
Medical Application. Subjects were prompted by MMA for calibration by SMBG 
measurements (a minimum of 2 each day, approximately 12 hours apart and 
pre‐meals) using the study glucometer. Subjects were trained in proper sensor 
calibration on the day of sensor insertion. Subjects were asked to charge the 
transmitter each day for 15 mins according to verbal and written instructions. 
Subjects were allowed to observe the glucose values displayed from the primary 
transmitter while successfully calibrated between in‐clinic visits. Glucose alert 
and alarm features of the primary transmitter were functional. The study 
glucometer meter was used to document the time of each CBGT and incidents 
of hypo‐ and hyperglycaemia.   
Incidents of hospitalization due to hypoglycaemia, hyperglycaemia and 
ketoacidosis were documented at the subsequent in‐clinic visit. 
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 Sensor Calibration 
Briefly, the system required calibration of the sensor from the readings from their 
Accu-chek Aviva meter. The sensor calibration automatically moved through 
three phases: warm up, initialization, and daily calibration. The warm up duration 
was the first 24 hours after insertion and glucose values were not displayed. 
Initialization was performed a minimum of 24 hours after sensor insertion. 
Following the warm up phase, entering four successful calibration SMBG 
readings within 24 hours were required for successful completion of sensor 
initialization phase. Glucose values were displayed after the second SMBG 
reading in the initialization phase was successfully entered. Daily calibration 
updates required entering 2 calibration SMBG readings. 
If the subject failed to wear the transmitter for more than 24 hours or was unable 
to enter a successful calibration SMBG measurement, then glucose was not 
displayed, and the patient would have to re‐enter the initialization phase. 
 Safety Management 
Baseline safety laboratory tests conducted at screening visits were: Full Blood 
Count, Coagulation profile, Electrolytes, Liver Function tests, Dexamethasone 
& Iron level. In each subsequent in- clinic visits, blood sample were taken for 
dexamethasone determination.  
During in clinic visits, standard protocols were followed in the event of 
hyperglycaemia, hypoglycaemia and ketosis. Briefly, glucose levels <3.33 
mmol/L were treated with carbohydrate and glucose levels >16.67 mmol/L were 
treated with correction insulin as appropriate per clinic standard‐of‐care. 
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In each subsequent visit, blood sample were taken for dexamethasone 
determination. Blood dexamethasone concentration was measured to ensure 
the dexamethasone from sensor was not absorbed systemically. 
 Other Laboratory Tests 
HbA1c was measured at visit 3 (day 90) and Visit 10 (day 180) or earlier if the 
designated time for sensor removal was reached. 
 Quality of Life Measures 
Quality of Life was assessed using validated health questionnaires at screening 
visit, visit 3 (day 90) and Visit 10 (day 180) or earlier if the designated time for 
sensor removal was reached. However, the CGM Impact Scale was not done at 
baseline but at the end of 3 months or earlier if the designated time for sensor 
removal was reached.  
 
Subjects completed the following questionnaires: 
 Beck Depression Inventory II (BDI‐II)  
This contained 21 questions that were scored on a scale value of 0 to 3. Higher 
total scores indicate more severe depressive systems[286]. 
 Diabetes Quality of Life Measure (DQOL)  
This contained 46 questions that were scored on a scale of 1 to 5. Higher scores 
indicate higher quality of life[287]. 
 CGM Impact Scale  & Device Acceptance questionnaires  
 This is a scale containing 16 items [288]  intended to gauge impact of CGM on 
various aspects including behavioural, cognitive and emotional domain.  
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Furthermore, 33 customised questionnaires were also developed with a view to 
assess user acceptance to this CGM system[289]. This was assessed at the 
end of the 3 months of the study or earlier if the designated time for sensor 
removal was reached.  
 Sensor Insertion Procedure 
Two sensors were inserted in each subject’s upper arms (Day 0) with the 
primary sensor inserted in the participant’s self-reported non dominant hand 
unless participants preferred to use the dominant arm. All the sensors in 
Cambridge were inserted by me under local anaesthesia following aseptic 
precautions as per the hospital protocol policy.  Study supplied insertion tools 
were used for the procedure. The sensor site was marked and documented. 
 Sensor removal Procedure 
Sensors were removed on Visit 10 (Day 180) or earlier when the designated 
time for sensor life was reached. Sensor removal was done by me under local 
anaesthesia (except one- as described below) following full aseptic procedure 
as per the hospital protocol.  
 Analytical methods: 
Arterialized plasma glucose was measured using a Yellow Springs analyser 
(YSI STAT Plus, Farnborough, UK, intra- assay coefficient of variation (CV) 1.5 
% and inter assay CV 2.8 %). 
HbA1c was measured with ion exchange high-performance liquid 
chromatography (G8 HPLC Analyzer, Tosoh Bioscience, CA, USA; inter-assay 
coefficients of variation 1.3% at 31.2mmol/mol, 0.8% at 80.5mmol/mol). 
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Dexamethasone was measured using a highly sensitive liquid chromatography 
–tandem mass spectrometry with a lower limit of detection of 2ng/mL[290]. 
 
 Statistical analyses 
Numerical and clinical accuracy outcomes were calculated using Sigma Plot 
version 9.0 (Systat Software, Inc., San Jose California USA) and statistical 
analyses were conducted using SPSS version 21(IBM Software, Portsmouth, 
United Kingdom). Data were compared using the paired t-test. Results are 
presented as mean±SEM.  All p-values less than 0.05 were considered 
statistically significant. 
 
Senseonics CGM System sensor accuracy was evaluated using data collected 
during in clinic use. Numerical accuracy was assessed by overall mean of 
absolute relative deviation (MARD) where ARD is the absolute relative 
difference of paired (within 5 minutes) Senseonics CGM system and YSI 
readings divided by the YSI reading for YSI readings. Main measured outcomes 
included mean ARD for overall pairs in all glucose range, pairs in the 
euglycaemic range (4.0–10.0mmol/l), hypoglycaemic range (≤3.9mmol/l) and 
hyperglycaemic range (>10.0mmol/l) stratified according to reference plasma 
(YSI) glucose measurements.  





   
The % of data points of the Clarke Error Grid was used to evaluate clinical 
accuracy.  Clinical accuracy was assessed using the Clarke Error Grid Analysis 
(EGA) [291]. The EGA takes into account not only the difference between the 
system‐generated and reference blood glucose values but also the clinical 
significance of this difference. The grid breaks down a scatterplot of a reference 
glucose meter and an evaluated glucose meter into five regions: 
1.  Region A contains values within 20% of the reference Sensor 
2. Region B contains values that are outside of 20% but would not lead to 
inappropriate treatment 
3. Region C contains values leading to unnecessary overcorrection in treatment 
4. Region D contains values indicating a potentially dangerous failure to detect 
hypoglycaemia or hyperglycaemia 
5. Region E contains values that could lead to errors in treatment of 
hypoglycemia for hyperglycaemia and vice‐versa 
Percent of measures in the clinical accuracy Zone A was estimated along with 
95% confidence interval.  
A Bland-Altman analysis plot was used to compare the limits of agreement 
between Senseonics continuous glucose sensor and YSI glucose values. This 
plot compared the difference in readings between the Sensor and YSI to the 
average of the two readings across the accuracy evaluation period.   
 Alarm Performance (Low/High Alert/Alarm):  
An important usability and acceptability aspect of all CGM systems is whether 
the alarms function effectively and accurately, allowing detection of a blood 
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glucose that is out of range (particularly hypoglycaemia) without an 
unacceptable number of false alarms. 
The glucose alert and alarm performance of the Senseonics CGM System was 
evaluated retrospectively on sensor data collected. For the alarm performance 
evaluation, the following definitions were used:    
1. Hypoglycaemic event: Two or more successive YSI measurements 
below the alarm threshold or one YSI measurement 0.33 mmol/L below 
the alarm threshold.       
2.  Hyperglycaemic event: Two or more successive YSI measurements 
above the alarm threshold or one YSI measurement 6% above the alarm 
threshold.  
3. True Threshold Alarm: A threshold alarm that occurred ±30 minutes 
from the start of a hypoglycaemic or hyperglycaemic event.     
4. True Alarm Rate:  The percentage of time the glucose level was beyond 
the threshold and an alarm was activated. 
True alarm rate = events detected by true threshold alarms / total 
events x 100    
5. Missed Alarm Rate: 
The percentage of time the glucose level was beyond the threshold and 
an alarm was not activated.     
Missed alarm rate = events not detected by true threshold alarms / total
 events x 100    
6. False Threshold Alarm: 
A threshold alarm that occurred when YSI measurement within ±30       
minutes was not beyond the threshold setting.     
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7. False Alarm Rate: The percentage of time an alarm that occurred when 
the glucose level was not beyond the threshold setting.     
False alarm rate = false threshold alarms /total threshold events x 100. 
 
Projected alarms occurred when the glucose value and the rate of change of  
glucose predicted the crossing of an alarm threshold at a future time determined
 by the sensitivity setting – the low sensitivity was 10 minutes, the medium 
sensitivity was 20 minutes, and the high sensitivity was 30 
minutes. Projected alarms were designed to alert the patient to the possibility of 
a future high or low glucose event. The above performance parameters were 





One Cambridge participant was withdrawn from the study, two weeks after the 
insertion of sensor, due to a medical reason unrelated to the study procedure or 
devices (suspected chronic fatigue syndrome). This participant’s CGM data prior 
to being withdrawn were used for analysis of accuracy of CGM. 
 In Cambridge, the mean life of all sensors was 100±16 days (mean±SEM). Life 
of sensor reached 6 months in 2 participants.  The average number of clinical 
sessions was 5.56±1.88 and number of days use was 105.8± 50.23. Duration of 
home use was 101.68±48.85 days (mean ±SEM). Data from all 10 participants 




   
 





Table 4-1 Baseline characteristics 
 Adults  
(n=10) 
 
Age (years) 37.6±3.2  
Gender (male/female) 4 / 6  
Insulin regime (CSII/MDI) 8/1  
Body mass index (kg/m2) 28.3±1.2  
Haemoglobin A1c (%) 8.1±0.2  
HaemoglobinA1c (mmol/mol) 65.0±2.6  
Duration of diabetes (years) 17.4±2.8  





 Sensor numerical accuracy 
The total number of days that participants spent between sensor insertion and 
sensor removal (or earlier if designated time of sensor reached) in Cambridge 
was 1044 days. The total duration of sensor use for the whole Cambridge cohort 
was 21,880 hours. This was equivalent to 96% of total study duration.  
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A total 313,448 sensor data points were collected during inpatient clinical visits. 
A total of 2431 sensor–YSI glucose pairs (within 5 minutes) were available for 
the analysis. The overall numerical sensor accuracy expressed as mean ARD 
was 11.8±0.2 % (Table 4-2).  The mean ARD in the euglycaemia (4-10 mmol/l 
range) was 12.6±0.3 % (N = 1,434 pairs). Senseonics CGM System sensor 
accuracy as measured by mean ARD was lowest in the hyperglycaemic range 
[(>10.0 mmol/l) (9.8±0.3%, N = 935 pairs)]. The mean ARD was highest in the 
hypoglycaemic range [(≤3.9 mmol/l) (mean ARD 26.0±3.8%, N= 62 pairs)] & 
[(≤3.0 mmol/l) (mean ARD 59.4±3.8%, N= 6 pairs)]. However mean AD in the 
hypoglycaemic range was 0.9±0.1 mmol/l (≤3.9 mmol/l) & 1.6 ±0.8 (<3.0 mmol/l) 
Of note, sensor accuracy was significantly reduced in the 6th month of use, p 






   
Table 4-2 Sensor accuracy for Cambridge participants for the whole glucose range and 
stratified according to reference glucose (YSI) during the clinic visits  






Table 4-3  Sensor accuracy for Cambridge participants for the whole glucose range and 
stratified according to month since transplant during the clinic visits. 
Month (s) since implant   Number*    ARD     
 
1   10 10.6±0.3 
2  9 11.1±0.4 
3  5 11.5±0.5 
4  4 12.8±0.6 
5  2 9.5±0.9 
6 2 21.2±0.4 
   
Data are mean± SEM  





































11.8±0.2 12.6±0.3 9.8±0.3 26.0±3.8 59.4± 29.9 
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 Sensor clinical  accuracy 
In Cambridge participants, the Senseonics CGM System sensor had 99.3% of 
measurements in CEG zones A + B [(A: 81.71%, B: 17.6%, C: 0.0%, D: 0.7%, 
E: 0.0 %) as shown in Figure 4-9. 
 
 
Figure 4-9. Clarke error grid of sensor and YSI  
 
Solid black line represents the mean difference between the sensor and capillary glucose 







   
Information related to sensor accuracy over the range of glucose values 
defined is shown in Bland –Altman in Figure 4-10 
 
 
Figure 4-10: Bland-Altman plots of sensor and YSI glucose  
 
Solid black line represents the mean difference between the sensor and capillary glucose 




 Glycaemic control  
The study was not designed / powered to study changes in HbA1c. There were no 
significant changes in HbA1c during the study period. (Table 4-4). 
  
 
Table 4-4. Comparison of change in HbA1c and QOL Health questionnaires at the end 
of study compared to baseline values  
 Baseline  3 months    
6 months/End of 
Study   
 















    
    




   
 
 
 Hypoglycaemia  
Time spent in hypoglycaemia (<3.0 mmol/l) during the study period (home use) 
based on sensor glucose data decreased in the second month (0.8%) compared 
to the first month (1.1%). This was sustained until 3rd month (0.8 %) but rose in 
subsequent months ( Table 4-5). 
 
Performance of CGM in clinic alarm for hypoglycaemia threshold (glucose 
values ≤3.9 mmol/L) showed a True Detection Rate of 100 % with a false alarm 
rate of 43 % ( Table 4-6).  Alarm performance for glucose values below 3.0 
mmol/l could not be analysed as alarm threshold was already set for higher 




   
 
Table 4-5.  Percentage of time spent on hypoglycaemia over time based on Sensor 
glucose data during study duration (home and clinic use)  
Months  
 
Time spent on Hypoglycaemia 
(Glucose (<3.0 mmol/l ) 
  























 % (n/N) % (n/N) % (n/N) 




   
 
 QOL Health questionnaire 
QOL Health questionnaires at baseline, 3 months and 6 months / end of the 
study is shown in Table 4-7. 
 
 
Table 4-7. Comparison of change in QOL Health questionnaires at the end of study 
compared to baseline values  
 Baseline  3 months    6 months/ End of study  
 






DQOL 64±8 54±5 64±7 
  N=9 N=6 




Overall QOL score did not change significantly at 3 or 6 months compared with 
baseline (Table 4-7). This is perhaps not unexpected as this is a broad scale 
examining generic quality of life.  
However, CGM had much positive impact on their perception of diabetes self-
management. 67 % felt that they were more motivated to manage their diabetes. 
CGM had brought element of safety among participants with 83.3 % reporting 
feeling safer during exercise and 50 % during sleep. 67 % reported less fear of 
hypoglycaemia and same proportion were confident of avoiding serious 




   































































1. Do you now feel more confident or less 
confident that you can control your diabetes? 
2.00±0.26 16.7% 66.7% 16.7% 0.0% 0.0% 
2. Do you now feel more or in control or less 
in control of your life and your diabetes? 
2.33±0.21 0.0% 66.7% 33.3% 0.0% 0.0% 
3. Do you now feel more hopeful or less 
hopeful that you can avoid long-term 
complications? 
2.50±0.22 0.0% 50.0% 50.0% 0.0% 0.0% 
4. Do you now feel more motivated or less 
motivated to keep up with your diabetes 
management? 
2.17±0.31 16.7% 50.0% 33.3% 0.0% 0.0% 
5. Is it now harder or is it easier to adjust your 
insulin doses correctly? 
2.50±0.34 16.7% 16.7% 66.7% 0.0% 0.0% 
6. Have your blood glucoses become more or 
become less of a “roller coaster”? 
2.50±0.34 16.7% 16.7% 66.7% 0.0% 0.0% 
7. Has your A1C improved or has it 
worsened? 
2.50±0.34 16.7% 16.7% 66.7% 0.0% 0.0% 
8. Do you now feel more free or less free to do 
the things in your life you really want to do? 
2.67±0.33 16.7% 0.0% 83.3% 0.0% 0.0% 
9. Do you now feel more safe or less safe 
when exercising? 
1.83±0.31 33.3% 50.0% 16.7% 0.0% 0.0% 
10. Do you now feel more safe or less safe 
about sleeping? 
2.33±0.33 16.7% 33.3% 50.0% 0.0% 0.0% 
11. Do you now feel more fearful or less 
fearful about hypoglycemia? 
2.00±0.37 33.3% 33.3% 33.3% 0.0% 0.0% 
12. Do you now feel more confident or less 
confident that you can avoid serious 
hypoglycemia? 
2.00±0.37 33.3% 33.3% 33.3% 0.0% 0.0% 
13. Do you now feel more safe or less safe 
while driving? 
2.17±0.40 33.3% 16.7% 50.0% 0.0% 0.0% 
14. Are your relationships with your family and 
friends now better or worse? 
3.00±0.00 0.0% 0.0% 100.0% 0.0% 0.0% 
15. Is your partner now worrying less or 
worrying more about sleeping at night? 
2.33±0.42 33.3% 0.0% 66.7% 0.0% 0.0% 
16. Are your friends and family now bothering 
you less or bothering you more about your 
diabetes? 





   
 Free Text Responses  
These were the free text responses from the participants about their view on this 
CGM system:   
1. ‘‘I was very impressed with CGM system’’ 
2. ‘‘I liked it. It was useful, easy to use, easy to wear’’ 
3. ‘‘Thought it was excellent. Found it much more accurate than other CGM’’ 
4. ‘‘Very positive, Brilliant’’ 
5. ‘‘Good for wearability and being able to walk away from the iPod without losing 
data but inaccurate and failed early’’ 
6. ‘‘Very good product’’ 
7. ‘‘Some alarms need to be worked on as low sensor temperature happened quite 
a lot and wouldn't display glucose for a very long time. Other than that, loved it’’ 
8. ‘‘Calibration was awkward especially when the ‘low temperature’ meant it would 
not read BGs & therefore calibration’’ 
9. ‘‘Really liked the accuracy and the graphics and ease of current BG & trend’’ 
10. ‘‘Ipod/transmitter issue was frustrating and placing the transmitter was a bit 
fiddly’’ 
11. ‘‘It was awkward to analyse more than few hours of data, the way it calibrates 
low temperature & calibration issue’’  
12. ‘‘High ambient light even with black arm band’’ 
13. ‘‘Brilliant once you get into routine of charging extra devices’’ 
14. ‘‘Alarms low sensor temperature would happen quite a lot’’ 
15. ‘‘Sometimes transmitter would get knocked on my arm. If the transmitter could 
be reduced in size, then the CGM system would be more appealing to me’’  
16. ‘‘Mildly annoying – just the warning high light and cold’’ 
17. ‘‘Dislike having to scroll data rather than see days of data altogether’’ 
18. ‘‘Sensor too cold alarms, transmitter falling off during exercise’’ 
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 Safety  
The CGM system was safe with no device related events. There was 1 report of 
mild inflammation post-extraction, but this did not result in a clinically significant 
infection.  Dexamethasone level remained below level of detection in all the 
participants for all the visits. This confirmed that there was no systemic steroid 
absorption from the sensor.  
One participant required surgical removal of sensor by surgeons as I failed to 








The objective of the study was to assess the efficacy and safety of this novel 
implantable continuous glucose monitoring sensor. 
 
The sensor had an accuracy similar to other current CGM systems with a MARD 
of 11.8 % for overall glucose values. MARD was higher in the hypoglycaemic 
range (26%) which is similar to other standard CGM[70, 72]. However mean AD 
was satisfactory in hypoglycaemic range at 0.9mmol/l. In our subjects, sensor 
accuracy was significantly worse during month 6. These data from the 
Cambridge cohort are comparable with the overall PRECISE I study findings 
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[MARD 11.6 % for overall glucose values and 21.7 % in hypoglycaemia range 
(defined as ≤4.2mmol/L in the PRECISE I paper)]. 
   
Importantly the sensor performed well on the clinically-weighted accuracy 
analysis. Specifically, there were no glucose values in Clarke Error Grid Analysis 
in Zone C (zone indicating risk of over-correction leading to hypoglycaemia). 
Further, there were no values in Region E (zone indicating potential errors in 
treatment of hypoglycaemia for hyperglycaemia and vice‐versa).   
Time spent in hypoglycaemia (below ≤3.0 mmol/l) was reduced within a month 
into the study period but this was not sustained beyond 3 months.  
The accuracy of CGM systems in general have much improved in the last 
decade or so with latest CGM’s MARD around 10 % as opposed to near 20 % 
MARD for earlier devices[72, 90].  For example, the first commercially available 
MiniMed CGM had MARD of almost 20 %. [60, 63, 70, 71]. The FDA recently 
approved a CGM device for non-adjunctive use (i.e. without the need to confirm 
this from SMBG) for insulin dosing with a reported MARD of less than 10 % [87].  
However, there is an ongoing debate about whether this cut of value of 10 % 
MARD for a CGM device to be considered for non-adjunctive use is appropriate. 
Shapiro and colleagues have suggested that this is a flawed approach [69, 88].  
However, Kovatchev et al. suggested that if a CGM device has MARD of 10 % 
or less, it would be feasible to use the device for insulin dosing based on a 
mathematical modelling study. The group went on further to conclude that 
increase of sensor accuracy below the 10% MARD threshold did not contribute 
substantively to better glycaemic outcomes. This however was based on 
assumption that the sensor produces reliable data without signal interruption or 
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loss of sensitivity[86]. It would be ambitious to believe that future CGM would 
completely eliminate errors in glucose measurement based on the way CGM 
measures interstitial glucose. 
The CGM system appeared to have a positive impact in their self-perception of 
diabetes with more than 4/5th reporting that they felt much safer during exercise 
and 2/3rd had less fear of hypoglycaemia and were confident to avoid serious 
hypoglycaemia having been on CGM for 3 months. The CGM in clinic alarm 
performed very well with True Detection Rate of 100 % for hypoglycaemia (blood 
glucose below 4 mmol/L).  
The CGM system was used by the participants 96% of the time over the study 
period. This is highly encouraging, confirming acceptability of device by the 
users especially when compared with previous studies. For example CGM was 
used by 70% of the time only by participants in HypoCOMPaSS study.[225]   
Previous studies have shown that the benefit of CGM is highest compared to 
self-monitored glucose monitoring using finger prick method if used with a 
positive approach and if used most of the time [71, 80, 278]. 
 
Further, there was no serious procedure related adverse reaction except for 
minor skin inflammation which settled without intervention. This is important as 
previous implantable sensors have failed to reach the commercial market due 
to various physical factors – acceptability issues, procedure related problems 
[64, 281, 292-296].  
 
An advantage of implantable CGM is that it does not require weekly self-
insertion of a sensor compared to currently available transcutaneous sensor 
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system. This also has the added advantage of not requiring users to remove the 
sensor as detaching transmitter alone was enough when not using the system, 
allowing greater flexibility for users. This also minimises skin and adhesive 
issues faced by people using transcutaneous CGM [278]. 
 
Transcutaneous Real-time CGM systems such as Dexcom G4, MiniMed Sof-
Sensor, Medtronic Enlite and also Flash FreeStyle® Libre (Abbott Diabetes 
Care, Inc., Alameda, CA, USA) that rely on electrochemical sensors are  
susceptible to varying degrees of interference from several medications 
including acetaminophen, salicylates, and ascorbic acid[75, 76]. This 
interference is dependent on the voltage applied to the sensor electrode and 
also on the sensor membrane[75].  
Eversense® CGM sensor uses non–enzyme based fluorescent polymer to 
measure glucose and does not contain an electrode[279]. In a study, 
substances such as acetaminophen (paracetamol) and ascorbic acid that were 
frequently reported to interfere with enzymatic, electrochemical-based 
transcutaneous CGM systems did not affect Eversense® sensor readings. 
However, other less common drugs mannitol  & tetracycline still did interfere 
with the Eversense®  sensor readings [282].  The latest generation Dexcom G6 
sensor was also shown to have non-significant interference with 
paracetamol[76]. 
 
There are drawbacks though. Firstly, and probably most importantly, this 
approach requires invasive technique to insert and remove the sensor. With 
commercialisation, this requires separate training for the clinicians performing 
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this. Also, of note, a specialist surgeon may be required to remove the sensor if 
fibrosis/scarring and/or sensors inserted too deeply. 
   
There is also the concern about repeated use of sites which may scar. It is 
possible that other insertion sites might be tested and become licenced in the 
future with the development of a smaller transmitter in the current commercial 
model compared with the one used in these studies [278]. 
 
Other frustrations for participants were those who experienced frequent ‘low 
temperature’ alarm and connectivity issue when the transmitter failed to connect 
with the display. Improved sensor life and accuracy up to or beyond 12 months 
would likely change the cost- benefit ratio for many more people who might be 
prepared to undergo procedures. 
 
Clarke Error Grid (CEG) has some drawbacks and have not been widely 
embraced[297]. The zone boundaries are not connected sequentially therefore 
a small change in glucose concentration reported by a sensor can move a result 
from the correct value zone A to the critical zone D, or vice versa[298]. So more 
refined Consensus Error Grid has been developed. This grid is based on a 
consensus of 206 international clinicians whose responses were analysed and 
processed into a risk error grid. Compared to Clarke Error Grid, Consensus Error 
Grid is continuous, and each point of the grid has its own risk value. This 




   
In summary, the Cambridge cohort data were consistent with those seen at other 
PRECISE I sites, showing that the Senseonics CGM system appears safe and 
shows accuracy comparable with current transcutaneous CGM system [71, 79]).  
Participants reported high device use satisfaction and were more confident of 

















   
5 Exhaled Breath Volatile Organic Compounds  
during Hypoglycaemia in Type 1 Diabetes  
 
 Background  
 
The rationale for this study was to extend my interest in looking for novel ways 
to detect hypoglycaemia to improve overall hypoglycaemia burden in people 
with T1D. Hypoglycaemia and/or fear of hypoglycaemia limit the ability to 
achieve intensive glucose lowering in diabetes, desirable to reduce complication 
risk  [105]. 
It is desirable for people with T1D to be managed on intensive insulin therapy to 
lower average glycaemia and minimise/ prevent long term complications but 
also avoid severe hypoglycaemia at the same time. Hence, people with T1D 
(with support from their clinical teams / carers / families etc.) have the difficult 
task of achieving and sustaining a high level of self-management skills to 
maintain this balance.  
In order to guide insulin therapy,  people with T1D are advised and expected to 
monitor their capillary blood using a finger prick test several times a day as per 
the standard recommendation[231]. Unfortunately, these Capillary Blood 
Glucose testing (CBGT) are painful and inconvenient [232, 233, 301]. People 
with diabetes find these CBGT tests more painful than insulin injections[302]. 
Even children with T1D are expected to do these painful tests several times a 




   
Despite decades of research exploring alternative to obtaining glucose values 
using finger prick test, currently people with diabetes (particularly those with 
T1D) are still required to monitor their glucose on a daily basis using these 
painful methods of capillary glucose measurement.  
 
 Alternatives to Capillary Blood Glucose Testing (CBGT) 
Efforts have been made over the last few decades to develop a non-invasive 
alternative to CBGT. These methods measure glucose in various body fluids for 
example sweat, tears, urine, or across skin. Methods such as infra-red, Raman, 
photo acoustic and thermal spectroscopy, polarimetry, glucose-sensing contact 
lenses and electrical impedance have all been tried. Some of these are optical 
whereas others are non-optical based [306, 307].  
Some of these technologies worked well in vitro but struggled when faced with 
an in vivo system. As an example, in 2002, the US Food and Drug Administration 
approved a reverse iontophoresis-based device (‘Gluco Watch’) as an adjunct 
to CBGT. However, there were major limitations of the device (costs, lag time, 
procedural hassle, local skin irritation and poor accuracy) and it was withdrawn 
from the market[308]. Pendragon Medical Ltd. (Zurich, Switzerland) developed 
a wrist-band-based glucose monitor called “Pendra in 2003 using bio impedance 
spectroscopy which was also withdrawn from the market because of poor 
reliability[309]. There has been some success with minimally invasive 
continuous glucose monitoring (CGM) devices which are self-implanted under 
the skin. However, some CGM still has significant drawbacks - it requires self-
implantation of sensors under the skin, cost, the requirement for the patient to 
possess a degree of technological ability and, for most devices, the continued 
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need for calibration using CBGT [79, 185, 310, 311]. Despite having some 
supportive NICE guidance [62, 182, 312], current penetrance is very patchy 
across the UK [313].  Abbotts’ recent commercially available Flash Glucose 
Monitoring FreeStyle ‘Libre’ and latest generation Dexcom CGM system have 
eliminated the need to calibrate by CBGT  (and other systems in near future will 
probably also reduce this burden) but it is still painful system [95] and may 
perform less well at hypoglycaemia[191].  Endeavours to find suitable 
noninvasive methods /devices are still ongoing [306, 314]. 
Over the last few decades, breath Volatile Organic Compounds (VOCs) have 
been investigated as a tool for diagnosing and monitoring various disorders in 
human beings. VOCs in human may arise from both endogenous (e.g. 
respiratory surfaces and peripheral tissues from the metabolic by-products of 
various physiological and metabolic pathways[236]) and exogenous sources 
(breathed in environmental air). Some inhaled VOCs, once absorbed into the 
bloodstream, may undergo complete or partial enzymatic metabolism, altering 
the ratio between inhaled and exhaled concentrations [236, 315]. For example, 
80% of ethyl benzene is metabolized by hepatic enzymes, leading to exhaled 
concentrations that are substantially lower than inhaled air [236, 315] . Acute 
metabolic changes may also modify this inhaled/exhaled ratio linking the 
exhaled levels to specific metabolic events. As an example, a reported study 
observed a 2-fold increase in exhalation of aromatic compounds (e.g. ethyl 
benzene) during experimental hyperglycaemia. This could have been explained 
by an increase in glucose load and blood flow to the liver inhibiting enzymatic 
catabolism of several VOCs, resulting in greater fractions of these compounds 
being exhaled [235, 315]. The internal lung surface has also been reported to 
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modify or generate some of the VOCs which in turn affect the exhaled gas 
mixtures [236, 316]. 
 VOCs and diabetes 
 To date, there has been some limited research interest in some of the VOCs 
shown to be associated with diabetes. Pulmonary vasculature and lung function 
are thought to be impaired in people with diabetes due to thickening of epithelial 
and endothelial capillary basement membrane [317, 318]. Furthermore, the 
binding of advanced glycation end products to their receptors (RAGE), which 
occurs in the lung in healthy subjects and significantly increases in diabetes, 
further increases reactive oxygen species production, and promotes fibrotic 
growth factors [318-320]. These factors could potentially interfere with 
quantification and interpretation of various VOC in diabetes. 
 
A small number of VOCs that could potentially be used as non-invasive 
diagnostic tools in diabetes, have been reported in the literature [235, 316, 321-
326].  Various studies have suggested a correlation between some specific 
VOCs and blood glucose. This however has not been convincingly and 
consistently replicated in other similar studies.  
 
Key VOCs reported to be associated with diabetes in the above mentioned 
studies are acetone, isoprene, ethanol, methyl nitrate, ethyl benzene and 
propane. I have briefly discussed each of these below.  
A. Ethanol: Ethanol is a product of glucose fermentation by gut 
flora and is affected by blood glucose level. A study by Kulikov et 
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al. found that light hydrocarbons like ethanol were raised in the 
exhaled breath of women who had risk factors for T2D [324, 327]. 
B. Ethyl Benzene: This is an aromatic hydrocarbon, exogenous in 
origin and is partly metabolized by hepatic enzymes. Hence, 
exhaled ethyl benzene could conceivably be affected by liver 
function and blood flow change during hyperglycaemia [235, 236, 
324].  
C. Methyl Nitrate: This is an alkyl nitrate is commonly found in 
atmosphere. Analysis of exhaled breath in children with T1D 
during euglycaemia or “spontaneous hyperglycaemia” revealed a 
strong correlation between the kinetic profiles of plasma glucose 
and exhaled methyl nitrate [328]. Exhaled methyl nitrate has been 
suggested to be a marker of oxidative stress [325, 329]. Methyl 
nitrate may be a reflection of metabolic changes due to 
hyperglycaemia, rather than hyperglycaemia per se in people with 
T1D [328].  
D. Acetone: Ketone bodies (b-hydroxybutyrate, acetoacetate) are 
produced by the liver during fatty-acid metabolism, and are used 
as an energy source when glucose is not immediately available.  
Acetone is derived by the decarboxylation of acetoacetate and the 
dehydrogenation of isopropanol[330]. In a study, intake of glucose 
in healthy people resulted in reduction of breath acetone[234]. 
Linear correlation of exhaled acetone with the plasma glucose in 
people with T1D has been reported but this correlation did not 
seem to be robust in T2D [236, 331, 332].   
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E. Isoprene: It is one of the most commonly studied VOCs to 
understand and predict underlying metabolic activity because it is 
easily measurable and also found to be sensitive to underlying 
metabolic and physiological changes [333]. It is the most abundant  
biogenic hydrocarbon emitted by earth’s vegetation i.e. present in 
the atmosphere and is also a major hydrocarbon endogenously 
produced by mammals [334]. It is an unsaturated hydrocarbon 
and chemically known as 2-methyl-1, 3-butadiene. This has a 
molar mass of 68.11g/mol and boiling point of 34.1 C [335].  Insight 
into origin of isoprene is based on in vitro studies from rodent liver 
[336, 337]. In human beings  it has been suggested that liver may 
be the source of isoprene based on indirect evidence  from statin 
studies[337]. In human beings the main source of isoprene has 
been reported to be derived from the cholesterol synthetic 
mevalonate pathway [337] in which acetyl-CoA is converted into 
mevalonate which then is transformed into dimethylallyl 
pyrophosphate (DMPP). In vitro study of rat hepatocytes has 
suggested that isoprene is derived from acidic decomposition of 
DMPP [336, 337]. 
The mevalonate pathway has also shown to be linked to cell 
proliferation & DNA replication further strengthening the potential 





   
Whilst some groups report individual VOCs correlating with glucose in 
experimental setting, others report the need for more than one exhaled 
compound to generate a “fingerprint”. For example, the Galasseti group 
observed that glucose correlated significantly [correlation coefficient of 0.91 
(range r = 0.70–0.98)] when ethyl benzene, methyl nitrate, ethanol and acetone 
when combined together in a prediction model in a glucose tolerance study 
[234].  
 
There are anecdotal reports of behavioural patterns in dogs in response to 
glycaemia in human beings, with rescue dogs being trained to detect 
hypoglycaemia in their owners with T1D [339]. Dogs may be alerted in many 
ways, but at least in part in human may be by some of the exhaled VOCs in 
breath. 
 
In summary, a niche exists for alternative non-invasive cheap and convenient 
methods for monitoring changes in blood glucose in diabetes. Any such 
noninvasive methods would be extremely beneficial in children and could be 
used by care-givers or parent in certain scenarios for example while children are 
asleep or when they are non-compliant.  
 
 
 Study Objectives  
 
The primary objective of the study was to examine changes in VOCs under 
controlled experimental hyperglycaemia and hypoglycaemia. I hypothesized 
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that I would see changes in VOCs at different blood glucose levels, particularly 
hypoglycaemia. 
 
 Study Design  
 
 Participants  
Adults aged 18 or above with a clinical diagnosis of T1D of at least 6 months 
duration were recruited from the Wolfson Diabetes Clinic at Cambridge 
University Hospitals Foundation Trust. Smokers or those with chronic lung 
conditions were excluded from the study. There were no other exclusion criteria. 
People with history of Diabetes Keto Acidosis, SH, IAH or those with poor 
glycaemia were able to take part in the study.  An independent research ethics 
committee approved the study in advance and all subjects provided written 
informed consent.   
 Insulin Clamp studies  
Participants were randomised to 2 clamp study days using a locally generated 
random-number computer code in this single blinded cross over study design. 
Participants were studied on 2 separate days at least a week apart.  
Prior to each study day, I provided participants with clinical advice on insulin 
dosing to prevent hypoglycaemia during the 24 hours prior to study. Participants 
fasted from midnight and were admitted to the Wellcome Trust Clinical Research 
Facility at 7AM and received variable rate intravenous insulin to stabilize glucose 
before starting the clamp study at 10:30 AM.   
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For the clamp study, a primed continuous intravenous infusion of soluble human 
insulin (Actrapid, Novo Nordisk, Crawley UK) was run at 0.3 mU/Kg/min for 120 
minutes then increased to 1.5 mU/kg/min for the final 140 minutes). In parallel, 
a 20% dextrose infusion was adjusted according to arterialized plasma glucose 
measured every 5 to 10 minutes (Yellow Springs Instrument 2300 STAT Plus™ 
Glucose & Lactate Analyzer), sampled from a retrograde cannula on the dorsum 
of the hand warmed to 50-60 °C. The clamp activity is summarized in the Figure 
5-1. 
On one study day (STEP), plasma glucose was raised sequentially in 40-minute 
steps for 120 minutes (targets 6.5, 8.5 and 10.5 mmol/L). After increasing insulin 
infusion to1.5 mU/kg/min, plasma glucose was then lowered to 4.5 and 2.8 
mmol/L (60 minute and 40 minute step respectively). On control days (CON), 
procedures were identical, except that plasma glucose was maintained 






   
Figure 5-1: Clamp Study design - Insulin Infusion and target plasma blood glucose on 




Breath was sampled every 20 minutes in two 1.1 litre breath bags (Fischer 
Analysen Instrumente GmbH) as shown in Figure 5-2. To minimize dead space 
sampling, subjects held their breath for a count of 3 seconds and partially 
exhaled before breathing fully into the breath bags.  Breath Bags were sealed 
immediately. Sealed breath bags were transported to Oxford Medical 
Diagnostics, Oxford on the day of each clamp study. 
 
Breath samples collected in breath bags were sealed and analysed within 24 
hours of each study days. From previous literature, we identified isoprene, 
acetone, methyl nitrate, ethanol, ethyl benzene and propane as candidates for 
measurement. We also measured oxygen and carbon dioxide. Samples of 
ambient air from the clinical research facility were also taken for analysis.  
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Plasma samples were taken every 20 min for the measurement of B-
Hydroxybutyrate and every 40 min for measurement of glucagon and insulin. In 
addition, at every 20 mins interval point of care ketone (β-hydroxybutyrate) was 
measured using Abbott’s FreeStyle Optium Ketone meter using FreeStyle 
Optium B –ketone test strips. 
 
 





On each day, the total clamp study period was 220 minutes aiming to finish at 
2PM when participants were given a meal and recommenced on regular 
subcutaneous insulin regimen. Participants contacted me a day after clamp 
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procedure and I ensured they had safe blood glucose and also provided with 
further advice regarding insulin adjustments if necessary. 
 
 Analytical Methods  
 
 Breath samples  
Breath samples were analysed by collaborators at Oxford Medical Diagnostics 
within 24 hours of each clamp study. VOCs (isoprene, acetone, methyl nitrate, 
ethanol, ethyl benzene and propane) were measured using Soft-ionisation mass 
spectrometry (V&F Airsense Compact Ion-Molecule-Reaction Mass 
Spectrometer)[340]  shown in Figure 5-3. This was measured by a researcher 
blinded as to clamp study order and glucose values. Mean of 2 values for VOCs 
obtained at each time point was used for the purpose of analysis. 
 
 






   
  Blood Samples:  
Arterialized plasma glucose was measured in real time using Yellow Springs 
analyser (YSI STAT Plus, Farnborough, UK, intra- assay coefficient of variation 
(CV) 1.5 % and inter assay CV 2.8 %). 
Insulin, Glucagon and b-OH Butyrate was measured at Core Biochemical Assay 
Laboratory (CBAL), Cambridge University Hospitals NHS Foundation Trust, 
Cambridge, UK.  All samples were measured in the same batch.  
Plasma Insulin samples were assayed on a Diasorin Liaison XL automated 
immunoassay analyser using a one-step chemiluminescence immunoassay 
(Intra-assay CV 3.0% at 69.6 pmol/L, 2.0% at 649.8 pmol/L and Inter –assay CV  
11% at 34 pmol/L, 7.0% at 135 pmol/L, 6.7% at 365 pmol/L & 5.9% at 1204 
pmol/L). 
Mercodia (Uppsala Sweden) Glucagon ELISA immunoassay was used for the 
quantification of glucagon (Intra-assay CV 5.1% at 10.5pg/ml; 3.6% at 
18.2pg/ml; 3.3% at 76.7pg/ml and Inter -assay CV 9.5% at 70.3pg/ml, 9.5% at 
202.7pg/ml). 
Stanbio B-Hydroxybutyrate Liquicolour kit (Texas, USA) was used to measure 
Beta Hydroxybutyrate (Intra-assay CV 1.7% at 290 µmol/L, 1.4% at 1090 
µmol/L, and Inter-assay CV 4.6% at 195µmol/L, 6.2% at 528µmol/L & 3.1% at 
958 µmol/L). 
Where glucagon and B-Hydroxybutyrate were below lower level of detection (4.5 




   
 Statistical Considerations 
Powering for isoprene from previous work from the host lab, assuming an SD of 
280 ppb, a sample size of 8 gave 80% power at a significance level of 0.05 to 
detect a difference of 80 ppb  between STEP and EU [326]. We aimed to 
complete 8 paired studies.  
Raw VOC values were adjusted for exhaled CO2 (to 5%) to correct for breath 
sample contamination with airways dead-space. To examine the effects of 
altering plasma glucose on breath, VOC values obtained on CON days were 
subtracted from those obtained at identical times on STEP days. To look 
specifically for a biomarker of low blood glucose, VOC during hypoglycaemia 
(2.8 mmol/l on step days) were compared with values from non-hypoglycaemia 
range. Two sample t test was used to compare the values. 
Spearman correlation test was used to examine correlation between plasma 
glucose and VOCs (STEP – CON) across the range of experimental glucose 
values.  
Data were analysed using IBM SPSS Statistics for Windows, Version 22.0. 
(Armonk, NY: IBM Corp) and p value less than 0.05 was considered statistically 
significant. All data are presented as mean with SEM. 
 
 Results 
We recruited 9 participants. One participant (male) sadly died at home with a 
witnessed nocturnal severe hypoglycaemic episode (unrelated to the study) 4 
weeks after the first arm and before completing the second clamp of the study. 




   
 Baseline characteristics: 
All were females, mean ±SEM (range) for age was 46.3± 4.8 years (19 to 60) 
years); duration of diabetes 22.9± 6.9(2 to 59 years); weight 72±4.9 kg (53.6 to 
90 kg). All but 1 used insulin pump therapy. 
 
 Plasma  Glucose & Dextrose infusion  Rates (DIR)  
Plasma glucose was progressively altered on STEP days (7.1±0.8, 8.7±0.4, 
10.7±0.1, 4.3±0.3 and 2.8±0.1 mmol/L) and maintained on CON at 6.2±0.1 
mmol/L (Figure 5-4).   As anticipated, more dextrose was needed during STEP 
studies during hyperglycaemic steps and less during hypoglycaemic phase 
(Figure 5-5). Plasma Insulin levels were similar on both study days (Figure 5-6). 
 
Figure 5-4: Plasma Glucose during studies 
















































   
 
 
Figure 5-5 : Dextrose Infusion Rate (DIR) during studies  










































   































 Plasma Glucagon & B-Hydroxybutyrate  during studies  
 Plasma glucagon  
Plasma glucagon levels were similar on both study days at non-hypoglycaemia 
level. However, there was a small statistically significant (but probably clinically 
insignificant) rise in glucagon at hypoglycaemia (13.7 + 3.4 vs 5.9+0.9 pg/ml, P 





   





























Data shown are mean ±SEM  




 Plasma B-Hydroxybutyrate 
Plasma B-Hydroxybutyrate levels were similar on both study days at all glucose 
values. As anticipated, B-Hydroxybutyrate gradually and inexorably fell during 






   
Figure 5-8 Plasma B-Hydroxybutyrate levels during studies 











































 Exhaled VOCs during studies  
 Exhaled Acetone, ethanol , methyl nitrate, ethanol, ethyl benzene 
and propane  
There was no obvious correlation between exhaled propane, acetone, methyl 
nitrate, ethanol & ethyl benzene and plasma glucose across the range of 




   
Figure 5-9: Exhaled Propane during studies 
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Figure 5-10: Exhaled Acetone during studies 
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Data shown are mean ±SEM  
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Figure 5-11: Exhaled Methyl Nitrate during studies 
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Figure 5-12 Exhaled Ethanol during studies 
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Data shown are mean ±SEM  
 
 
Figure 5-13: Exhaled Ethyl Benzene during studies 
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 Exhaled isoprene during studies 
Exhaled isoprene rose significantly at experimental hypoglycaemia (220 minute 
values) compared to the averaged non-hypoglycaemia range (85 ± 15 vs. 34 ± 
6 ppb, p 0.007). Outside hypoglycaemia, there was no correlation between 
exhaled isoprene and plasma glucose across the broader range of experimental 
plasma glucose values as shown in Figure 5-14.  
 
Figure 5-14: Exhaled breath isoprene during studies 
**
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Data shown are mean ±SEM 






   
 
Receiver operating characteristic (ROC) curve analysis of Isoprene  
The Receiver Operating Characteristic (ROC) analysis of isoprene’s accuracy 
in identifying hypoglycaemia are shown in Figure 5-15 & Figure 5-16. 
Using a cut-off value 3 mmol/L to define hypoglycaemia, I found average 
predictive value of Isoprene with an area under the ROC curve (AUC) of 0.67(p 
0.06).  However, applying a cut off value of 2.8 mmol/L for hypoglycaemia 




Figure 5-15: ROC of Isoprene in detecting hypoglycaemia with plasma glucose of < 3 
mmol/L 
 
AUC: 0.67; SE: 0.08; CI: 0.51, 0.83; p: 0.65 
Here Sensitivity (true positive rate) of exhaled Isoprene is plotted in function of false positive 
rate (1-Specificity) to predict hypoglycaemia using 3mmol/L of plasma glucose as 
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hypoglycaemia cut-off point. Each point on the curve represents a sensitivity/specificity pair. 
Ideal ROC curve with 100 % specificity & 100% sensitivity would pass through the upper left 
corner. Here area under the curve shows that exhaled Isoprene cannot distinguish 








AUC: 0.84; SE: 0.08; CI: 0.67, 0.99; *p: 0.021 
 
Here Sensitivity (true positive rate) of exhaled Isoprene is plotted in function of false positive 
rate (1-Specificity) to predict when plasma glucose of 2.8mmol/L of plasma glucose as 
hypoglycaemia cut-off point. Each point on the curve represents a sensitivity/specificity pair. 
Ideal ROC curve with 100 % specificity & 100% sensitivity would pass through the upper left 
corner. Here area under the curve shows that exhaled Isoprene can distinguish hypoglycaemia 








 Discussion  
 
In keeping with my hypothesis, breath isoprene increased significantly when 
plasma glucose was low under these experimental conditions. On the basis of 
this finding, I speculate that breath isoprene may be used as a potential 
biomarker target for detecting low glucose during hypoglycaemia. However, one 
of the major limitations of the potential use of the VOCs including isoprene in 
diagnosis and monitoring of therapy in diabetes is the fact that the source of 
endogenous isoprene remains undetermined and that there is not a great deal 
of understanding of metabolism of this VOC in diabetes. 
Isoprene, an unsaturated hydrocarbon also known as 2-methyl-1,-3-butadiene, 
is one of the commonest human breath VOCs [334]. The source of endogenous 
isoprene remains undetermined although rodent studies suggest it may form 
during breakdown of dimethylallyl pyrophosphate in the cholesterol synthetic 
pathway[336]. In keeping with this, exhaled isoprene can be altered by statin 
therapy  [337]. In this study, all but one participant was not on statin therapy. As 
participants were advised not to eat after 10 pm the night before the study, the 
participant on statin may have omitted statin the previous night of the study.  
It is however unclear why a fall in glucose should result in increased breath 
isoprene. Glucose can alter hepatic lipid synthetic pathways, acting via 
carbohydrate response element binding protein (CHrEBP) to induce 
transcriptional changes [341]. However, known CHrEBP targets are in fatty acid 
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synthetic pathways (fatty acid synthase, acetyl CoA carboxylase and stearyl 
CoA desaturase) rather than cholesterol biosynthesis per se. Furthermore, 
transcriptional changes induced by a fall in glucose would be predicted to 
decrease flux into lipogenesis pathways [342]. Exhalation of endogenously-
produced VOCs may be affected both by formation/-breakdown, delivery into 
pulmonary vasculature and ventilation. Given the speed in the rise of isoprene 
that we observed, another possible explanation for our findings is increased 
delivery of isoprene to pulmonary vasculature during hypoglycaemia [343]. 
Dynamic circulatory changes at low blood glucose include increased heart rate, 
systolic pressure and hepatic blood flow. Against this, we saw no changes in 
other VOCs which might have been altered in parallel by haemodynamic 
changes.  
 
Of note, the small rise in glucagon at hypoglycaemia was largely accounted for 
by one participant with short duration T1D who mounted a glucagon response 
to hypoglycaemia.  
 
One of the major strengths of this study is that the insulin clamp technique with 
control comparison study days allowed us to match carefully exposure to 
circulating insulin. This is important as insulin is a potential confounder in other 
studies as insulin is likely to have effects independently of changes in blood 
glucose. As an exemplar, a previous study also used insulin clamps in a T1D 
cohort, reporting that clusters of VOCs identified by multi-linear regression 
rather than an individual VOC correlated with plasma glucose  [344] but failed 
to perform control studies as we have done. A second major strength of our 
 
194 
   
study is that the association between (experimental) hypoglycaemia and VOCs 
was examined, something which has not been published in literature. Thirdly we 
subjected participants to various blood glucose levels including hypoglycaemia 
mimicking the values experienced by people with T1D at home on a regular 
basis. 
 
A limitation of our approach however is that we could only measure a discrete 
repertoire of candidate VOCs and it is possible that other unmeasured VOCs in 
breath might also change during hypoglycaemia, perhaps adding to the 
diagnostic power. The study design terminated the participants study at 
hypoglycaemia range, so we cannot predict isoprene curve during recovery 
when the glucose level was raised back to euglycaemia or hyperglycaemia 
range. 
In summary, these data suggest that breath VOCs could offer a non-invasive 
alternative or adjunct to capillary or interstitial blood glucose testing for 
monitoring changes in blood glucose in diabetes, particularly for detection of 






   
6 In vitro stability of  diluted insulin aspart in 
insulin pump (CSII)  
 
 Background to current study  
 
The rationale for this study was to look into ways that would ultimately help 
minimise hypoglycaemia in different subgroup of people with T1D.   
Infant, toddler, elderly people and some adults with diabetes may require low 
dose of insulin and sometimes this may be less than 5 units per day. So, the 
margin of error is small in these individuals to prevent both hypoglycaemia and 
hyperglycaemia. [220, 238, 345-347]. American Diabetes Association (ADA) 
has acknowledged the need of lower doses of insulin in young children who may 
require as low as 0.5-1U/kg/day and could be even lower during honeymoon 
phase[348]. Some people are sensitive to insulin due to co- morbid conditions 
such as Addison’s’ disease, hypopituitarism, chronic kidney diseases[237-240]. 
Those people who are sensitive to insulin may need less than 1 unit of insulin 
for each dose adjustment to prevent hypoglycaemia[238, 346, 349-351]. It has 
been speculated that high frequency of hypoglycaemia observed in children and 
adolescent could be due to errors in administration of small amount of insulin 
[346, 351]. 
A study by Keith et al. compared accuracy of low dose insulin administrations 
using insulin syringes, pen devices and an insulin pump device. In this study, 
pen and pump devices were found to more accurate than the syringes at the 1-
unit and 2-unit doses of U100 (100 units/mL) insulin delivery with pump devices 
being the most precise of all. Unsurprisingly, all devices were reasonably 
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accurate and precise at higher dose at 5 units of insulin delivery. Worryingly, the 
syringes were highly inaccurate at doses lower than 5 units, overdosing by as 
much as 31% at the 1-unit target dose[345].  
U20 (20 units/mL) insulin were withdrawn from the market when U100 (100 
units/mL) insulin were standardized[351, 352]. This left a gap in in the market 
for insulin dosing below 1 unit. Insulin pens that deliver half unit insulin have 
been designed to help those people who are sensitive to insulin [351, 353-355]. 
At the moment accuracy of insulin below 0.5 unit is achieved through insulin 
pump only [351].  Currently, commercially available insulin  pumps in the UK can 
deliver as low as 0.025  of bolus  insulin[356]. Recently a study examined in vitro 
accuracy of bolus and basal insulin delivery of 10 different commercially 
available insulin pump devices. All insulin pump systems, with the exception of 
patch pump, delivered at least 95% of all 1U boluses within 15% of target. 
Precision of individual boluses was found to be higher with the larger 
boluses[357]. Large deviations were observed in the basal insulin delivery in the 
first 12 hours although variations were much lower in overall 72 hour 
period[357]. 
In our clinical practice as well, as discussed above, some of the people with T1D 
have required very low doses of insulin to control glycaemia in keeping with 
reported literature [237-240]. These people are prone to hypoglycaemia in spite 
of low dose insulin, in part because of the challenges of delivering small amounts 
of insulin accurately[351].  
Short acting insulin analogues are nearly always used in CSII. Insulin aspart, 
insulin glulisine and insulin lispro are the analogue insulins currently used in 
CSII. A more rapid formulation of NovoRapid (Fiasp) was been approved in April 
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2017 in UK but sparsely used to date. In a systematic review, safety and clinical 
efficacy of these analogue insulin have been found to be comparable during 
CSII use in various in vitro and clinical studies [358].  
One overnight study performed recently showed short term (<24h) stability and 
no effect of dilution on pharmacokinetics [359]. 
The rationale for the work described in this chapter is based on the overarching 
hypothesis that diluting the insulin analogue in people with T1D with very low 
insulin requirements would allow an increase in infusion rates and thus minimise 
glycaemic variability including hypoglycaemia in people with T1D. 
There is only one product in the market available to be used in diluting analogue 
insulin. Novo Nordisk supplies diluting ‘Diluting medium for NovoRapid® (insulin 
aspart) and Levemir® (insulin detemir). This Diluting medium is only 
recommended for diluting NovoRapid® and Levemir®. This has been 
recommended to be is used in the treatment of people with diabetes requiring 
extremely low doses of insulin. The medium contains Glycerol, Disodium 
phosphate dihydrate, Metacresol, Phenol, Sodium hydroxide, Hydrochloric acid 
and Water for Injections. NovoRapid® diluted with Insulin Diluting Medium for 
NovoRapid® and Levemir® in a sterile sealed glass vial may remain in patient 
use at ambient temperature (below 30 0 C for up to maximum of 28 days[360]. 
The Novorapid vial contains insulin aspart, Glycerol, Phenol, Metacresol, Zinc 
chloride, Disodium phosphate dihydrate, Sodium chloride, Hydrochloric acid (for 
pH adjustment), Sodium hydroxide (for pH adjustment), and Water for injections. 
A NovoRapid®(insulin aspart)  vial used in CSII , during use or when carried as 
spare can be stored for a maximum of 28 days [361].  
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Previous published work In vitro studies looking at the stability of analogue 
insulin in CSII were done in extreme lab settings [362, 363]. Similarly, clinical 
studies concentrated on cannula occlusion due to analogue insulin in CSII and 
the clinical outcome [358, 364] but did not look at stability and recovery of insulin 
analogue at the end of recommended 28 day in CSII users particularly when 
kept close to body temperature. Furthermore, there is no literature on the 
stability (once diluted in a vial as people might be expected to do) and use of 
diluted insulin aspart in CSII.   
   
 Study Objective 
To study in vitro stability of diluted insulin aspart at and beyond 30 days 
in a simulated use via CSII   
 
 Study Design 
Regular strength (100 U/ml) insulin aspart (NovoRapid®) was diluted at 1:1 by 
mixing with ‘Insulin Diluting medium® for NovoRapid’ (50 % dilution) by the 
researcher (myself). The following protocol was followed as shown in the 





   





 Study Procedure  
Day 1  
1) Make 50% dilutions of Insulin aspart (NovoRapid®) using ‘Insulin 
Diluting medium® for NovoRapid’) in 2 vials. The procedure was done 
under aseptic conditions and was kept ready to fill in plastic reservoirs 
for Medtronic Paradigm Veo™ pump.  
2) Keep 1 neat undiluted insulin aspart (NovoRapid®) vial ready to fill in 




   
3) Fill three plastic reservoirs with neat and diluted insulin aspart (1x neat, 
2x diluted insulin). 
4) Place all three reservoirs filled with neat and diluted insulin aspart in 
three different Medtronic Paradigm Veo™ pumps. 
5) Wear the three Medtronic Paradigm Veo™ at usual body sites to 
maintain the insulin close to body temperature simulating people with 
T1D on CSII.  
6) Samples sent to biochemistry lab for insulin assays drawn at 0, 24, 48 
and 72 hours post dilution from the reservoir over the 3 days (days 1, 2, 
3, 4).  
7) Store samples at minus 200C at biochemistry lab until assayed in batch.  
 
Day 4 to Day 30  
Store remaining insulin (1 neat insulin vial and 2x diluted insulin vials) at ambient 
temperature for 30 days. 
Day 30 
1) Fill three plastic reservoirs with stored neat and diluted insulin aspart 
(1x neat, 2x diluted insulin).  
2) Place all three reservoirs filled with neat and diluted insulin aspart in 




   
3) Wear the three Medtronic Paradigm Veo™ at usual body sites to 
maintain the insulin close to body temperature simulating people with 
T1D on CSII.  
4) Samples sent to biochemistry lab for insulin assays  drawn at t 0, 24, 48 
and 72 hours from the reservoir over the 3 days (days 30, 31, 32, 33, 
34).  
5) Store samples at minus 200C at biochemistry lab until assayed in batch.  
 
I followed the above protocol and wore three CSII pump devices Medtronic 
Paradigm Veo™ (Medtronic MiniMed, Inc.) for 3 days on 2 occasions 30 days 
apart.  
 
 Analytical Methods 
Insulin was assayed at Core Biochemical Assay Laboratory (CBAL), Cambridge 
University Hospitals NHS Foundation Trust, Cambridge, UK on a singleton  
DELFIA automatic immunoassay analyser using a two-step time resolved 
fluorometric assay (intra- assay CV 2.4% at 33.9 umol/L; 1.8% at 82.2 umol/L; 
1.7% at 181umol/L and inter-assay CV 3.1% at 29 umol/L , 2.1% at 79.4 umol/L, 
1.9% at 277 umol/L & 2.0% at 705 umol/L ). 
The assay measures NovoRapid with an estimated recovery of 138% (based on 
a 1:2,000,000 dilution). Theoretical concentration for the diluted insulin was 
300umol/l (Table 6-1).  




   
 
Table 6-1: Expected concentration of insulin in the diluted samples 













  1:2,000,000 300umol/l 




 Statistical Considerations 
Percentage of recovery of insulin aspart over the period of 33 days for diluted 
insulin is compared against the neat insulin value for the day. Mean and 
Coefficient of variation (CV) of the measured insulin was also analysed.  
Data were analysed using IBM SPSS Statistics for Windows, Version 21.0. 
(Armonk, NY: IBM Corp).  All data are presented as mean with SEM. 
 
 Results  
There were 8 samples each for neat, diluted 1 and diluted 2 insulin and 1 sample 
for control. One neat sample at 24 hr (Day 2) could not be measured due to a 
technical error. 
The neat samples all measured very close to the theoretical value of 600umol/l 
and all the 1:2 dilutions were very close to the expected with mean recovery of 
46% against the neat insulin aspart (NovoRapid®) value for corresponding days.  
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The baseline dilution of 274 umol/L & 295 umol/L for diluted 1 and diluted 2 
insulin aspart suggest that manual dilution at 1:1 was not perfect. However, 
concentration remained stable at 33 days with values of 282 umol/L & 276 
umol/L for diluted 1 and diluted 2 insulin respectively. Mean values and 
Coefficient of variation (CV) of the measured insulins is shown in the Figure 6-2  
& Table 6-2.  
 
 
Figure 6-2: Stability of Insulin Aspart over 33 day’s period with simulated use of neat 
and diluted insulin  
Insulin stability

































   
 
Table 6-2 : Stability of Insulin Aspart over 33 day’s period with simulated use of neat 






















Control  620          
Neat 583 - 597 539 567 601 605 598 584.3±9.0 4.08 
           
Diluted 1  
(50 %) 274 261 272 237 265 286 257 295 268.4±6.3 6.67 
           
Diluted 2  
(50 %) 282 269 245 277 269 280 281 276 272.4±4.3 4.46 
           
 
Diluted 1  
Recovery (%) 47.00 - 45.6 43.9 46.7 47.6 42.5 49.3 46.1±0.9. 4.99 
           
Diluted 2  
Recovery (%) 48.37 - 41.0 51.4 47.4 46.6 46.4 46.1 46.8±1. 6.63 





 Discussion  
 
In vitro study showed that all the 1:2 dilutions were very close to the expected 
value with mean recovery of 46% against the neat insulin aspart (NovoRapid®) 
value for corresponding day. Furthermore, the concentration remained stable at 
30 to 33 days. The coefficient of variation of the measured insulins was also 
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acceptable and satisfactory at 6.67% & 4.46%, well within experimental error 
taking into account the 1:1 million dilution involved in measuring the insulin 
concentration. It also shows that stability data can be replicated with similar 
results in both diluted insulin aspart samples.  
The data also confirm the product literature recommendation that neat insulin 
aspart (NovoRapid®) is stable for up to 28 days once opened and kept in 
ambient temperature.  
 
Overall my data confirm that diluted insulin aspart using recommended ‘Insulin 
Diluting medium® for NovoRapid’ use was stable beyond 28 day up to 33 days 
in vitro study during simulated insulin pump use.  
 
The strength of my study is that, to my knowledge this is the first study examining 
stability of diluted insulin aspart in a simulated CSII use mimicking the body 
temperature and in real clinical situations as any individual with T1D on CSII 
therapy would have done. It is possible that unpublished work performed by 
insulin manufacturers exists. I have also examined the stability of insulin aspart 
using recommended diluting medium in CSII. My data also confirm that neat 
insulin aspart is also stable at room temperature for 28 days. Previous work 
examined the stability of neat insulin aspart during simulated use in insulin 
pump. In contrast to my study, previous work was in a lab setting with physical 
fibrillation of samples for 7 days, and not mimicking any effect of exposure to 
potential temperature effects of being worn close to the body [362].  To my 
knowledge this is also the first study where recovery of neat insulin aspart at the 
end of recommended 28 days period of use in CSII has been looked at. 
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 Pilot Data  
As a clinical post-script and following the encouraging finding of this in vitro 
study, I diluted insulin aspart in CSII for one individual with T1D who had been 
experiencing frequent mild hypoglycaemia (more than 5 times per week) in spite 
of very low basal insulin dose requirement (5.5 units per day). As described 
below, diluted insulin aspart was clinically effective in reducing time spent below 
3.9 mmol/L and without worsening of glycaemic control. Patient also had a 
sustained improvement in overall glycaemic control even 15 months post 
dilution.  
 Baseline characteristics  
Age:   68 year  
Gender:  Female 
Weight:   52 .5 kg 
Duration of diabetes: 23 years 
Baseline HbA1c:  73 mmol/mol 
Current medications:  Novorapid (via CSII), Lisinopril 5mg   
Total daily dose of insulin: 13.8 units (Basal 5.5 units, Bolus 8.3 units).  
Carbohydrate ratio (g/U):  00:00 - 17.0  
13:30 - 17.0 
14:30 – 18.0 
19:00 – 12.0 
Insulin sensitivity (mmol per U):5.0 
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 Procedure followed: 
Patient was fitted with professional retrospective CGM (iPro®2, Medtronic 
MiniMed, Inc) for 7 days a week before using diluted insulin aspart in CSII.  
Patient was then trained to prepare diluted insulin aspart by mixing NovoRapid® 
with ‘Insulin Diluting medium® at 1:1 ratio (50 % dilution). Pump settings were 
adjusted to ensure she received same concentration of insulin for basal and 
bolus insulin post dilution i.e. insulin carb ratio was halved, basal insulin rate 
was doubled, and insulin sensitivity was halved. 
On the first day of training, person was trained to dilute insulin aspart. Thereafter 
they filled the insulin reservoir with diluted insulin every 3 days at home. She 
then stored the diluted but unused stored insulin in ambient temperature in a 
cool and dry place. Patient prepared the diluted insulin aspart at least every 28 
days.   
HbA1c was done at baseline and 3 months. She was fitted with professional 
retrospective CGM (iPro®2, Medtronic MiniMed, Inc) for 7 days at baseline and 
4 months post dilution.  
 
 Retrospective CGM data  
Mean glucose was higher at 3 months post dilution compared to baseline 
(9.1±0.1 vs 8.3±0.1 mmol/L). However, time spent in glucose ≤ 3.9 mmol/L was 
reduced from 4 % at baseline to 1% at 3 months post dilution. Number of days 
blood glucose was ≤ 3.9 mmol/L, was reduced from 4 days at baseline to 1 day 
at 3 months. Details of CGM are shown in Table 6-3,Figure 6-3, Figure 6-4 & 
Figure 6-5.   
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Baseline HbA1c was 73 mmol/ mol (pre-dilution).  Post -dilution HbA1c was 75 




Table 6-3: Comparison of retrospective (blinded) CGM data at baseline and 4months 
after insulin aspart dilution for the CSII (pre and post dilution) 
CGM Glucose 
 (mmol/L) 
Pre -Dilution Post - Dilution 
 
Number of  
sensor values  1874 1875 
Mean±SEM  8.3±0.1 9.1±0.1 
High excursion(number)  21 24 
Low excursion(number) ≤ 3.9 mmol/L glucose  6 2 




Figure 6-3: Time spent in various glucose levels as per the CGM sensor data at baseline 










   
 
Figure 6-4: Time spent in various glucose levels as per the retrospective CGM sensor 





Figure 6-5: Number of days spent in glucose levels below 3.9 mmol/L as per the CGM 





















Days with BG < 3.9mmol/L


























   
 
 Discussion :  
Within the limitation of sample size (n=1), diluted insulin aspart was clinically 
effective in reducing time spent in glucose below 3.9mmol/ L and improve and 
maintain glycaemic control. The limitation of my approach in this pilot study is 
that this individual’s hypoglycaemia frequency had started to improve already 
before insulin dilution possibly due to health care support. Therefore, the 
baseline CGM may not have captured the frequency of hypoglycaemia she 
usually experienced before being invited for this pilot study. I speculate that use 
of CGMS longer than 1 week could have captured more information both at 
baseline and after the dilution. Sustained improvement in glycaemic control 
could be due to combination of HCP support and improved accuracy of low dose 
insulin delivery by virtue of higher volume also observed by a recent report[357]. 





   
7 Conclusions 
 
Hypoglycaemia still remains a problem for some people with T1D despite 
improvement in insulin delivery, glucose monitoring and structured education 
and psychological support. Because there are likely many multifactorial 
contributors to hypoglycaemia risk (physiological, demographic, social, 
psychosocial/ behavioural), a single therapeutic approach or intervention to 
reduce hypoglycaemia burden is unlikely to work for all. We need to have a 
holistic approach to address the problem of hypoglycaemia in people with T1D. 
The work in my thesis involved investigation of three domains of clinical 
hypoglycaemia: prediction of hypoglycaemia, detection of hypoglycaemia (using 
a novel glucose monitoring system) and exploring better insulin delivery. 
 
8.1 Prediction of Hypoglycaemia   
 
I examined the HypoCOMPaSS clamp data looking for possible factors that 
could predict response to clinical interventions in those with a significant burden 
of hypoglycaemia. I could not find any obvious biomedical indicators that might 
potentially be targeted to reduce hypoglycaemia burden in this well phenotyped 
cohort. This apparently negative result however is encouraging for clinical 
practice as the absence of irreversible factors that could contribute to 
hypoglycaemia suggests that intensifying clinical strategies aimed to reduce 
hypoglycaemia burden could still work for anyone with problematic 
hypoglycaemia i.e. there is no particular group of T1D that is obviously resistant 
to clinical intervention(s). 
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Findings from the ACE genotype sub study showed that homozygous deletion 
(DD) in the polymorphism of DD ACE gene was associated with risk of SH in 
HypoCOMPaSS participants, thus confirming the suggestion from literature that 
some people with T1D are biologically prone to severe hypoglycaemia.  On the 
basis of the clamp data, this association could perhaps be explained by a greater 
decline in those with the DD polymorphism in cognitive function during 
hypoglycaemia, thus making these individuals prone to severe episodes. I 
speculate that centrally acting ACE inhibitors may be beneficial in those with 
homozygous deletion of ACE gene to prevent severe hypoglycaemia.  However, 
the findings need to be further explored. Importantly, there is a need for more 
mechanistic work targeting the ACE/RAS system directly in brain. Of note, my 
host laboratory for my thesis is currently exploring hypoglycaemia mechanisms 
in mice models including brain targeting approaches. 
Measuring ACE level and identifying ACE gene polymorphism may detect some 
who are more prone to severe hypoglycaemia. The importance of my finding is 
that (i) this might allow clinical strategies to be targeted by genotype (e.g. 
reinforcing for some that they are more likely to experience cognitive dysfunction 
during hypoglycaemia) and (ii) perhaps future drug therapy with agents working 
via central ACE/RAS pathways might be another therapeutic approach to 
minimise severe hypoglycaemia in some people with T1D. 
 
8.2 Detection of Hypoglycaemia 
 
Benefits of traditional CGM systems for reducing hypoglycaemia are dependent 
on user compliance with the devices. Multiple factors including skin adhesive 
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issues, skin reactions and the requirement to change the sensor every week can 
play a part in the compliance with standard CGM system. The (currently novel) 
implantable glucose monitoring device developed by Eversense® CGM System 
can minimise these issues. My analysis of Cambridge participants showed that 
this system was safe, and participants found it easier to use. The efficacy was 
comparable to standard commercial CGM system. Furthermore, it was reliable 
in hypoglycaemia range level as well. This formed part of the evidence for the 
pivotal multi centred European PRECISE1 study which allowed the licensing of 
this CGM system. As this system is safe and effective, this could potentially be 
used in the ongoing closed loop (CL) studies.  It has recently been reported that 
this implantable continuous glucose system may be integrated with automated 
insulin delivery including the Boston group’s “bionic pancreas” system. The data 
I present in this thesis have helped pave the way for exciting and advanced 
technological approaches to glucose monitoring and insulin delivery already.  
Hypothetically, there are no scientific reasons why one could not extend the 
system for the use in people with Type 2 diabetes as well.  
Although CGM systems have advanced in the last 2 decades with improved 
accuracy and connectivity, these systems still need further refinement to 
facilitate further development of AID system.  CGM’s signalling error and signal 
drop-outs needs to be minimised[70, 365]. Further accuracy metrics of CGM 
needs to be based on direct interstitial glucose measurement as reference 
glucose rather than currently used venous glucose reference [89, 365, 366]. The 
latest CGMs systems that do not need calibration is without a doubt an important 
step towards AID advancement. Longevity of sensor such as Eversense® CGM 
system has paved the way for sensors with longer life. This system is still limited 
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by the fact that it needs SMBG for calibration and that the sensor needs  warm 
up phase which again is hindrance to the AID[365] .  
In people with T2D  benefits of advance diabetes technologies has not been 
investigated  as much as in people with T1D  and the lack of data makes it 
difficult to predict its benefit[367, 368]. One of the challenges seems to be that 
hyperglycaemia is more pronounced than hypoglycaemia in T2D in contrast to 
those with T1D[81]. There are reports suggesting that fully automated system is 
not necessarily the best way to achieve better glycaemic controls as similar 
results were achieved  in some studies through fixed bolus using pen device 
[367]. Further question remains if the costs and complexity of AID are justified 
in people with T2D [367].   
My data from our study of exhaled breath Volatiles Organic Compounds is 
encouraging for those who are still exploring non-invasive approaches of 
glucose monitoring. The rise in exhaled isoprene during hypoglycemia is indeed 
very interesting. This has gained interest in the public and media as well. A major 
limitation to this approach for the future studies is the gap in our understanding 
of the basic biology of isoprene metabolism in the human body.  
These limitations notwithstanding, I speculate that medically trained dogs which 
detect hypoglycaemia may have been detecting (at least in part) exhaled volatile 
compounds (including perhaps isoprene) in the breath of their owners. One 
could scientifically explore dog’s response to experimentally  controlled 
hypoglycaemia  in human T1D subjects in a controlled environment and indeed 
also study the response of trained dogs to exhaled volatile compounds[369].   
Recent studies (published after my study was completed) however did not 
support the popular anecdotal reports of diabetes trained dogs reliably alerting 
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humans to hypoglycaemia[369, 370]. Gonder-Frederick et al.  examined dog’s 
alerts records by owners and compared these with blinded CGM readings in 14 
people with T1D over 29 median days. In this study dogs did not accurately 
detect either hypoglycaemia or hyperglycaemia.  Dogs only detected 35.9% of 
low blood glucose events during waking hours and 22.2% during sleeping 
hours[370]. In a separate similar study of the dogs trained to detect 
hypoglycaemia owned by people with T1D using blinded CGM, dogs provided 
timely alerts only in 36% of all hypoglycemia events. However this study was 
limited by small sample size of 8 and that there were variations in breed, age, 
training duration of the dogs that could influence accuracy of the alerts and 
hence the result of the study [369].  
 
Future research could also look into development of innovative breath sensing 
technology for earlier detection of hypoglycemia to prevent severe 
hypoglycemia, perhaps using an individualised fingerprint of individual volatile 
compound or indeed multitude of compounds.  One could speculate that an 
“artificial nose” could be designed to help detect hypoglycaemia early. Similarly, 
breath sensing smart pillows could be developed to detect hypoglycaemia 
during sleep.  Tiny sensor devices that could detect exhaled breath compounds 
could be implanted in the nasal cavity. Such an approach could particularly be 
of huge benefit for those who have little or no awareness of hypoglycaemia 
during sleep. Parents or care givers of children with T1D would welcome future 





   
8.3 Better Insulin Delivery  
 
Some people with T1D are prone to recurrent hypoglycaemia despite relatively 
lower basal insulin use. It is possible that reducing the variation in insulin 
absorption may address the problem. Results of my study on the stability of 
diluted insulin aspart over 33 days raises the possibility that diluted insulin aspart 
could be used in these groups of people.   
One recently published overnight study on diluted insulin showed short term 
(<24h) stability and no effect of dilution on pharmacokinetics [359]. However, a 
recent study by Freckmann observed that higher volume of insulin was 
associated with better accuracy of  bolus doses supporting my finding[357]. This 
needs to be replicated in larger randomized studies. This observation was 
however not consistent with all other examined bolus and basal and bolus 
doses. 
This finding could potentially be utilised widely. Diluted insulin use could be 
utilised in those with low basal insulin requirement to prevent hypoglycaemia. 
Furthermore, this could be used in children who by nature require much less 
insulin compared to adults and so need much finer insulin dose adjustments. 
Broadly this could also be used in closed loop insulin delivery system to allow 
for much finer insulin dosing increments.  
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8 Appendices  
 
Appendix 1 
ADA/WHO Definition of Diabetes Mellitus 
1. FPG ≥ 7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. 
OR 
2. Symptoms of hyperglycemia and a casual plasma glucose ≥11.1 mmol/l. 
Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of hyperglycemia include polyuria, polydipsia, and 
unexplained weight loss. 
OR 
3. 2-h plasma glucose ≥ 11.1 mmol/l during an OGTT. The test should be 
performed as described by the World Health Organization, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water.  
 
In the absence of unequivocal hyperglycemia, these criteria should be confirmed 










   
Appendix 2 
Cognitive function Tests  
 
A. Four choice reaction time 
In this test, participant is presented with a computer screen which is divided into 
four quadrants. A computer-generated signal appears randomly in one quadrant 
at a time and the participant is asked to clear each signal that appear   by 
pressing a corresponding button on a box [371]. 
 




B. Stroop Black & White  
In this test, participant is presented with names of colour written in Black & White 




   
Sample of Stroop Black & White  
BLUE RED GREEN TAN 
RED GREEN BLUE RED 
GREEN TAN RED GREEN 
TAN  BLUE GREEN RED 
RED TAN BLUE TAN 
BLUE GREEN RED RED 
GREEN TAN TAN BLUE 
BLUE RED GREEN TAN 
RED BLUE RED BLUE 
GREEN RED GREEN RED 
TAN  GREEN  TAN GREEN 
BLUE RED TAN TAN  
RED BLUE GREEN BLUE 
GREEN TAN RED GREEN 
 
 
C. Stroop Colour 
In this test participant is presented with series of ‘X’ in different color inks and is 
asked to name the color of each ‘X’ [246]. 
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Sample of Stroop Colour Test  
 X   X   X   X 
 X   X   X   X 
 X   X   X   X 
 X   X   X   X 
 X   X   X   X 
 X   X   X   X 
 X   X   X   X 




D. Stroop Colour Word  
In this test participant is presented with series of the words ‘blue’, ‘red’, ‘green’, 
‘tan’ printed in ink of a contrasting colour. Participant is asked to name the colour 
of the ink. 
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Sample of Stroop Colour Word  
BLUE RED GREEN TAN 
RED GREEN BLUE RED 
GREEN TAN RED GREEN 
TAN  BLUE GREEN RED 
RED TAN BLUE TAN 
BLUE GREEN RED RED 
GREEN TAN TAN BLUE 
BLUE RED GREEN TAN 
RED BLUE RED BLUE 
GREEN RED GREEN RED 
TAN  GREEN  TAN GREEN 
BLUE RED TAN TAN  
RED BLUE GREEN BLUE 












   
Appendix 3 
 
Table: Baseline characteristics of the participants who took part in main 
HypoCOMPaSS study  
•  All 
Insulin comparison Monitoring comparison 
MDI CSII SMBG RT 
Baseline HbA1c 
     
 <8% 41 (43) 22 (44) 19 (41) 21 (44) 20 (42) 
 ≥8% 55 (57) 28 (56) 27 (59) 27 (56) 28 (58) 
HbA1c (%) 8.2 ± 1.2 8.2 ± 1.3 8.2 ± 1.2 8.3 ± 1.3 8.2 ± 1.1 









































26.3 ± 4.4 26.1 ± 4.3 26.9 ± 4.7 
Insulin dose 






















   
Appendix 4 
Edinburgh Hypoglycaemia Survey (including The Gold Score) 
1.  Please score the extent to which you experience the following symptoms 
during a typical dayt ime hypoglycaemic episode (circ le a number for each 
symptom)  
         Not present     Present a great deal 
 
Confusion   1 2 3 4 5 6 7 
Sweating    1 2 3 4 5 6 7 
Drowsiness   1 2 3 4 5 6 7 
Weakness   1 2 3 4 5 6 7 
Dizziness    1 2 3 4 5 6 7 
Warmth    1 2 3 4 5 6 7 
Difficulty Speaking  1 2 3 4 5 6 7 
Pounding heart   1 2 3 4 5 6 7 
Inability to concentrate  1 2 3 4 5 6 7 
Blurred vision   1 2 3 4 5 6 7 
Hunger    1 2 3 4 5 6 7 
Nausea    1 2 3 4 5 6 7 
Anxiety    1 2 3 4 5 6 7 
Tiredness    1 2 3 4 5 6 7 
Tingling lips   1 2 3 4 5 6 7 
Trembling   1 2 3 4 5 6 7 
Headache   1 2 3 4 5 6 7 
 
2.  Do you know when your hypos are commencing?  Please circle a number: (The 
Gold Score) 
 
         Always aware    Never aware 
 

























   
Appendix 6  
Additional characteristics and analysis of all participants who 
took part in clamp procedure at the end of 6 months RCT 
 
 
Baseline characteristics of all participants who took part in clamp procedure at end of 























Age (years) 48.6 ± 1.8 45.3±3.9 50.9±1.6 0.11 
Duration of diabetes 
(years) 
35.7±2.1 30.6.9±4.1  38.7±1.9 0.06 
HbA1c (%) baseline 7.9±0.2 8..0±0.3 7.9±0.3 0.97 
 
HbA1c (mmol/mol) baseline 63.8±2.1 63.9±3.4 63.8±2.8 0.97 
Severe Hypoglycaemia 








Gold Score at baseline 5.3±0.1 5.4±0.2 5.4±0.1 0.27 
Data shown are mean ±SEM or Median (IQR) 
* Independent sample T-Test or Mann Whitney U Test    






   
Plasma glucose for all participants who took part in clamp procedure at end of the 6    
months RCT  












































Dextrose Infusion Rate (DIR) for all participants who took part in clamp procedure at 
end of the 6 months RCT  






































   
Symptoms and hormonal responses at end RCT clamped hypoglycaemia in all 
participants - at risk ‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes 










Glucose levels subjects 



























Autonomic  812.5±323.4 358.5±84.8  0.11  
Neuroglycopenic 607.5±222.5 513.8±84.5  0.65  
Total Cognitive  
Dysfunction Symptoms§ 
 
















     
Data shown are mean ±SEM or Median (IQR) 
* Independent sample T-Test or Mann Whitney U Test     




Glucose (mmol/l) threshold at which cognitive function deteriorated in End RCT 






























     
Data shown are mean ±SEM  





   
Cognitive Function Tests in End RCT clamped ypoglycaemia in all participants - at risk 
‘DD’ Vs ‘Non DD’ (ID/II) ACE genotypes 








     
Cognitive Function AUC      
 
Four Choice Reaction Time  
 
 
















     
Stroop Colour                            
 
 













Data shown are mean ±SEM  










   
 
Appendix 7 
Publications during PhD  
➢ Exhaled Breath Isoprene Rises During Hypoglycemia in Type 1 
Diabetes: Sankalpa Neupane, Robert Peverall, Graham Richmond, 
Tom P.J. Blaikie, David Taylor, Gus Hancock, Mark L. Evans, Diabetes 
Care 2016 Jul; 39(7): 97-98. 
 
➢ Accuracy and Longevity of an Implantable Continuous Glucose 
Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, 
Pivotal Trial, Jort Kropff, Pratik Choudhary, Sankalpa Neupane, 
Katharine Barnard, Steve C. Bain, Christoph Kapitza, Thomas Forst, 
Manuela Link, Andrew Dehennis, J. Hans DeVries, Diabetes Care 2017 
Jan; 40 (1): 63-68. 
 
➢ Acceptability of Implantable Continuous Glucose Monitoring 
Sensor: Barnard KD, Kropff J, Choudhary P, Neupane S, Bain SC, 
Kapitza , Forst T, Link M, Mdingi C, DeVries JH, J Diabetes Sci 




Presentations during PhD  
➢ Detecting Hypoglycaemia in Breath- Exhaled Isoprene and Acetone 
as Biomarkers of Blood Glucose. S. Neupane, G. Richmond, T. 
Blaikie, R. Peverall, D. Taylor, I. Campbell, G. Hancock, M.L. Evans, 
European Association of Study of Diabetes, Stockholm, Sweden , 
September 2015(Poster)[372] .  
 
➢ Risk of hypoglycaemia in Type 1 diabetes is associated with 
homozygous deletion (DD) allelic variation in the angiotensin-
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converting enzyme (ACE) in the Hypo-COMPASS study. S Neupane, 
L Leelarathna, S Little, E Walkinshaw, HK Tan, A Lubina-Solomon, S 
Barendse, J Speight, D Kerr, D Flanagan, S Heller, J Shaw, M L Evans, 
Diabetes UK Annual Professional Conference, Liverpool, March 2014 
(Oral)[373].    
 
➢ Accuracy and Longevity of an Implantable Continuous Glucose 
Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, 
Pivotal Trial. J H Devries, J Kropff, P Choudhary, S Neupane, S C Bain, 
C Kapitza, T A Forst, M Link, A D Dehennis, American Diabetes 
Association, 76th Scientific Sessions, New Orleans, Louisiana, June  




   
Appendix 9 
Study related responsibilities  
A. HypoCOMPaSS sub Analysis: Examination for potential predictors 
of severe hypoglycaemia from baseline hypoglycaemic clamp study 
(chapter 2) 
The main HypoCOMPaSS was planned and commenced before I started my 
PhD. 
1. Development of statistical analysis plan 
2. Data cleaning and statistical analysis 
3. Writing manuscript  
B. HypoCOMPaSS ACE genotype sub study (chapter 4) 
1. Genotyping of the DNA samples  
2. Development of statistical analysis plan 
3. Data cleaning and statistical analysis  
4. Providing report and update to the Ethics Committee 
5. Writing manuscript 
6. Presentation of results at the diabetes UK Annual Professional 
Conference 2014 and Institute of Institute of Metabolic Science, Away 





   
C. Novel  Accuracy & Use of a novel Continuous Implanted Glucose 
Sensor (chapter 4) 
 
1. Producing study-related documents, such as study guidelines booklet, 
Hypoglycaemia and Hyperglycaemia SOP etc.  
2. Recruitment of participants  
3. Liaising with participants and WTCRF and coordinating multiple in-clinic  
visits  
4. Leading the study and conducting all aspects of the study including 
Insertion & removals of sensors, Hyperglycaemia & hypoglycaemia 
challenge, training subjects on using the system etc.  
5. Providing report and update to the Data & Safety Monitoring Board 
6. Development of statistical analysis plan 
7. Data cleaning and statistical analysis 
8. Contribution to manuscript  
9. Co-author when overall PRECISE I study findings presented in American 




   
 
D. Exhaled Breath Volatiles Organic Compounds during 
Hypoglycaemia in Type 1 Diabetes (chapter 5) 
 
1. Contribution to study design and protocol 
2. Producing study-related documents, such as Participant Information 
Sheet, Consent form and GP letter 
3. Application for ethics application and gaining approval  
4. Recruitment of participants  
5. Contacting  the subjects to make any necessary changes in insulin 
regimen prior to the participants attending the study in the Wellcome 
Trust Clinical Research Facility (WTCRF)  
6. Performing all aspects of the clamp procedure including sampling of 
blood, breath and making changes to the continuous dextrose infusion 
(initially under supervision by Dr Mark Evans, subsequently 
independently)  
7. Providing report and update to the Ethics Committee. 
8. Development of statistical analysis plan 
9. Data cleaning and statistical analysis 
10. Writing manuscript 





   
 
E. In vitro stability of diluted insulin aspart in insulin pump (CSII) 
(chapter 7)  
 
1. Contribution to study design  
2. Liaising with biochemistry lab  
3. Development of statistical analysis plan 
4. Data cleaning and statistical analysis 
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